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Abstract 
 
This work seeks to develop a high quality prognostic model for the CARE-HF data; 
see (Richardson et al. 2007). The CARE-HF trial was a major study into the effects of 
cardiac resynchronization. Cardiac resynchronization has been shown to reduce 
mortality in patients suffering heart failure due to electrical problems in the heart. The 
prognostic model presented in this work was motivated by the question as to which 
patient characteristics may modify the effect of cardiac resynchronization. This is a 
question of great importance to clinicians. Efforts are made to produce a high quality 
prognostic model in part through the application of methods to reduce the risk of 
over-fitting. One method discussed in this work is the strategy proposed by Frank 
Harrell Jr. The various aspects of Harrell’s approach are discussed. An attempt is 
made to extend Harrell’s strategy to frailty models. Key issues such as missing data 
and imputation, specification of the functional form of the model, and validation are 
examined in relation to the prognostic model for the CARE-HF data. Material is 
presented covering survival analysis, maximum likelihood methods, model selection 
criteria (AIC, BIC), specification of functional form (cubic splines and fractional 
polynomials) and validation methods (cross-validation, bootstrap methods). The 
concepts of over-fitting and optimism are examined. The author concludes that whilst 
Harrell’s strategy is valuable it is still quite possible to produce models that are over-
fitted. MDL (Minimum Description Length) is suggested as potentially useful 
methods by which statistical models can be obtained that have an in built resistance to 
over-fitting. The author also recommends that concepts such as over-fitting, optimism 
and model validation are introduced earlier in more elementary courses on statistical 
modelling. 
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E-HF data (Richardson et al. 2007).  The CARE-HF trial is a landmark trial 
benefits of cardiac resynchronization therapy. Cardiac resynchronization 
has been shown to significantly reduce mortality in patients suffering heart 
ue to electrical abnormalities in the heart (Ellenbogen et al. 2005), (Cleland et 
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identify possible treatment modifiers of cardiac resynchronization therapy 
nic. 2009). It is of great importance that those patient characteristics which 
dify the beneficial effects of cardiac resynchronisation are identified, i.e. 
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 subgroups of patients are identified who may enjoy the most benefit from cardiac 
resynchronization therapy. My main aim is to produce a model that has been 
developed with the aim of minimising the risk of over-fitting and maximising its 
predictive power. This will entail amongst other techniques an application of an 
approach suggested by Frank Harrell Jr. I attempt later in this work to apply Harrell’s 
approach in fitting a frailty model, an issue which Harrell does not address. I also seek 
to identify some of the limitations of Harrell’s methods. My main objective is the 
development of a high quality prognostic model for what is an important real world 
application. The purpose of including some of the more theoretical material is to 
provide a framework in which I can understand issues that arise in developing a 
prognostic model. 
1.1.0 Prognostic Models 
I shall be concerned almost exclusively with prognostic models in this thesis. A 
prognostic model can be regarded as a tool by which a doctor can produce a prognosis 
for a patient. Prognosis from the Greek πρόγνωσις, can be defined as a doctor’s 
prediction of how a patient’s illness will develop and their chance of recovery. For 
example; given a patient’s age, weight, blood pressure, a doctor could determine what 
if any beneficial effect a patient might experience if he or she were to receive a 
particular treatment or therapy. For general discussion of prognostic models the reader 
is directed toward Abu’s paper (Abu & Lucas 2001). A prognostic model is a 
predictive tool; its purpose is to predict the level of increase in a beneficial effect, or 
the decrease in risk of some adverse event, for instance, death A prognostic model can 
assist a doctor in making clinical decisions, for example in trying to determine which 
patients might benefit from a particular treatment or therapy given that the treatment 
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 is costly. The following papers provide excellent material on prognostic models 
(Wyatt & Altman 1995), (Moons et al. 2009) and (Royston et al. 2009).  
The decision as to whether a patient will be given a particular treatment may well be 
based upon evidence obtained through the application of a prognostic model. 
Therefore, the importance of being able produce a reliable and accurate model is 
immediately seen. A method by which it is possible to assess the predictive accuracy 
of the prognostic model is also required. What steps can be taken in order to maximise 
the chances of producing a good model? These questions have led researchers to 
formulate a number of approaches to the modelling process with the aim of obtaining 
a parsimonious model that does not suffer from over-fitting and has good predictive 
accuracy.  
1.2.0 Survival Analysis Background 
 
If a new drug or treatment has been developed an important question is how effective 
is the drug or the treatment? Evidence for the efficacy of a drug or treatment is 
gathered by setting up a clinical trial. A simple situation might be as follows: A 
sample of patients suffering from some disease or illness is obtained. Patients from 
this sample are then randomly allocated to one of two groups. The first group is called 
the treatment group; patients allocated to this group receive the drug or treatment. The 
second group is called the control group, patients allocated to this group do not 
receive the drug or treatment, they may for instance be given a placebo. A researcher 
might then consider how many patients died in the treatment group compared to the 
control group (or more positively how many patients did not die). In the simple 
situation described above a researcher might use logistic regression to estimate the 
probability of death, the model might include variables such as patients age, sex. Also 
if a variable indicating to which group the patient belonged was included in the 
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 model, and was subsequently found to be statistically significant then this may 
provide evidence for a treatment effect, i.e. probability of a patient dying is dependent 
upon whether or not they have received the treatment. In the example above the 
outcome is a binary one, dead or alive. It might well be that a patient’s life is 
prolonged by taking the drug, but by how long? It might be a few months or it could 
be 20 years. In many clinical trials the question of the efficacy of a drug or treatment 
is addressed in terms of the time to event, i.e. how long until a patient dies or 
experiences the event of interest. In this case survival analysis is the appropriate 
method. A few words should be said on the matter of randomisation. One of the 
principal reasons for adopting randomisation when developing a prognostic model is 
to avoid biased estimates of treatment effects. In attempting to develop a prognostic 
model it is important that the treatment and control groups are balanced in terms of 
the distribution of variables that may be strong predictors of the outcome. 
Randomisation also reduces the risk of obtaining biased estimates of the treatment 
effect due to missing or unknown variables. It should be borne in mind that 
randomisation does not guarantee that estimates of treatment effects will be unbiased 
in all situations (Gail et al. 1984). I should like to point out however that 
randomisation can be considered as a controversial topic (Royall 1991). However R.A 
Fisher (Fisher 1966) argues that if we assume that a real treatment effect is absent, 
then the result from any experiment is due to chance alone. Fisher (Fisher 1966) 
provides a very clear argument to support of randomisation. I shall now review some 
of the fundamental ideas in Survival analysis, what follows is a standard derivation of 
the basic results. I make no claim whatsoever to have developed anything new. These 
are well known results attributable to others. Similar derivation may be found in any 
number of statistics textbooks, see Dobson’s textbook (Dobson 2002) for example.  
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  Considering the indicator variable jx  we can write jee yHyH β+= )(log)(log 01 , the 
natural logarithms of the cumulative hazard functions differ by the constant jβ . F
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1.3.0 The Modelling Process  
 
Harrell et al. (Harrell et al. 1996) identify the following as potential problems in the 
modelling process: 
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•
 
statistical model the resea cher i ften compelled to make a number of 
simplifications and assumptions. Real world situations are often too complex to model 
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 Omission of Important Predictors 
• Missing Data / Incorrect Imputation 
• Over-fitting 
 
Each of the above may lead to an ill-fitting prognostic model; predictions based on 
such a model will not be reliable. When attempting to fit any mathematical or 
r s o
tions. In fitting a prognostic model three 
basic assumptions shall be made; the first is a distributional assumption, the second an 
ssumption regarding functional form and the third an assumption about 
additivity.The prognostic models that I shall consider in this thesis are based on the 
Cox Proportional Hazards model (Cox 1959), (Cox 1964), (Cox 1972), of course 
prognostic models can be developed for other forms of Generalised Linear Models 
(GLM) see (Nelder & Wedderburn 2009), (Baker & Nelder 1978) and (Dobson 2002).  
In a linear model , the GLM extends the linear model to situations where 
e relationship between and  is not linear, this is achieved through the link 
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 function ()Lf , so that YEf L (( x~
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1.4.0 Violation of Assumptions 
Although this thesis is concerned with over-fitting and optimism it is considerable 
im ic assumptions are examined as to their validity. For example with 
the Cox m del is the proportional hazards assumption valid?  Are assumptions about 
the function form of the model appropriate? Once a model has been obtained is it 
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assumption is violated, it is possible to include a time dependent variable i
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 hazards is to stratify the model based on the variable for with the proportional hazar
assumption is violated.  
 
Specifying an appropriate functional form for the model is important. The assumption 
of a simple relationship between Y and
ds 
1.4.2 Functional Form 
X  such as XY =  may not be appropriate. 
There may be a more complex relationship between Y  and X .  In this situation it is 
required to transform X , examples of typical transformations are )(log Xe , X . 
However the crucial point is that the model is linear in the parameters. The models 
errorXY ++= 110 ββ and odels i.e. the right 
hand side in both cases is a linear eters  
errorXY ++= 2ββ 110 are both linear m
combination of the param 0β  and 1β . In recent 
of work has been carried out in the study of cubic splines and their 
application to statistical models. There are instances when the fit of a model can be 
improved by using cubic splines in the sp
n tatistical 
and (Herndon & Harrell 1990). Another extremely interesting approach to 
transformations is that of the Fractional Polynomial (Royston & Altman 1994), 
(Royston Patrick et al. 1999) and (Royston & Sauerbrei 2004). The reader is 
encouraged to read Royston and Altman’s paper (Royston & Altman 1994), further 
useful material can be found in (Royston et al. 1999), (Royston & Sauerbrei 2004) 
l rea etail 
years a great deal 
ecification of the functional form. The 
following authors provide very useful material o  the use of cubic splines in s
modelling, (Wegman & Wright 1983), (Smith 1979), (Poirier 1979), (Royston 2000) 
and software for fitting fractional polynomials is documented in (Meier-Hirmer et al. 
2003). Both cubic splines and fractional polynomia s will be covered in g ter d
in Chapter 4.   
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 1.4.3 Additivity 
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eaningful interaction terms should be included in the model. In  the simple model 
in
te
If it is found that the a
m
02132111 * ββββ +++= XXXXY , let X  be the patients age in years, 
2
21
modifies the effect of treatment. 
1
and indicate whether the patient has received treatment or not, then the 
term , represents an interaction term, the interaction term describes how age 
X
* XX
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 1.5.0 Omission of Important Predictors and Missing Data 
1.5.1 Omission of Important Predictors  
The omission of important predictors can lead to an inaccurate model in the sense that 
estimates of treatment effect will be biased. It may be that some important predicto
of outcome is as yet unidentified, or it is a known predictor and has been omitte
some reason. Randomisation offers a way of reducing the risk of biased estimates for 
the treat
 
r 
d for 
ment effect when important predictors have been omitted for whatever reason.  
 
Missing data will have a bearing on the final model, distorted estimates of predictor 
variables may result from missing data. A variable that appears not to be statistically 
significant due to a high level of missing data, may in fact be of considerable 
predictive value. Missing data may categorised as being missing completely at 
random, missing at random, and missing not at random.  
It is important that the missing data mechanism is identified. For an introduction to 
some of the terminology used in connection with missing data see the website 
operated by LSHT (London School of Hygiene and Tropical Medicine 2008). Missing 
data and imputation will be discussed in Chapter 7. For the present, suffice it to say 
that once the nature of the missing data has been established steps can be taken to deal 
with this problem, i.e. the missing data is imputed. It is important that the correct 
imputation method is applied. Imputation is a complex problem, for a detailed 
treatment of developing prognostic models when missing data is present see (Marshall 
2007). 
 
 
1.5.2 Missing Data  
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 1.6.0 Over-fitting and Optimism 
 
Over-fitting may be described in the following way.  In dealing with a binary 
outcome, for example dead or alive, it may be that interest is focused on predicti
deaths, the ratio of deaths/predictor degrees of freedom can be used to gauge the lev
of what is known as over-fitting. If the number of events of interest is small and a 
large number of independent variables are included it is likely that the model w
over-fitted. It will be found that independent variables are included in the model 
(deemed statistically significant) due to their being ’locally important predictor
validating the model it may be found that these independent variables are not 
significant. In over-fitting a model, noise and localized features in the data attain a 
spurious statistical significance and lead to biased m del. Considering predictive 
accuracy when over-fitting is present, this means that the predictive accuracy of 
model when validated on an external dataset will be seen to deteriorate. The 
predictive accuracy of the model using the data on which it was developed may be 
quite good; yet when the model is applied to a new (but similar) data set it is
that the predictive accuracy is poor in comparison, this is known as optimism or 
statistical optimism.  
1.7.0 Data Reduction and Shrinkage 
 
Data reduction can be described as a means of reducing in the number of independent 
variables that might be included during the modelling process (reduction of the 
dimensions of the data). If an attempt is made to fit a model with 70 variables to a 
data set of 50 patients, then the model will be severely over-fitted. By e loying data
reduction it may be possible to reduce the risk of over-fitting, a classical data 
reduction technique is principal components analysis, see Sharma (Sharma 1995). 
Empirical rules have been arrived at which can be applied to determine if data 
ng 
el 
ill be 
s’. On 
o
the 
 found 
mp  
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 reduction should be used. One such rule for the Cox proportional hazards model is 
based on the ratio 
p
N E  (events per variable), where N   is the numbeE r of uncensored 
umber 
cluded in the model. If  
events, and p  is the predictor degrees of freedom, p can be thought of as the n
of independent variables in 10<
p
N
over-fitting, consequently we should look to performing data reduction, i.e. reduce th
numb r of independent variables that are included in the model, (Peduzzi et al.
provides background on events per variable rules. In a good model a linear 
relationship should be observed between the observed (i.e. new data) and predict
(i.e. predictions made using the original data) values, i.e. YY ˆ
E  there is some risk of 
e 
e  1996) 
ed 
=  (the line has a slope 
of and passes through the origin), departure from a slope of  indicates that 
ver-fitting has occurred. Over fitting is not the only cause o  a departure from the 
slope, for instance if assumptions relating to the error term in the model have 
been violated a departure from will be observed, for example term the error does not 
have a constant variance, the error terms are not independent. This departure from the 
o45 o45
o f
o45
o45 slope due to over-fitting is known as shrinkage, a measure of the shrinkage gives 
a measure of over-fitting. Van Houwelingen and le Cessie (Van Houwelingen & le 
Cessie 1990) have developed a heuristic estimator of shrinkage 2ˆ χ
χγ p−=  , 
2
is the total model log likelihood ratio statistic used in testing for associations here 2χ
between X  and , it can be seen that as  the predictor degrees of freedom Y p
decreases so does γˆ .  
 
Use of the entire data set in developing the model allows for the extraction of 
maximum information, as Harrell (Harrell et al. 1996) points out “data are too 
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 precious to waste”. Outliers or highly influential observations offer some clues about 
possible over-fitting. If for some X  there exist one or two extreme values, it may
that 
 be 
X appears as a significant predictor, these extreme values can lead to the 
le tion of spurious predicto lting in a model that has been over-fitted, the 
mo  
se c rs, resu
del is not general. After validation X  may be found to be not significant, the 
extrem drove’ the modelling process.  
1.8
 
Once a m
earlier that the predictiv
developed m
generally good (Altman & Royston 2000). The model must be validated using new 
data v
that per ed to perform well when 
app d t may appear to have been 
labo e f 
gen l
par f ter 6. Over the years many 
oth t
reliable
accurac
1.9.0 Harrell et al.’s Approach  
 
Harrell et al. (Harrell et al. 1996) have devised a systematic approach to fitting a 
prognostic model which may be summarised as follows: 
 
e values in a particular data set ’
.0 Validation  
odel has been obtained it should be validated using a new data set. I said 
e accuracy of the model for the data on which it was 
ay be quite good, however this is not sufficient to claim that the model is 
, e en if it is found that for the original data the model performs well. A model 
forms well on the original data set is not guarante
lie  to a new but similar set of patients. This poin
ur d somewhat, but it is crucial when fitting a model we have in mind the idea o
era isabilty. Bootstrapping, validation, calibration and discrimination (component 
ts o  predictive accuracy) will be discussed in Chap
er s atisticians have been engaged in research into the problem of producing 
 models that do not suffer from gross over-fitting and possess good predictive 
y. I shall now briefly outline some of this work   
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 • Obtain an accurate and large sample of data. 
issing is 
te 
e 
 sample to 
m transfo . 
s. 
ab e. 
 backward stepdown variable selection. 
nt 
lifying 
• Formulate a sharp hypothesis. 
• Discard observations with missing Y, provided Y missing at random. 
• For missing X investigate factors related to missingness, if the number of 
observations   that would be excluded is small or variable that is m
unimportant, then exclude observations with missing values. Otherwise impu
missing X. 
• If the number of variables included in the model is large in comparison to th
number of events of interest, use data reduction. 
• Use the entire develop the model. 
• Check linearity assumptions and perfor rmations on Xs if required
• Check additivity assumptions, include clinically motivated interaction term
• Check for outliers or influential observations. 
• Check distributional assumptions, for Cox Proportional Hazards model, 
proportional hazards assumption, if violated include time dependent vari l
• Perform
• Variables obtained from stepdown procedure form the final model. 
• Validate model using the bootstrap. 
• If using stepwise variable selection, supply a Table showing how importa
predictors vary over the bootstrap samples. 
• Estimate shrinkage. 
1.10.0 Ambler, Brady and Royston’s work 
 
Ambler, Brady and Royston have investigated methods for estimating and simp
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 full models (Ambler et al. 2002). In (Ambler et al. 2002) the authors aim to produce 
simplified models that retain their prognostic power. Based on simulation studies 
using two different data sets, Ambler et al state that the results of model 
mplification based on the stepdown variable selection, using maximum likelihood 
and penalised maximum likelihood depended upon whether or not all the independent 
variables (predictors) were influential. Harrell advocates limited variable selection 
based on the stepdown method. The stepdown method makes use of the idea of a 
prognostic index, if are independent variables then the prognostic index is 
a linear combination of , i.e. 
si
pXXX ..., 21
p21 ppXXX ..., XaXaXa +++ ...2211
ombina
. Regression of the 
linear c tion on the independent variables results in a perfect fit, 12 =R , if any 
of the independen 2R  will decrease. A simplified t variables are omitted, then 
mX  pro o bination formed by removing the 
which causes the smallest d e
gn stic index is defined as the linear com
ecreas  in 2R , this process is carried out until further 
removals of mX  would result in α<2R , where α  is a predefined value for 2R . 
Ambler et al suggest the Akaike Information Criteria (AIC) provides a good way of 
selecting a simplified model, the background to the AIC will be presented in C
5. ). In my review of Harrell’s approach I referred to events per variable, and ho
reducing p it is possible to avoid over-fitting. Models produced using a criterion such 
as 
hapter 
w by 
10<N E
p
n as full m lexity or size of the model is 
. Ambler et al make a very 
 are know odels, the comp
determined by the number of events of interest in the data
important point; full models are liable to be very complex when we have data 
containing a large number of observations and a large number of possible predictor 
variables. Large and complex models have attached to them financial and practical 
drawbacks. This may be seen as a drawback to Harrell’s approach.  
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 1.11.0 Van Houwelingen’s work 
Hans C. van Houwelingen describes methods fo
 
r determining the predictive accuracy 
evelops what he calls validation by calibration; he illustrates this method by the 
following example using simple linear regression: 
•  Fit , then  is the calibrated model. 
Van Houwelingen explains that his strategy is to compare a particular model with the 
new (validation) data set and not a new model obtained from the validation data set. 
From a theoretical perspective his method is appealing in its simple and clean 
approach. Van Houwelingen proposes a method whereby the Cox proportional 
hazards and the non-proportional hazards model may be calibrated (van Houwelingen 
2000).  
 
ing Harrell’s approach. 
of prognostic survival models; see (van Houwelingen 2000). Van Houwelingen 
d
•  Plot Y  against elXY mod  for new data. 
•  If YY ˆ=  appears to hold (points lie on o45  line through (0,0) ), then model is 
valid. 
•  If  YY ˆ= does not appear to hold (points do not lie on o45  line through 
• (0,0)), correct model by calibration. 
ˆ β′=
eYY ++= ˆβα YYcal ˆˆˆ βα +=
1.12.0 Extension of Cox Proportional Hazards Model 
Initially I shall develop a prognostic survival model using Cox Proportional Hazards 
model, in a later Chapter I will look at how Cox Proportional Hazards model can be 
extended to deal with heterogeneous data through the use of frailty (Vaupel et al. 
1979). The frailty model is an interesting advance in modeling. Harrell et al’s 
approach as far as this author is aware does not address frailty. In Chapter 8 I attempt 
to fit a frailty model us
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 1.13.0 Current Modelling Strategies 
 
Are issues such as over-fitting and specification of functional form for a prognostic 
model routinely addressed? Has the approach suggested by Harrell been widely 
adopted? I have carried out an informal survey of three journals; BMJ, JAMA and 
Circulation. Papers were selected from these journals based on the key words such as 
prognostic, survival, Cox model, and risk score. It appears that over-fitting is not 
routinely addressed. Where it might be appropriate specification of functional form 
using cubic splines or fractional polynomials is not widely adopted practice.    
 
 It is hoped that the reader may glean some practical guidance on how to employ 
Harrell et al’s approach, and perhaps become aware of some of the difficulties that 
can arise. If by reading this thesis the reader who may not be a statistical expert, 
acquires a better understanding of the important issues surrounding the development 
of a prognostic model then I would have accomplished a main objective. That 
 steps to ensure that the chances of over-fitting a model are 
onsider 
n 
Failure 
everyone should take
minimised is of course highly desirable.  However it may be worth trying to c
some of the natural and inherent limitations to the statistical method. There is no 
correct model, every model is an approximation; to quote G.E.P Box, "Essentially, all 
models are wrong, but some are useful.” (Box & Draper 1987). The whole question of 
generalizabilty is a complex one. Should we expect to achieve more general results i
the physical sciences? In the next Chapter I shall consider the development of a 
prognostic survival model for the Cardiac Resynchronization Therapy in Heart 
(CARE-HF) data set.  
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 CHAPTER 2 THE CARE-HF STUDY 
 
7). T
ctors that 
 
2.0.0 Introd
• Ca
pat
• Wh
res
• To
• Isc
ind
car
• Sy  
as 
In this work
Resynchron
randomized
of follow-up
al. 200
fa
resynchroni
patients who
responders)
may determ
 rdiac resynchronization therapy significantly reduces mortality in 
ients with heart failure 
at patient characteristics may modify the effects of cardiac 
ynchronization therapy? 
 investigate treatment modifiers a prognostic model is developed 
haemic aetiology, more severe MR, and increased NT-pro-BNP were all 
ependent predictors of an increased risk of death or unplanned 
diovascular hospitalization irrespective of randomised treatment (CRT)  
stolic blood pressure and Interventricular mechanical delay are identified
treatment modifiers ction 
hese attributes make it a valuable resource for the investigation of those 
predict the likelihood that a patient will or will not respond to cardiac 
t (non 
 
u
 a prognostic model was fitted to data obtained from the Cardiac 
isation in Heart Failure Trial (CARE-HF). CARE-HF is one of the largest 
 studies of cardiac resynchronization therapy (CRT), has a longer duration 
 than any other, and has a robust primary clinical endpoint (Richardson et 
sation therapy (CRT). Clinicians view CRT in the context of those 
 will derive benefit from CRT (responders) and those who will no
. If a patient is in receipt of CRT what characteristics of that individual 
ine the likelihood of them receiving benefit from the treatment? This leads
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 us (Richardson et al. 2007) to consider treatment modifiers, i.e. those patient 
attributes that modify the effect of CRT. CRT is a treatment that aims to restore and 
improve cardiac function in patients who suffer electrical conduction problems in the
heart as a result of heart failure (Medtronic 2009). Heart failure is a common and
serious condition with a complex and varied pathophysiology (Cleland et al. 1999). A 
substantial minority of patients with heart failure due to left ventricular (LV) sys
dysfunction have prolonged QRS, QRS represents ventricular depolarisation and 
amongst these patients there is a high prevalence of cardiac dyssynchrony, which 
leads to a decline in cardiac efficiency through diverse mechanisms, see (Xiao et al. 
1993), (Daubert et al. 1999) and (Auricchio et al. 1999). For patients with heart 
failure due to cardiac dyssynchrony who have persistent moderate or severe 
symptoms despite standard pharmacological therapy, CRT improves cardiac functio
leading to an improvement in well-being and a reduction in morbidity and mortality, 
see (Abraham et al. 2002),(Bristow  et al. 2004),(Cleland et al. 2005) and (Freemantl
et al. 2006). 
 
 
tolic 
n 
e 
RT is delivered by means of a physical device akin to a pacemaker, see (Medtronic 
09). The aim of this analysis was to evaluate the relationship between prospectively 
defined clinical, echocardiographic and neurohormonal variables, collected at baseline 
uring the CARE-HF trial, on overall outcome in all patients and on the response to 
RT. 
 
The prognostic model presented in this work, is that developed by Richardson, 
Freemantle, Calvert, Cleland and Tavazzi (Richardson et al.  2007) based on 
Individual patient data collected during the CARE-HF trial. The design and results of 
the CARE-HF study have been reported previously (Cleland et al. 2005), (Cleland et 
C
20
d
C
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 al. 2001). In brief, the CARE-HF trial enrolled 813 patients recruited from 82 centres 
cross Europe. Eligible patients were at least 18 years of age, had evidence of heart 
ilure for at least 6 weeks, and were in New York Heart Association class (NYHA) 
I or IV despite receipt of standard pharmacologic therapy, with a LV ejection 
action (EF) of < 35%, a LV end-diastolic dimension of ≥ 30 mm (indexed to height), 
nd a QRS interval of > 120 ms on the electrocardiogram. Patients with a QRS 
terval of 120–149 ms were required to meet two of three additional criteria for 
 of more than 140 ms, an interventricular 
 
 
 
 a 
 
a
fa
II
fr
a
in
dyssynchrony: an aortic pre-ejection delay
mechanical delay (IVMD) of > 40 ms, or delayed activation of the posterolateral LV
wall. The IVMD was calculated as the time difference between the onset of forward
flow in the LV (APET) and RV (PPET) outflow tracts: IVMD =APET – PPET (Ghio
et al. 2006). A total of 409 patients were randomized to CRT and medical therapy, 
whereas 404 received medical therapy alone (Richardson et al.  2007). The primary 
outcome was the time to death from any cause or an unplanned hospitalization for
major cardiovascular event. Patients were followed up for a mean of 29.4 months. 
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2.1.0 Developing the Prognostic Model 
A number of potentially important clinical, echocardiographic, and neurohormo
variables collected at baseline were specified a priori for evaluation in a prognostic 
model. These were mitral regurgitation (MR), en
 
nal 
d-systolic volume index, aetiology 
schaemic and non-ischaemic disease), EF, use of beta-blockers, age, QRS interval 
RS), supine systolic blood pressure (SBP), glomerular filtration rate, N-terminal 
ro-brain natriuretic peptide, as determined by Roche Assay (NT-pro-BNP), and 
 in 
 to death 
ox 
Hosmer 
ch 
(i
(Q
p
IVMD ,see (Talwar et al. 1999), (Pitzalis et al.. 2005), (Doust et al. 2005).  MR was 
defined as area of colour flow Doppler regurgitant jet divided by area of left atrium
systole, both in square centimetres. The primary composite outcome was time
from any cause, or an unplanned hospitalization for a major cardiovascular event. C
Proportional Hazards models were fitted to identify predictors of risk of death from 
any cause or an unplanned hospitalization for a major cardiovascular event (main 
effects) and to identify any predictors modified by cardiac resynchronization (
& Lemeshow 1992) and (Lee 1992) ,the SAS code for producing theses models is to 
be found in Appendix 1.0.0. The modelling strategy was based upon the approa
suggested by Harrell et al 1996, see Chapter 1 for an introductory discussion of 
Harrell's approach. In order to evaluate whether any of the variables had a non-linear 
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 relationship with outcome, transformations of each variable using the natural 
logarithm and cubic spline were assessed (Herndon & Harrell 1990), (Wegman & 
Wright 1983), (Poirier 1979), (Smith 1979) and (Royston 2000) see Chapter 4 for a 
further discussion of cubic splines, SAS code used for fitting cubic splines is to be 
found in Appendix 1.0.0.  The Akaike Information Criterion (AIC) was used to 
determine the most appropriate transformation (Akaike 1974), see Chapter 5 for a 
more detailed discussion of the AIC. The validity of any transformations was furt
assessed by examining plots of the cumulative Martingale residuals versus the
transformed variable (Verweij et al. 1998), (Therneau & Grambsch 1990). The 
proportional hazards assumption was also assessed. Statistically significant variables
identified from univariate analyses (Table 2.2). 
 
 
 
All analyses were performed in SAS v 9.1 using the PHREG procedure and th
macro (Heinzl & Kaider 2006). The RCS macro was used to fit cubic splines with 
four knots, Herndon and Harrell (Herndon & Harrell 1990) suggest based on 
empirical studies, that 4 knots are sufficient to model most data, this point will be 
considered further in Chapter 4. For the continuous variables, with the knot positions
specified PHREG was then used to generate a model from which it was possib
determine whether the cubic spline was an appropriate transformation for the 
particular variable concerned. All analyses were undertaken according to the intent
to treat principle, i.e. the effect of a treatment is assessed based on the planned 
treatment rather than the actual treatment (ICH E9. 1999). In a clinical trial use of 
intention to treat principle allows for an unbiased estimate of the effect of a treatment 
her 
 
 
e RCS 
 
le to 
ion 
the 
 - 24 -   
 in situations where a number of patients may not adhere to the treatment programm
Alternative approaches are to e
them in the group the treatment group, this approach lead
e. 
xclude those patients who do not adhere or to include 
s to a biased estimate of the 
treatment effect (Montori & Guyatt 2001). To validate the final model two further 
teps were taken. First, a bootstrap revalidation process was used to estimate the 
ess (Har
library in the statistical package R was used to undertake this validation (Design 
Library Harrell Frank E. 2009a). Second, multiple imputation using the SAS 
procedures MI (SAS Institute. 2009), and MIANALYSE were employed to examine 
t must be 
a ed with identifying possible tre m  
 
presented in (Richardson et al. 2007) a  
odifiers where the prim
not claim that this approach is the right way. Those variables identified to be 
significantly (P< 0.05) associated with the primary composite outcome (time to death 
from any cause, or an unplanned hospitalization for a major cardiovascular event) 
were entered in a multivariable Cox Proportional Hazards model using a forward 
forward selection procedure was 0.05, meaning a variable has to be significant at the 
s
degree of over-fitting from the model fitting proc rell et al. 1996). The design 
the effect of missing data on the final model.  In (Richardson et al. 2007) i
stressed th t the authors were concern at ent modifiers
i.e. interactions with CRT. The approach to identifying possible treatment modifiers
nd this thesis are open to question and 
criticism. It can be argued that if there is a genuine interaction between CRT and 
another independent variable then this interaction will be identified using the 
conventional approach of first fitting main effects and then going on to fit interaction 
terms. The approach to identifying interaction terms adopted in this thesis had been 
employed in previous work and was suggested to myself as a way of dealing with fact 
that treatment m ary concern as opposed to main effects. I do 
stepwise selection to obtain the final model (Table 2.3). The entry criteria for the 
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 0.05 level before it can enter the model. When using a forward selection method I 
start by fitting the Cox models )exp()( 0 ii Xyh ββ += , where i= (1,2…,m),  m is the 
number of independent variables, i.e. I have the models 
)exp()( 110 Xyh ββ += , )exp()( 220 Xyh ββ += ,…, )exp()( 0 mm Xyh ββ += . 
 
For each of these models once the p-value p for was determined, I can identify 
i
iX
candidate variables for inclusion in the model by considering all  whereX α<p , α  
being a prescribed significance level. If there are several iX  that satisfy α<p , then I 
select kX , where kX is the  iX  with the smallest p-value from amongst the 
candidate iX s. We then fit the models )exp()( 0 iikk XXyh βββ ++= , ki ≠ . From 
these models the iX that has the smallest p-value (denoted lX  ) is included i.e. I now
have )exp()( XXXyh
 
k0 iillk ββββ +++=   liki ≠≠ , . This process is repeated 
until there are no independent variables left. In the forward selection method a 
variable will remain in the model no matter what new variables are included. In the 
is refined in the following way. The p-value p of each independent variable that is 
forward stepwise selection procedure the fo
already included in the model is examined at each step. If  is greater
rward selection procedure described above 
p α  , then kX is 
rem odel. Also, if has been removed previously from the model it 
a  is less than 
oved from the m kX
y re-enter if p αm , but it may re-enter only once, it cannot enter more 
e. In forward stepwise selection I start by fitting the 
models
than twic
)exp()( 110 Xyh ββ += , )exp()( 220 Xyh ββ += ,…, )exp()( 0 mm Xyh ββ +=  
these models will under-fit the data. Harrell suggests that the ‘limited’ backward 
ion be employed; it is claimed that this method has advantages over the stepwise select
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 forward stepwise selection, a comprehensive discussion on backward methods can be 
(Beale 1970) offers some interesting cr  of
Mantel’s arguments. In ba k rd stepw ction I star ith the fu
tter  po t. The choice between backward or forward 
n my v a matt  the idua earcher, ould
 considering the fact that all autom
s, including backward ds can be criticised as 
odels. Ira Berstein ha ethods as “data 
ch s”, (Ul  1997 l ough su sting 
ise ction (Harrell e 996 nts out t tepw
ver- g, and mme  v bles are ined 
e 
epwise selection method. This appears strange, variables that are not statistically 
ber of 
 does 
found in (Mantel 1970). Beale iticism  
c wa ise sele t w ll model, which 
it could be argued is a be  starting in
stepwise selection is i iew er for  indiv l res  it w  be 
misleading to dismiss forward selection without atic 
variable selection method metho
producing suspect m s described Stepwise m
driven variable selection s eme rich ), Harre l alth gge that a 
researcher perform stepw  sele t al. 1 ) poi hat s ise 
methods do not tackle o fittin reco nds that aria reta in the 
model irrespective of their p-values, as this leads to a model with better 
discriminatory power compared to a model produced solely on the basis of th
st
significant and might be regarded as being redundant are important in terms of the 
discriminatory power of the model (they may be clinically significant). Forward 
stepwise selection is useful in situations where I might wish to fit a large num
interactions. Which selection method is best? A definite answer to this question
not appear to exist. All variable selection procedures posses some defect, and so 
whichever method a researcher adopts he or she must carefully examine the final 
model and perform some type of validation. 
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2.2.0 Results 
The baseline characteristics of patients from the CARE-HF trial are shown in Table 
.1. 
 
Table 2.1 Baseline characteristics of patients total number in study N=813 
tes for Table 2.1 IQR (interquartile range). Mitral regurgitation defined as area of colour flow 
oppler regurgitant jet divided by area of left atrium in systole, both in square centimeters. 
These data are consistent with the patients having, on average, moderate to severe LV 
systolic dysfunction, dilatation and dyssynchron it a e, 
renal dysfunction. About 40% of patients had is art failu
i yses were used to ide y those variables that were 
s e to death from ause, or n
h vent) irre ive of tre o
       
2
 Control   Treatment   
 n median (IQR) n median  (IQR) 
Age (years) 403 66 (59–72) 409 67 (60–73) 
Aetiology (ischaemic Y/N) Y=153 
N=250 
  Y=186 
N=223 
  
Sys
(m
tolic blood pressure 
mHg) 
399 110 (100–
125) 
404 110 (100–
125) 
Glomerular filtration rate 
L/min/1.73m2) 
372 61 (46–73) 367 60 (46–73) 
(m
N-terminal pro-brain 
atriuretic peptide (pg/ml) 
370 1806 (719–
3949) 
362 1920 (744-
4288) n
Use of beta-blockers (Y/N) Y=288 
N=116 
  Y=298 
N=111 
  
QRS width (ms) 394 160 (152–
180) 
401 160 (152–
180) 
In
delay (m
terventricular mechanical 
s) 
370 50 (30–66) 365 49 (32–67) 
E
(m
nd-systolic volume index 
L/m2) 
376 117 (94–
147) 
356 121 (92–
151) 
Ejection fraction (≤ 35%) 378 25 (22–29) 367 25 (21–29) 
Mitral regurgitation 303 23 (11–34) 302 21 (12–33) 
 
No
D
 
 
y w h a low arteri l pressur and 
chaemic he re due to 
schaemia. Univariate anal ntif
ignificant predictors of outcome (tim any c an unplan ed 
ospitalization for a major cardiovascular e , spect atment all cation, 
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 and those variables shown to predict response to CRT (indicated by the CRT * 
v .2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ariable interaction term) (Table 2
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 n Hazard ratio  95% CI  P-value 
     
Mitral regurgitation 605 2.14 1.68–2.71 0.0001  a  
CRT   1.85 0.59–5.08 0.2938 
CRT *  Mitral regurgitation  0.72 0.50–1.02 0.0670  a
 
 
 
   
Interventricular mechanical delay (ms) 735 0.99 0.99–1.00 0.0028 
CRT  0.92  0.62–1.36 0.6784 
CRT * Interventricular mechanical delay (ms)  0.99  0.99–1.00 0.0473 
 
 
 
   
End-systolic volume index (mL/m2) a 732 1.52  1.08–2.14 0.0175 
CRT    0.62 0.04–9.88 0.7354 
CRT * End-systolic volume index (mL/m2) a   1.00  0.5 –1.77 0. 78 6 99
 
   
 
 
Glomeruler filtration rate (ml/min/1.73 m2) 739 0.99  0.9 –0.99 0. 05 8 00
CRT    0.74 0.3  0.3964 8–1.48
CRT * Glomeruler filtration rate (ml/min/1.73  1.00 0.9  0.m2)  9–1.01 5811 
 
 
 
   
Systolic blood pressure (mmHg) 803 0.99 0.9  0.0011 8–1.00
CRT    0.14 0.0  0.3–0.63 0097 
CRT * Systolic blood pressure (mmHg)   1.01 1.0  0.0–1.03 0491 
 
 
 
   
Ejection fraction (%)a 745 0.38  0.2 6 0.2–0.6 0006 
CRT   0.38 0.0  0.2–5.44 4298 
CRT * Ejection fraction (%)a   1.24  0.5 –3.03 0. 41 1 63
 
 
 
   
 
N-terminal pro-brain natriuretic peptide (pg/m
732 
1.47 1.3  0.L) a  1–1.66 0001 
CRT     0.33 0.08–1.37 0.1275 
CRT *  
n natriuretic peptide (pg/mL) a  
 
1.08 0.91–1.29 0.3833 N-terminal pro-brai
 
 
 
   
Age (years) 813 1.02 1.01–1.04 0.0011 
CRT   0.87 0.21–3.6 0.8416 
CRT * Age (years)   1.00  0.97–1.02 0.6400 
 
 
 
   
schaemic (yes/no) 812 1.68 1.I 29–2.19 0.0001 
CRT    0.48 0.35–0.66 0.0001 
CRT * Ischaemic (yes/no)   1.49 0.99–2.26 0.0583 
Table 2.2 Potential predictors of risk: results of univariable analyses 
Notes for Table 2.2  
ce 
or absence of CRT. The term CRT * log(MR) is a treatment modifier, this means that the beneficial 
a = loge transformed, * denotes an interaction 
 
Mitral regurgitation represents the results of fitting single Cox Proportional Hazards model, a patient’s 
time to the primary event being assumed to be dependent on mitral regurgitation and also the presen
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 effect of CRT may be reduced or increased depending on the patients level of mitral regurgitation. 
log(MR) > 0.05 so mitral regurgitation does not significantly change the benefit a patient may recei
from CRT.  
 
The most appropriate transformation of each variable is indicated (for example a 
logarithmic transformation led to the best model fit based on the AIC for MR). T
remaining variables (beta-blocker use and QRS width) were not significantly 
associated with outcome and did not predict response to CRT. Those variables 
identified to be significantly (P < 0.05) associated with the primary composite 
outcome, time to death from any cause, or an unplanned hospitalization for a major 
cardiovascular event were entered in a multivariable Cox Proportional Hazards model
(Table 2.3) 
 
 
 
Mitral regurgitation is a significant predictor of outcome, P < 0.0001, however, the P-value for CRT * 
ve 
he 
 
 
 
    
 
Transformati
on 
 Hazard 
ratio 
 95% 
CI 
 P-
value 
Significant Predictors of overall outcome     
Mitral regurgitation    Loge 1.71 
1.38–
2.12 0.0001 
N-terminal pro-braina natriuretic peptide 
(pg/ml)   Loge 1.31 
1.17–
1.47 0.0001 
Systolic blood pressure (mmHg)    Linear 0.99 
0.98–
1.00 0.0698 
Interventricular mechanical delay (ms)   Linear 1 
0.99–
1.01 0.7617 
Aetiology (ischaemic) (yes/no)    Factor  1.89 
1.45–
2.46 0.0001 
CRT (yes/no)  Factor   0.608 
0.47–
0.79 0.0003 
Predictors of response to CRT     
Systolic blood pressure (mmHg)*CRT Linea
1.00–
r 1.02 1.03 0.0183 
Interventricular mechanical delay 
Linear 0.99 
0.98–
(ms)*CRT 1.00  0.0084 
Table 2.3 Significant Predictors of outcome and response to CR
itral regurgitation and N-terminal pro-brain natriuretic peptid have been iden fied as statistically 
gnificant predictors of outcome. The terms CRT * SBP T * IVMD rep nt modifiers  
essure and in mechanic
 the beneficial effect of CRT. The P-values for CR  * S  CRT * I <
rventricular nical dela lly
T 
 
Notes  for Table 2.3  
M
si
e 
R
ti
reseand C
terven
of
response to CRT, i.e. both systolic blood pr tricular al delay may 
modify T BP and VMD are both  
0.05,indicating that systolic blood pressure and inte  mecha y are statistica  
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 significant. Note that individually systolic blood pressure r interventricular mechanical delay are 
atistically significant, in other words they are not predictors o tcome. The P-value for CRT  
sion of the CRT f he model
nd incr d ro-BNP
ned planned l
ised treat  (CRT) (Hazard ratio (HR) 1.89, 
CI 1.38 to .12 a  1.31,  t
.47, respectively) and increasing SBP with a decreasing risk of an event (HR 0.99, 
I 0.98 to 1.00) (Figure 2.1A–E). Note, in igures 2.1A-E refer to median 
alues, for the combined data, i.e. the median for the treatment and control groups 
RT*Interventricular Mechanical Delay nd C ystolic r
le, orthogonalization 
nuous variables and re-coding of the a iables c t
raction terms. A Continuous aria
 no
st f ou is
relatively large (0.0347) due to the inclu  modi iers in t . 
 
 
Ischaemic aetiology, more severe MR, a ease  NT-p  were all 
independent predictors of time to death or unplan  or un  cardiovascu ar 
hospitalization irrespective of random ment
95% CI 1.45 to 2.46, HR 1.71, 95% 2 nd HR 95% CI 1.17 o 
1
95% C  F
v
combined. The prognostic model for the CARE-HF data includes two interaction 
terms C a RT*S Blood Pressu e. 
These interaction terms involve a continuous and a binary variab
of the conti  bin ry var an be of grea  help 
in interpreting inte  v ble X is transformed in the 
following way XX − , a binary variable - as 0.5 a l
iate analyses as in Tab  2.2 ntinuou a
T is much more stable across the univariate models compared with 
 
 
 
 
 
)0,1(I is re coded nd -0.5 . Tab e 2.2a 
presents the same univar le  but co s variables h ve 
been transformed as described above along with re-coding of binary variables. The 
hazard ratio for CR
those presented in Table 2.2   
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 n Hazard ratio  95% CI  P-value 
     
Mitral regurgitation a 605 1.807 1.511 - 2.610 <.0001 
CRT   0.692 0.541 - 0.883 0.0031 
CRT *  Mitral regurgitation a  0.716 0.501 - 1.024 0.0670 
 
 
 
   
Interventricular mechanical delay (ms) 735 0.989 0.985 - 0.992 <.0001 
CRT  0.632 0.507 - 0.787 <.0001 
CRT * Interventricular mechanical delay (ms)  0.992 0.985 - 1.00 0.0473 
 
 
 
   
End-systolic volume index (mL/m2) a 732 1.515  1.138 - 2.018 0.0044 
CRT    0.618  0.497 - 0.768 <.0001 
CRT * End-systolic volume index (mL/m2) a   0.999  0.564-1.771 0.9978 
 
 
 
   
Glomeruler filtration rate (ml/min/1.73 m2) 739 0.986 0.980 - 0.991 <.0001 
CRT    0.611 0.489 - 0.764 <.0001 
CRT * Glomeruler filtration rate (ml/min/1.73 m2)   0.997 0.986 - 1.008 0.5811 
 
 
 
   
Systolic blood pressure (mmHg) 803 0.993 0.987 - 1.00 0.0364 
CRT    0.631 0.513 - 0.775 <.0001 
CRT * Systolic blood pressure (mmHg)   1.013 1.00 - .025 0.0491  1
  
    
Ejection fraction (%)a 745 0.422 0.270 - 0.659 0.0002 
CRT   0.639 0.516 - 0.792 <.0001 
CRT * Ejection fraction (%)a   1.242 0.509 - 3.028 0.6341 
  
    
 
N-terminal pro-brain natriuretic peptide (pg/mL) a  
732 
1.534 1.403 - 1.676 <.0001 
CRT     0.593 0.470 - 0.750 <.0001 
CRT *  
N-terminal pro-brain natriuretic peptide (pg/mL) a  
 
1.082 0.906 - 1.292 0.3833 
 
 
 
   
Age (years) 813 1.021 1.011 - 1.032 <.0001 
CRT   0.621 0.506 - 0.763 <.0001 
CRT * Age (years)   0.995 0.974 - 1.016 0.6400 
 
 
 
   
Ischaemic (yes/no) 812 2.058 1.671 – 2.534 <.0001 
CRT    0.589 0.478 - 0.725 <.0001 
CRT * Ischaemic (yes/no)   1.494 0.986 – 2.263 0.0583 
 
Table 2.2a Results of Orthogonalization Potential predictors of risk: results of univariable analyses 
a = loge transformed, * denotes an interaction  
Notes for Table 2.2a  
Mitral regurgitation represents the results of fitting single Cox Proportional Hazards model, a patient’s 
time to the primary event being assumed to be dependent on mitral regurgitation and also the presence 
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 or absence of CRT. The term CRT * log(MR) is a treatment modifier, this means that the beneficial 
effect of CRT may be reduced or increased depending on the patients level of mitral regurgitation. 
Mitral regurgitation is a significant predictor of outcome, P < 0.0001, however, the P-value for CRT * 
log(MR) > 0.05 so mitral regurgitation does not significantly change the benefit a patient may receive 
from CRT.  
 
 
 
 
(A) 
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(F) 
Figure 2.1 (A) Time to first primary event by systolic bl sure. (B) Time to first primary event 
by interventricular m elay. (C) Time to first ary event by aetio gy (ischae
Time to first primary by mitral regurgitation e to first prim ent by N- a
brain natriuret  Time to first pri  by Cardi nchronis
 
 
Only two variables, IVMD and SBP predicted response to CRT, with modest 
statistical precision (Figures
receive reduced benefit from CRT (HR 1.02, 95% CI 1.00–1.03), whereas those 
pa ar to benefit more from treatment (H
95%
 
ood pres
echanical d
 event 
prim
. (E) Tim
lo
ary ev
mia). (D) 
termin l pro-
ic peptide (pg/ml).(F) mary event ac Resy ation 
 2.2 and 2.3). Patients with increasing SBP appear to 
tients with more severe IVMD appe R 0.99, 
 CI 0.98–1.00). 
 
 
 
 
 
 
 
 
 
 It is important that the validity of the proportional hazards assumption is assessed. 
option in PHREG is used to test the 
proportional hazards assumption for the e
 
The following SAS code shows how the ASSESS 
final mod l. 
ods graphics on; 
   proc progex3; phreg data=card.
      class Ischemic treat /desc; 
 tre ra ch s       model futime*primary(0)= at mit l_r Ro e supsy  IVMD   
Ischemic trsup trivm; 
      assess PH/  resample seed=7548; 
      run; 
ods graphics off; 
 
 
In the above code assess PH specifies that proportional hazards assumpti te
Tab pe sup  te opo  ha
produced by ESS uses the s o in & Y 9
From Table 2.4 there is some evidence that the proportional hazards assumption is 
ption. The non proportional hazards for CRT could be 
ealt with by fitting a model with a time dependent variable, this could be achieved by 
introducing the term CRT*loge (time) .The time dependent variable must be defined 
after the model statement in PHREG .The results of fitting this model are shown in 
Table 2.5. Since the main objective of the model presented in this thesis is to identify 
modifiers of CRT and not to determine the effect of CRT itself, it might be argued 
hat the non proportional hazards for CRT could be ignored and that the model 
resented in Table 2.3 would be adequate for the purposes of identifying modifiers of 
CRT. Another approach to accommodating non proportional hazards would be to 
develop a stratified model, the strata being the variable for which proportional hazards 
is violated. This approach is valid if the stratification is based on a variable which is 
not of primary interest.   
on are sted, 
le 2.4 shows the Kolmogorov ty remum st for pr rtional zards 
 ASSESS, ASS  method f Lin  (L , Wei ing 19 3). 
violated for CRT (p=0.0380). The remaining variables appear not to violate the 
proportional hazards assum
d
t
p
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Supremum Test for Proportional Hazards Assumption 
Variable Maximum 
Absolute 
Value 
Replications Seed p 
CRT 1.4477 1000 7548 0.0380 
Mitral regurgitation  0.9270 1000 7548 0.3620 
N-terminal pro-brain natriuretic peptide 
(pg/ml) 
0.7351 1000 7548 0.6200 
Systolic blood pressure (mmHg) 0.9699 1000 7548 0.2390 
Interventricular mechanical delay (ms) 0.8972 1000 7548 0.5110 
Aetiology (ischaemic Y/N) 0.9108 1000 7548 0.3930 
7548 0.9030 
Interventricular mechanical delay 
(ms)*CRT  
1.0169 1000 7548 0.3300 
Table 2.4 Tes gitation and N-
nal pro-brain natriure e re s
 
 
Systolic blood pressure (mmHg)*CRT  0.4964 1000 
 
t of Proportional Hazards (Note Mitral regur
termi tic peptid  (pg/ml) a  loge  tran formed) 
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  Parameter Standard Chi-
Estim o  
p Hazard
Ratio 
0.69621 0.58332 1.4245 0.2327 2.006 
i  0.54294 0.10870 24.9468 <.0001 1.721 
natriuretic peptide 
(pg/ml) 
0.27144 0.05912 21.0796 <.0001 1.312 
Systolic blood pressure (mmHg) -0.0002648 0.00369 0.0051 0.9428 1.000 
Interventricular mechanical delay (ms) -0.00528 0.00255 4.2932 0.0383 0.995 
Aetiology (ischaemic Y/N)i 0.62633 0.13515 21.4765 <.0001 1.871 
Systolic blood pressure (mmHg)*CRT 0.01723 0.00727 5.6161 0.0178 1.017 
Interventricular mechanical delay 
(ms)*CRT 
-0.01202 0.00497 5.8433 0.0156 0.988 
CRT*loge (time) -0.22803 0.10857 4.4116 0.0357 0.796 
able 2.5 Model with time dependent variable CRT*loge (time) (Note Mitral 
rain natriuretic peptide (pg/ml) are loge  
ansformed) 
 
 
 
 
 
ate Err r Square
CRT 
Mitral regurg tation
N-terminal pro-brain 
 
T
regurgitation and N-terminal pro-b
tr
 
. 
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 Figure 2.2 Time to first primary event by systolic blood pressure (mmHg) and cardiac 
resynchronization therapy. 
Number at risk Systolic Blood Pressure (SBP) 
 
 
 
SBP 1 Month 3 Months 6 Months 12 Months 
<117 (mmHg) without CRT 198 173 154 125 
<117 (mmHg) with CRT 193 179 166 141 
>117 (mmHg) without CRT 186 171 161 133 
>117 (mmHg) with CRT 191 181 167 147 
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Figure 2.3 Time to first primary event by interventricular mechanical delay (ms) and cardiac 
 
Number at risk Interventricular Mechanical Delay (IVMD) 
resynchronization therapy. 
IVMD 1 Month 3 Months 6 Months 12 Months
<49 ms without CRT 202 179 164 130 
<49 ms with CRT 213 194 179 145 
>49 ms without CRT 181 165 151 128 
>49 ms with CRT 176 169 159 147 
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2.2.1 Discussion 
he CARE-HF trial demonstrated that CRT exerts a substantial reduction in 
morbidity and mortality with little evidence of heterogeneity in pre-defined subgroups 
(Cleland et al. 2005). This more detailed analysis provides evidence that IVMD and 
to a lesser extent SBP predict a patients’ response to CRT. These finding must be 
treated with a degree of caution as the model is exploratory and the interactions 
between CRT and either IVMD or SBP were not strong. However, the observed 
teraction between IVMD and the effects of CRT are consistent with the view that 
cise physiological marker of cardiac dyssynchrony, the problem 
refore 
 
 
 
 
T
in
IVMD is a more pre
that CRT is designed to treat, than any other variable analysed. IVMD could the
potentially be used as an inclusion criterion in future randomized controlled trials 
examining the effects of CRT in patient populations not included in CARE-HF, such
as patients with less severe symptoms or with shorter QRS intervals. Whether IVMD
should now be used in preference or in addition to QRS duration to identify whether a 
patient should receive CRT is a matter for the individual clinician to decide and for 
future research. It is of great importance to note that IVMD is the best predictor of 
response to CRT in a population having large volumes, low EF, and broad QRS. We 
cannot state that IVMD is a better predictor of response to CRT in other populations 
(Ghio et al. 2004). 
 
Patients recruited to the study had severe heart failure (NYHA class III–IV) and 
therefore had an inherently high risk of experiencing the primary outcome during the 
study follow-up (which ranged from 18 to 44.7 months). The hazard functions from 
the model are based upon prediction of event rates across the maximum follow-up
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 from the study, which had reached 55% in the control group a mean 29.4 months of 
follow-up. In order to estimate the absolute risk of an event with changing SBP and 
IVMD, the remaining clinical predictors were held constant. It is important to not
that since these are also strong clinical predictors of outcome changing these val
from the median has a large impact on the estimates of absolute risk. For example, 
a non-ischaemic patient not receiving CRT with a SBP of 117 mmHg, use of lower 
interquartile range values for mitral regurgitation and NT-pro-BNP results in an 
estimate of absolute risk of approximately 0.84, an absolute reduction of around 13%
The plasma concentration of NT-pro-BNP was a strong predictor of clinical o
Other competing measures of ventricular dysfunction were eliminated from the 
multivariable model. CRT reduces the severity of mitral regurgitation and plasma 
concentrations of NT-pro-BNP, and CRT has substantial clinical benefits in a broad 
range of patients with evidence of cardiac dyssynchrony, poor LV systolic fu
and persistent symptoms despite pharmacological therapy. This analysis provides 
further evidence that a measure of cardiac dyssynchrony rather than the QRS interval 
on the ECG is currently the best marker of dyssynchrony. However, the predicted 
benefits from the model indicate that CRT appears worthwhile across the range o
patients included in the CARE-HF trial. In the next chapter we will consider the 
function form of the model, and how the correct form can be specified by use of cubic 
splines or fractional polynomials.  
e 
ues 
in 
. 
utcome. 
nction, 
f 
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 CHAPTER 3 RISK ESTIMATION 
 
 
 
he purpose
ltman 199
atient. Pro
heart attack
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• Re
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• Ris
3.0.0 Introd
T
A
p
and rational
example it m
doctor can d
Some treatm
may be nece
positively to
rely on a pro
the risk (Sed
instance giv
receiving tr
 lative and absolute risk  
k score produced using the prognostic model for the CARE-HF data
k score calculators for the CARE-HF data are presented  of a prognostic model is to aid clinical decision making (Wyatt & 
5). A prognostic model can enable a doctor to assess risk for an individual 
gnostic models can be used by a doctor to assist in making an informed 
tment a patient should or should not receive. For 
 
pond 
might 
rmine 
patient suffering a 
? When considering risk for an individual patient the term absolute risk is 
f instead of individual patients groups of patients are considered e.g. 
uction 
 choice as to what trea
ay be that several treatments are available, by using a prognostic model a 
etermine the treatment that will offer maximum benefit to the patient. 
ents may be very costly and unfortunately due to financial constraints it
ssary to target resources at those patients who are most likely to res
 a particular treatment regime. Bodies such as NICE (NICE 2009) 
gnostic model in targeting resources. A doctor often needs to dete
gwick 2001) that a patient will experience some event of interest. For 
en a patient’ age, weight, blood pressure and  the fact that the patient is 
eatment for a heart condition, what is the chance of the 
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 patients receiving treatment versus those not receiving treatment, male versus female 
patients; then the term relative risk is employed. Relative risk is a comparison of the 
risk of some event of interest occurring in two groups of patients. The fact that a 
odel will be used in the ‘real’ world to guide a clinician in making 
important decisions emphasises the need for good quality models. Also the model 
needs to be available in a form that is easily used by a clinician to calculate risk. The 
an as a risk score calculator. A 
risk score calculator is an implementation of the prognostic model in software form. 
e EuroScore (Euroscore Website) calculator is an example of a risk score 
calculator. I have produced two simple risk score calculators using the prognostic 
tem at a GP’s surgery, or if installed on a laptop computer or hand held 
device could be used in a bedside prognosis in a hospital ward or a patient’s home. 
Figure 3.1 below shows the risk score calculator produced by the present author 
running on Microsoft Windows XP. The calculator was written using Visual Basic 
For Applications (VBA) and is embedded in a Microsoft Excel workbook. Figure 3.2 
shows the risk score calculator running on GNU/Linux, this version of the calculator 
was written using Gambas (Benoît Minisini Website 2009) a free software equivalent 
to Visual Basic and is a standalone program. 
 
prognostic m
prognostic model can be made available to the clinici
Th
model for the CARE-HF data (Richardson et al. 2007). The calculators allow the 
clinician to quickly and easily calculate a risk score for an individual patient. The risk 
score gives a measure of how likely a patient is to die from any cause or be 
hospitalised due to a major cardiovascular event. The calculators could be used on a 
computer sys
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Fi re 3.1 Risk Score Calculator developed by the author running on Microsoft Windows XP gu
 
Figure 3.2 Risk Score Calculator developed by the author running on GNU/Linux  
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3.1.0 Calculation of risk scores 
Once a prognostic model has been developed it is possible to determine both absolu
and relative risks. Also the prognostic model can be used to generate a risk score, this 
risk score is the linear predictor kk xx
 
te 
βββη +++= ...110 . For the CARE-HF model 
the risk score does not include 0β .To illustrate how these estimates of risk are 
obtained I shall use the prognostic model developed for the CARE-HF data 
(Richardson et al.  2007). 
The coefficients of the final model can be used to generate a risk score for an 
individual patient. A quick and convenient way of estimating risk for an individual 
patient is to substitute patient characteristics in the Cox Proportional Hazards model. 
An example showing how the risks score is calculated as follows: 
Risk score for patient with mitral regurgitation of 38.1, NT-pro-BNP of 2858 pg/ml, 
systolic blood pressure of 100 mmHg, IVMD of 13.8 ms, ischaemic, and in receipt of 
CRT would be calculated as follows: 
Risk Score 
IVMDSBPBNPproNTMR ee 0055.00001.0)(log2717.0)(log5379.0 −−−−+=  
CRTIVMDCRTSBPCRTischaemic 4978.0)*(0131.0)*(0172.06340.0 −−++  
So for the patient above we would have Risk Score  
)9.498.13(0055.0())117100(0001.0()43.7)2858((log2717.0)94.2)1.38((log5379.0 −×+−×−−+−= ee
  
4978.0())9.498.13(5.0(0131.0))117100(5.0(0172.0)5.06340.0( 48.0)5.0×−−×−−×+×+
 
Figure 3.3 shows a plot of the risk score versus the probability of experiencin
primary event. By using the predict option in PHREG the survivor function estimate s
g the 
 
=
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 can be obtained, a new data set containing the risk score and the probability of 
experiencing the primary event (1-s) before the end of the follow up period can then 
be created.  
 
igure 3.3 Risk score vs. probability of primary event before end of follow-up period.  F
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Figure 3.4 Histogram of risk scor ients re end - riod. 
 and the absolute risk 
e for pat befo  of follow up pe
 
 
 
3.2.0 Estimation of absolute risk 
 
stimates of the survival function E )(tS )(1 tS−   
ere produced using the SAS procedure PHREG . Estimation of absolute 
sk using real patient data provides clinically relevant estimates of risk. Risk 
stimates were derived on the basis of the maximum follow-up in the CARE-HF 
udy, which was 44.7 months, although including censorship patients were only 
 any cause or an unplanned 
w
ri
e
st
followed for on average 29.4 months. Thus predicted event rates are considerably 
higher than those actually observed in the trial. The effect of SBP and IVMD on the 
absolute risk of a patient experiencing death from
 - 51 -   
 hosp nd absence of CRT 
or is  3.1 and 3.2, respectively. In both 
exam eld constant at the 
 in Tables 3.1 
othogonalization . The estimated absolute risk of experiencing 
se for a non-ischaemic 
dataset) on medical 
Table 3.1). Treatment of 
0.44. The presence of 
sk of experiencing event decreased with 
with a decrease in risk, the statistical interaction between SBP and CRT is associated 
with a small increase in risk. The absolute risk for a patient with IVMD of 49 ms vs. a 
patient with IVMD of 66 ms in the presence and absence of ischaemia and CRT is 
shown in Table 3.2. Increasing the IVMD from 49 to 66 ms leads to an increase in the 
absolute risk of experiencing an event, this result contradicts what would be expected 
 
 the survival 
experiencing a primary outcome event may seem surprisingly high in some cases 
(absolute risk of 0.99 as shown in Tables 3.1 and 3.2). However, patients recruited to 
w-up 
italization for a major cardiovascular event in the presence a
chaemic heart disease are shown in Tables
ples, mitral regurgitation, NT-pro-BNP, and IVMD were h
median values (see Table 3.3) the values NT-pro-BNP and IVMD given
and 3.2 are those after 
death or an unplanned hospitalization for cardiovascular cau
patient with a SBP of 117 mmHg (the median for the whole 
therapy (but not CRT) was 0.62 over the entire trial duration (
such a patient with CRT reduces the estimated absolute risk to 
ischaemia led to an increase in absolute risk to 0.67 and 0.84 in the presence and 
absence of CRT, respectively. The absolute ri
increasing SBP, this is due to the fact that although increased SBP alone is associated 
from the model given that the coefficient for IVMD is –ve. From figure 2.3 it appears
that increasing IVMD does diminish risk, however at around 1050 days
curves for patients not in receipt of CRT start to cross. The patients considered in 
Tables 3.1 and 3.2  had survived beyond 1050 days. . The estimated absolute risk of 
the study had severe heart failure (NYHA class III–IV) and therefore had an 
inherently high risk of experiencing the primary outcome during the study follo
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 (which ranged from 18 to 44.7 months). The hazard functions from the model are 
based upon prediction of event rates across the maximum follow-up from the study, 
which had reached 55% in the control group in mean 29.4 months of follow-up. In 
order to estimate the absolute risk of an event with changing SBP and IVMD, the 
atient Pressure (mmHg) 
Aetiology 
(Ischaemic) 
Cardiac 
Resynchronisation 
Therapy Absolute Risk 
1 -0.49 No Yes 0.44 
2 -0.49 No No 0.62 
-0.49 Yes Yes 0.67 
Yes No 0.84 
No Yes 0.48 
.5 No No 0.58 
.5 Yes Yes 0.71 
0.81 
ures (117–
130 mmHg) with and without cardiac resynchronisation therapy and in the presence and absence of 
chaemic heart disease. 
 
1 0.1 No Yes 0.44 
 
3 0.1 Yes Yes 0.67 
84 
5 17.44 No Yes 0.38 
63 
59 
85 
echanical 
delay (49–66 ms) with and without cardiac resynchronis rapy and in the presence and absence 
 
remaining clinical predictors were held constant. It is important to note that since 
these are also strong clinical predictors of outcome changing these values from the 
median has a large impact on the estimates of absolute risk. 
Systolic Blood 
P
3 
4 -0.49 
.5 5 12
6 12
7 12
8 12.5 Yes No 
  
Table 3.1 Estimated absolute risk of an event for patients with different systolic blood press
is
 
 
 
 
Patient 
Interventricular Mechanical 
Delay (ms) 
Aetiology 
(Ischaemic) 
Cardiac 
Resynchronisation 
Therapy 
Absolute 
Risk 
2 0.1 No No 0.62
4 0.1 Yes No 0.
6 17.44 No No 0.
7 17.44 Yes Yes 0.
8 17.44 Yes No 0.
 
 
Table 3.2 Estimated absolute risk of an event for patients with varying interventricular m
ation the
of ischaemia . 
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Table 3.3 Baseline characteristics of the patients,total number in study 813, IQR, interquartile range. a 
Mitral regurgitation defined as area of colour flow Doppler regurgitant jet divided by area of left atrium 
in systole, both in square centimetre. 
 
 
 
 
 
3.3.0 Obtaining Estimates of Absolute Risk  
 
It is worth commenting on what is involved in producing estimates of absolute risk 
using PHREG.  The following steps are needed  
       
 
 
 Control   Treatment   
 n median (IQR) n median  (IQR) 
Age (years) 403 66 (59–72) 409 67 (60–73) 
Aetiology (ischaemic Y/N) Y=153 
N=250 
  Y=186 
N=223 
  
Systolic blood pressure 
(mmHg) 
399 110 (100–
125) 
404 110 (100–
125) 
Glomerular filtration rate 
(mL/min/1.73m2) 
372 61 (46–73) 367 60 (46–73) 
N-terminal pro-brain 
natriuretic peptide (pg/ml) 
370 1806 (719–
3949) 
362 1920 (744-
4288) 
Use of beta-blockers (Y/N) Y=288 
N=116 
  Y=298 
N=111 
  
QRS width (ms) 394 160 (152–
180) 
401 160 (152–
180) 
Interventricular mechanical 
delay (ms) 
370 50 (30–66) 365 49 (32–67) 
End-systolic volume index 
(mL/m2) 
376 117 (94–
147) 
356 121 (92–
151) 
Ejection fraction (≤ 35%) 378 25 (22–29) 367 25 (21–29) 
Mitral regurgitation 303 23 (11–34) 302 21 (12–33) 
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 1. Create a dataset containing a subset of example patients 
2. Run PHREG with the baseline option 
3. Create a dataset containing the absolute risk estimates 
Step 1 can be accomplished using for example the following SAS code 
data card.mrisks; 
     input lmit lroc supsys IVMD ischemic trsup trivm treat; 
     datalines; 
 0.14 0.70 -0.49 0.100 0.5 -0.245 0.05 0.5 
      0.14 0.70 12.5 0.100 0.5 6.25 0.05 0.5 
      0.14 0.70 -0.49 0.100 -0.5 -0.24 0.05 0.5 
      0.14 0.70 12.5 0.100 -0.5 6.25 0.05 0.5 
      0.14 0.70 -0.49 0.100 0.5 0.245 -0.05 -0.5 
      0.14 0.70 12.5 0.100 0.5 -6.25 -0.05 -0.5 
      0.14 0.70 -0.49 0.100 -0.5 0.245 -0.05 -0.5 
      0.14 0.70 12.5 0.100 -0.5 -6.25 -0.05 -0.5 
; 
These patients have, lmit= (Mitral regurgitation) lroc= (N-terminal pro-brain 
natriuretic peptide), and Interventricular mechanical delay all held constant (set to the 
median) . Systolic blood pressure blood pressure is allowed to vary, as is aetiology 
(ischaemic), I compare the treatment and control groups. Step 2 is illustrated with the 
following code snippet  
Here I specify the names of the input variables and then construct a data set 
containing the example patients.  
elog elog
proc phreg data=card.valmod; 
  model futime*primary(0)=lmit lroc supsys IVMD ischemic trsup 
trivm treat/RL;  
  baseline covariates=card.mrisks out=card.PredFin  
survival=S/nomean;  
run; 
 based on the Cox proportional 
odel. The survival time for each patient is assumed to follow its own hazard 
function )  , exp()()( 0 βii Xyhyh = , where is an arbitrary and unspecified 
 
PHREG performs analysis of time to event data
hazards m
( yhi )
~~
baseline hazard function. The survivor function )iXyS can be written as 
)
)(0 yh
~,(
~~exp(
0 )(
βiXyS , where ∫=
y
duhyS 00 ))(exp)( . − u
0
(
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 The BASELINE option in PHREG results in a new SAS data set that contains 
baseline function estimates for the variables listed in the SAS data set 
card.mrisks. In the above SA o e the  survivor function )(tS  is estimated by the 
Breslow estimator (Breslow 1972) which is based on the empirical cumulative haz
function, alternatively the product limit estimator can be used (Kalbfleisch & Prentice 
1980). 
S c d
ard 
I can specify an out put dataset which will contain these estimates, (out=card.Predfin). 
The survival=S option means that I will obtain an estimate of the survivor function 
)(tS . Finally a dataset ontaining the estimates of absolute risk can be generated 
using the following SAS code 
 c
 
 
 
data card.absrisk; 
     set card.PredFin; 
  rsk=1-s;   
run; 
quit; 
Here the estimate of )(tS  contained in the dataset PredFin is used to generate the 
estimate of absolute risk (rsk=1-s) which is contained in the dataset absrisk. 
 
3.4.0 Which Measure of Risk Should Be Used? 
 
A patient w iting in hospital for an operation would naturally want to kn hat 
the benefit of undergoing surgery, he or sh uch would 
(Chao et al.. 2003) discusses the issue of whether reporting relative risk reduction, 
absolute risk  reduction, absolute survival benefit, or number needed to treat had an 
effect on a individuals decision to recommend that their mother undergo 
a ow w is 
e would want to know by how m
their risk (in the extreme case) of dying, be reduced . When considering a measure of 
risk reduction is there a benefit to using one measure as opposed to another? Chao 
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 chemotherapy (a hypothetical situation). Chao et al. found that the way in which risk 
reduction was presented does have a bearing on such a decision. They found that 
when an individual was presented with a relative risk reduction they were more lik
to choose chemotherapy. Which measure of risk reduction to presen
ely 
t is seemingly 
ependent on the patient’s understanding of terms such absolute and relative risk. 
ow one best presents risk to a patient is a very difficult question, I honestly do not 
elieve that I can supply a definite answer to this question 
d
H
b
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 CHAPTER 4 CUBIC NAL POLYNOMIALS 
 
developing 
motivated b
between the
 SPLINES AND FRACTIO
 
4.0.0 Introd
In this chap
al world cre
anner.  A 
f mortality
lines to m
ardiac surg
m
o
sp
c
• Ap
fra
 
roo
• Mo
• Re
 plication of transformations such as the natural logar
ctional polynomials  
ithm or the square
t to the independent variables may lead to improved model fit 
re complex relationships can be modelled using cubic splines or 
stricted  cubic spline applied to CARE-HF data a statistical model. The use of cubic splines and fractional polynomials is 
y consideration of the adequacy of the functional form of the relati
 dependent variable 
uction 
ter I will look at the use of cubic splines and fractional polynomials in 
onship 
and the independent variableY X . Unfortunately the 
onfronts us with situations where   is not related to Y X  in a simple 
good example of this is the relationship between body mass index and risk 
 for cardiac surgery see (Pagano et al. 2009). Pagano et al use cubic 
odel the relationship between body mass index and risk of mortality for 
ery, see figure 4.1.  
 
Cubic Spline (Dark Curve)  
Confidence Curves 
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 Figure 4.1 Non-linear (cubic spline) relation risk of mortality for 
 
It might be assumed for instance that a simple linear relationship cmxy +
ship between body mass index and 
cardiac surgery. Adapted from (Pagano et al. 2009). 
= is 
appropriate, but the data then leads the researcher to formulate a more complex 
model. One factor that will determine how ll a model fits the data is the function
form of the relationship between Y  and
 we al 
X . In developing a model, the researc
may make use of transformations of the independent variables in order to improve the 
fit, a typical example of such a transformation would be to consider my = log
Amongst the other standard transformations are
her 
e + . cx
x ,
x
1  .  It can be argued that it is 
natural to assume a linear relationship; if this proves not to be adequate then one 
might then consider taking the natural logari  or the square root. Once the sim
een applie hen use of the cubic spline or fractional 
e ‘best’ functional form may b lex 
sily obtained through analytic means, in this case n ical methods are 
thm ple 
transformations have b d t  
polynomial should be considered.  Th e quite comp
and not ea umer
used to approximate the relationship between  Y  and X .  One such method is the 
e of the basic theory relating to cubic splines. 
 
Before computer aided drawing software was available Engineers and Draughtsmen 
relied on a thin flexible rod called a spline. The spline was used to construct a curve 
awing board, and a 
n nd 
  points. 
In mathematical terms, a spline is an approximation of a curve. A spline is an example 
of polynomial interpolation, or more correctly piecewise polynomial interpolation. 
Interpolation is the process of approximating some function for , where  is in 
cubic spline. I shall now look at som
through a series of points. The spline was anchored to the dr
umber of weights were attached to the spline. The weights could then be moved a
so the spline could be adjusted to obtain the best fit curve through the specified
)(xf x x
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 the interv  of 
t )()( 11 nxfpxfxp
al ),( 0 nxx .  In polynomial interpolation we aim to find a polynomial (xp
degree n or less, such tha )(,...,),()( 00 nxxfxp
)
 )(=== . In the 
 is used instead of  and   instead of .The polynomial 
 is known as an interpolation polynomial.  There are various approaches to 
ial interpolation, for example Lagrange interpolation, 
pline interpolation. It may be helpful to look at the 
Lagrange method (Box 1) in order to appreciate the general principles of interpolation 
and also to identify possible problems. In my discussion of Lagrange interpolation 
and splines I follow the derivations and notation found in Kreyszig (Kreyszig 1993), 
 
 
 
 
 
 
 
literature )(xpn )(xp nf )( nxf
)(xpn
polynom Newton’s Divided 
Difference interpolation, and S
note an excellent explanation of splines can be found in Kreyszig’s book.  
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 Box 1 Lagrange Interpolation 
Lagrange interpolation uses the following approach. 
Assuming we have (),,( 1100 nn fxfx  (the point is known as a node) then we can , fx ),( ii fx),),...(
approximate the analytic function )(xf by  )()( fxLfxLp 11001 +=  , where 
10
1( xxL −0 ) xx
x
−=  and 
01
1 xx −
0)(
xx
xL
−= . Notice that at 0xx = , 1)(0 =xL  and 0)(1 =xL , similarly at  1xx = , 1)(1 =xL  
and (0 xL e ha  001 , xxfp0) = , so w ve ==  and 111 , xxfp == . This leads to the linear Lagrange 
polynomial 1
01
0
01 )( x
f
xx
xp −+−=  an example of linear nterpolation. Quadratic 10
1 f
x
xxxx −−
, this  i is
interpolation would require fxfxfx , this leads us to the second degree Lagrange ),(),,(),,( 221100
2211002 )()()()( fxLfxLfxLxp ++= , polynomial
e
))((
))(()(
2010
21
0 xxxx
xxxxxL −−
−−= ,
))((
))((
)(
2101
20
1 xxxx
xxxx
xL −−
−−= ,
))((
))((
)(
1202
10
2 xxxx
xxxx
xL −−
−−=wher  . 
The general Lagrange interpolation polynomial is . It can be shown that  ∑= n kkn fxLxp
0
)()( )(xnε the 
error in approximating  by  is given by)(xf  )(xpn  )!1(
)())...()((
)1(
10 +−−−
+
n
tfxxxxxx
n
n , where 
nxtx ≤≤0 . We might argue that given  )!1(
)())...()(()( 10 +−−−= n
tfxxxxxxx nnε , then as 
)1( +n
n becomes large  )(xnε  becomes small, i.e. the greater the degree of )(xp  the better the interpolation. Sadly n
this is not the case in general, there are functions f  for which )(xp  exhibits large oscillations between the n
nodes, this is an example of Runge’s phenomenon (Runge 1901). 
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4.1.0 Cubic Splines 
In trying to approximate some function )(xf  by a single a single polynomial it is n
uncommon to encounter problems of numerical stability ( )(xpn  exhibits large 
oscillations between the nodes). Splines offer a way of approximating )(xf  that can 
 
ot 
to a reasonable extent avoid problems of numerical instab  Spline in tion 
nomial interpolation. If  is defined on the 
ility. terpola
can be defined as piecewise poly )(xf
interval [a,b], then the interval [a,b] is split so that bxxxxa n =<<<<= ....210 . It 
can be seen that each subinterval ],[ 1+jj xx has a common endpoint, these endpoints 
are called nodes, in most statistical literature nodes are referred to as knots, I shall 
follow suit and use the term  in my discussion of splines.  A 
olynomial is required such that 0 nn xgxfxgf
 knot throughout
)(xg )()(),...,()( 0x ==p , also it is 
  
lines, a cubic spline 
f [a,b]). A   
 is a polynomial of not more than degree 3.  
Now by defi
by 
required that at the knots  can be differentiated several times, such a )(xg  is
called a spline. I shall concentrate on cubic sp
[a,b] is a continuous function and has continuous first and second derivatives, 
(continuous in [a,b] and all subintervals o lso for each subinterval of [a,b]
nition )(xg  is such that for each subinterval in [a,b], )(xg  must be given 
)  where )() jjj xfp =  , )()( 11 ++
)(xg
)(xg  defined on 
)(xg
(xp j (x = jjj xfxp  and jjj kxp =′ )( , 
11 )( ++ =′ jjj kxp . The degree of  )(xp j  must not be greater than 3. 
It can be seen that by replacing x by jx  and 1+jx  in )(xp j , where )(xp j  is given by 
)](21[)()()](21[)()()( 2222 −−−+−+−= xxcxxcxfcxxcxfxp  111 +++ jjjjjjjj
               (1) 
jjj xx
)()())(( 1
22
1
2
1
2
+++ −−+−−+ jjjjjjjj xxxxckxxxxck  
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 and 
jj
=
+1
1 , results are obtained that satisfy the definition for a cubic splin
Taking the second derivative to get 
11 24)(6)(6)( ++ −−+−=′′ jjjjjjjjjj kckcxfcxfcxp  (2) 
11
22
1 42)(6)(6)( +++ ++−=′′ jjjjjjjjjj kckcxfcxfcxp  (3) 
From the fact that )(xg  has continuous second derivatives 
)()( xpxp ′′=′′  for 1,...,1
j xx
c − e.  
−
22
−= nj  (4)  1 jjjj
Using  in the expressions for 1−j )( jj xp ′′  and )( 1+′′ jj xp  , the following result is 
obtained 
2 )))()(())()(((3)(2 1111111 jjjjjjjjjjjjj xfxfcxfxfckckcckc −+−=+++ +−−+−−− (5) 
The above result is a system of  1
2
−n  equations; the system has the unique solutio
11 ,..., −nkk , note that 11 ,..., −nkk  is )(xg
n  
′  at the knots. Assuming that the knots are 
equally spaced, say by a distance h , and writing  nxxxx ,...,,, 210  
as nhxxhxxhxxx n +=+=+= 002010 ,...,2,, . Also hxx jj
11
1 −+
Hence
c j == . 
, can 
now be written as 
)))()(())()(((3)(2 1
2
1
2
11111 jjjjjjjjjjjj xfxfcxfxfckckcckc −+−=+++ +−−+−−− j
)(3 −=+4 1111 −++− + jjjjj ffhkkk  for 1,...,1 −= nj  (6) 
Writing 210 ()( jjjjjjjj xxaaxp += king at 32 )()() xaxxax −+−+−  and then by loo
the Taylor series for )(xp j  to get  
jjj fxpa == )(0  
3
 - 63 -   
 jjjj kxpa =′= )(1    
)2(13
2
1
2h
)( 112 jjjjjjj kkh
ffxpa +−−=′′= ++)(
)(1)(21 )(
6 12133 jjjjjjj
kk
h
ff
h
xpa ++−=′′′= ++  
ombining the results directly above with (6) allows numerical values for the 
properties of splines are discussed. 
 
Box 2 Splines and Elastic Energy 
 S a
C
coefficients of  to be determined and hence . In Box 2 some further useful )(xp j )(xg
 
plines possess an extremely interesting and useful property. For the spline )(xg ,  )() afg ( ′=′  
and  Now using integration by parts )()( bfbg ′=′ .
∫∫∫ −==′′−′′′′
a
a
aa
dx
dx
vuvdx
dx
udxxgxfxg ][))()(((  
b
b
bb dv) du
0))()()(())]()( ′−′′′′−′−′′′′=
b
b dxxgxfxgxgxfg )(([ =∫
a
ax  
Therefore 
b
dxxgdxxfxg 2))(()()(  (8) ∫ ∫ ′′=′′′′b
a a
Now considering dxxgxf∫ ′′−′′ 2)]()([ ,  b
a
dxxgdxxdxxxf
aa
∫ ∫∫ =′′−′′ ()]()([ gxfdxxfg
a a
∫ ′′+′′′′−′′ 222 )())(2)( , using (8) to get b b bb
dxxgdxxfdxxgxf
b bb
a
′′−′′=′′−′′ 222 )()()]()([
a a∫ ∫∫  (9)  
The right hand side of (9) is , therefore 0≥
∫∫
a
b
a
 (10)  ′′≥′′
b
dxxgdxxf 22 )()(
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 I mentioned earlier that a spline as used by an Engineer or Draughtsman is a thin flexible rod. For )(xg , )(xg ′′  is an 
approximation of the curvature of )(xg . Treating  as a thin beam or rod we can say that the  of )(xg  curvature )(xg ′′
)(xg  is proportional the bending moment of the rod, also is proportional to elastic energy stored in the beam ∫ ′′b
a
dxxg 2)(
(Horn K.P. 1983). If the conditions  0)( =′′ ag  and 0)( =′′ bg are imposed on a cubic spline, then we have what is 
known as a natural or restricted cubic splin operty  is a minimum. When  e. The natural spline possesses the pr  ∫ ′′b
a
dxxg 2)(
)(xf is approximated using the natural spline )(xg  , the approximation is one that minimises elastic energy.   
 
 
 
 
by Wegman and Wright (Wegman & Wright 1983). The background m
4.2.0 Cubic Splines in a Statistical Context 
I shall now consider the use of splines in statistics. I shall make recourse to the paper 
aterial I have 
looked at so far concerning splines is what one would find in any useful textbook on 
Engineering Mathematics, I have not addressed the use of splines in statistical work. 
The data used in an engineering application of splines is different from the data that 
might be used in a biostatistical application f splines. Engineering data would tend to 
be less noisy, Wegman and Wright (We  Wright 1983) state: 
“More to the point, it is desirable in a statistical framework to create a type of spline 
that could pass near, in some sense, to the data but not be constrained to interpolate 
exactly” 
o
gman &
Wegman and Wright point out that in a statistical context fitting a spline goes beyond 
solving a linear system of equations, we have to consider a ‘genuine optimization 
routine’. Wegman and Wright identify three ways of fitting smoothing splines, viz 
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 penalised least squares, 100 percent confidence intervals and regression splines. I 
make extensive use of Wegman and Wright’s paper (Wegman & Wright 1983). I shall 
now examine in some detail the three methods as described by Wegman and Wright.
 
∑ ∫+− jj dxxLfyxf
1
1
0
22 ))(())(( λ , subject to mWf
 
4.2.1 Penalised Least Squares 
Using the notation in (Wegman & Wright 1983) for penalised least squares consider 
the solution to the following optimisation problem  
Minimise  
n
∈  (11) 
 
It is assumed that 1...0 21 <<<<< nxxx  and 0>λ  is a fixed parameter, (11) is 
2 m
note).It  can be seen that the integral that appears in (11) is similar to ∫ ′′b
a
dxxg 2)( , 
what is known as an objective function. The set of functions  on  such that 
,  is absolutely continuous and is in  is denoted by (see 
f ]1,0[
fD j 1−≤ mj fD m L W
 L
is a differential operator,  , where D  denotes differentiation, so with 
)(xLf is  equivalent to 
mDL = 2DL = , 
2
2 )(xfd .  The term ∫ 2))(( dxxLfλ  is known as a penalty term, dx
it penalises lack of smoothness. I need oothing, when I 
ooth data I am attempting to fit a curve to the data that picks up important general 
features, but leaves out fine grained local detail i.e. leaves out the noise. If 
1
0
to introduce the idea of sm
sm
λ  is 
allowed to get very close to 0, then there is no smoothing, if λ  is allowed to become 
extremely large, in fact let ∞→λ , then I have infinite smoothing. As 0→λ   then 
 becomes an interpolating spline, as)(xf ∞→λ , then  becomes a least squares )(xf
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 estimate. Informally I could describe a smoothing spline as a way of fitting a curve to 
a dataset with the aim of striking a balance between the interpolation spline which 
will fit the data to a very high degree and the least squares approach which may n
is important to distinguish between an interpolation spline and a smoothing spline, the 
interpolation spline would be the thing to use if I were int
ot. It 
erested in mathematically 
describing the shape of curved component in engineering, for example the curve of a 
heel arch on a car.  In the context of statistical modelling I might argue that the 
smoothing spline would be an appropriate tool, as in this case we are concerned with 
general overall patterns and relationships, and not with fine grained detail. I could 
express these points in terms of over-fitting and under-fitting, the interpolation spline 
will over-fit, the least squares estimate may lead to under-fitting. What can I say about 
the smoothing spline in regard to over-fitting and under-fitting? As Wegman and 
Wright point out the choice of 
w
λ  is of paramount importance, as the sample size 
increases thenλ  should be decreased. Wahba and Wold (Wahba & Wold 1975) 
develop a method for selectingλ using cross-validation. Wahba and Wold use the 
following criteria to selectλ : 
( )Using Wahba and Wold’s notation minimise ⎥⎦
⎤⎡
=
n
j
2
1
minimise the average mean square error. Note  is a spline the observed 
⎢⎣
−∑ jjn xgxgnE 2, )()(21 λ , i.e. 
data. The quantity 
)(, jn xg λ )( jxg
( ) ⎥⎤⎢⎡ −∑ jjn xgxgn 2, )()(21 λ  regarded as a function of ⎦⎣ =
n
j
2
1
λ is known 
as the cross-validation function, by introducing )(λw  (a weighting function) into the 
expression for the cross-validation function, the generalised cross-validation function 
is obtained, i.e. 
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 ( ) ⎥⎤⎢⎡ −∑n wxgxg2 2 )()()(1 λ . ⎦⎣ =
 matrices, the estimate of 
j
jjnn 1
,2 λ
It can be shown that this function can be represented using
λ obtained from the generalised cross-validation function is the best one to use in the 
 
g spline 
penalised least squares method.  
4.2.2 100 Percent Confidence Interval Method 
 
The second method for fitting smoothing splines discussed by Wegman and Wright is
100 percent confidence intervals. In (Wegman & Wright 1983) an interpolatin
is considered as the solution to an optimisation problem. Using the notation in 
(Wegman & Wright 1983) the interpolating spline )(xs  is the solution to: 
Minimise ∫∞∞− dxxfL 2))((( , subject to ),(2 ∞−∞∈ LfD j , mj ,...,1,0=  and ii yxf =)( ,
ni ,...,2,1= . (12) . 
2
 
 is a set of measurable integrable square functions. (NoteL  2L same as  , i.e. 
2
Lesbague space.  Square integrable  means 
L
∫ 2
tive 
2 , for the 100 percent 
nfidence interval method  the objective function is the same as for the penalised 
f over interval (a,b) is finite) 
Here ∫∞ dxxfL 2))(((  is the objective function. The interpolation spline )(xs  is a 
polynomial of degree 12 −m .It was seen that for penalised least squares the objec
∞−
function contained a least squares term ∑ jj yxf
1
))(( −
n
co
least squares case but the interpolating constraints are relaxed. For the 100 percent 
confidence interval method according to (Wegman & Wright 1983) I have the 
optimisation problem: 
Minimise ∫∞ dxxfL 2))((( , subject to iiim tfWf βα ≤≤∈ )(, , i n,...,2,1=  ∞−
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 From a statistical point of view the 100 percent confidence interval method can be 
understood in terms of the model iii xfy ε+= )( , ni ,...,2,1= . Assuming that  is iε
i..i.d on ],[ 21 ee− , then because 1ei −>ε  , )(1 iiii xfyey =−>+ ε . Because 2ei <ε ,  
)(xfyey =−<− 2 iii ε , so ),(y 12 eye iii +−  is a 100 percent confidence interval. As 
4.2.3 Regression Splines 
Wegman and Write point out the 100 percent confidence interval method is an 
example of the Generalized Hermite-Birkoff interpolation problem (Schoenberg 
1966). 
 
In (Wegman & Wright 1983) the penalised least squares and 100 percent confidence 
oothing splines are presented as optimization problems, 
 want to minimise curvature.  Regression splines can be regarded in the manner that I 
n 
interval methods for fitting sm
I
first introduced the idea of a spline, a continuous piecewise polynomial of degree m . 
Regression splines require that I determine several free parameters. I do not have 
assume that the knots are co-incident with the sx'  , I can choose the number and 
position of the knots. I can of course choose the degree of the spline. Also I ca
determine the free coefficients in the spline, there are 1++ Nm  free coefficients, 
there are continuity conditions placed on the first 1−m derivati
aining after these conditions have been met. Using 
ves of the spline,
free coefficients are those rem the 
notation in (Wegman & Wright 1983) consider the model  
 the 
. (13) 
21 n
iii xsy ε+)= ∆ ( , ni ,...,2,1=
In )(xs  the symbol ∆ denotes a mesh of knots, },.{∆ .. ζζζ <<<=∆ , where iζ  is 
degree (13) can be 
written as +−+ jxxy )( εζββ  (14) 
a knot. With N knots, and 1+N  polynomial segments of  m ,
∑∑∑
= =
+
=
N
k
m
j
ikikj
m
j
i
1 00
0= jij
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 Note that in (14) the term ix −(  a
− at
 jk +)ζ is written using Heaviside notation, th t is 
)()( atuatu −=− +  if 0) >u  and (( 0) =− +  if )atu 0( ≤− atu . 
he big advantage of (14) is that I can use ordinary least squares regression to obtain 
kj
T
estimates for the coefficientsβ . I said earlier that the knots do not have to be co-
incident with the , Wegman and Wright draw  attention to  Wold’s (Wold 1974) 
recommendation that knots should be located at data points. Wold (Wold 1974) also 
ore 
ent knots I have in effect defined the interval 
sx'
recommends that I use as few knots as possible, the more knots that are used the m
complex the model, i.e. I have to estimate more parameters. Also a large number of 
knots may lead to over-fitting. I must exercise caution when choosing the location of 
the knots, in selecting two adjac
],[ 1+ii ζζ , it might be that within this interval there are points for which the cur
passing through the points ),( yx  has a minimum or a maximum, or has a point of 
inflexion. If I wish to use cubic splines this is not a problem provided there are not 
multiple maximum and minimum points, and there are not multiple points of 
inflexion. Wold (Wold 1974) notes that if this is the case then we could not employ 
cubic spline. A cubic polynomial can have both a maximum and a minimum, and a 
single point of inflexion, but not multiple maximum and minimum points, and not 
multiple points of inflexion.  According to Wold (Wold 1974), maximum and 
minimum points should be located at the centre of the interval. Points of inflexion 
should be located close to the knots. A common choice for m  in (14) is 3, givin
cubic spline. The cubic spline is popular because it allows researchers to tack
range of data sets where a polynomial model is appropriate, the cubic spline avoids 
the overheads for splines of larger degree. Harrell (Herndon & Harrell 1990), (H
et al. 1996) advocates the use of cubic splines, specifically the restricted cubi
In (Herndon & Harrell 1990) the main focus is on the use of the restricted cubic spline
ve 
a 
g a 
le a good 
arrell 
c spline. 
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 in connection to the hazard function, Harrell finds that the restricted cubic spline can 
be used to model data where the hazard function may be one of several different 
apes. In (Herndon & Harrell 1 90) data from various distributions where 
considered. Earlier it was said that if the conditions 0)(
sh 9
=′′ ag  and 0)( =′′ bg  are 
imposed on a cubic spline, a restricted cubic spline is obtained. When trying to m
survival data the researcher should be aware that the cubic spline may present 
problems. Stone and K
odel 
oo (Stone & Koo 1986) have found that for points beyond the 
first and last knots the cubic s y
cubic spline does not exhibit strange behavi nd last 
k The restricted cub
4.2.4 Splines applied to the CARE-HF data 
The literature on the use of splines in statistics is considerable and large portion is of a 
high level of mathematical sophistication. I have confined myself to a discussion of 
some of the basic points. If I want to follow the advice of authors and researchers 
such a Harrell and adopt the use of splines in modelling how easily is this 
ented in a nu
-
ne to 
0
l fit a 
pline ma  exhibit strange behaviour. The restricted 
nots . ic spline is linear at points close to the first and last knots.  
our at points beyond the first a
 
accomplished? Cubic splines have been implem mber of statistical 
software packages. For SAS the RCS macro (Heinzl & Kaider 1997), (Heinzl & 
Kaider 2006) is available, for GNU R and S Plus Harrell’s Design (Design Library 
Harrell Frank E. 2009b) package provides the restricted cubic spline in a form which 
is easily used in a Cox Proportional Hazards model.  
I shall now look at a simple example of using the RCS macro to fit a cubic spli
the CARE-HF data (Richardson et al. 2 07). The aim of this example is to 
demonstrate basic usage of the RCS macro and to illustrate a simple and practical 
approach to the issue of functional form for a model. In the this example I shal
Cox Proportional Hazards model with systolic blood pressure and CRT as 
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 independent variables, however I shall include a cubic spline representation of 
systolic blood pressure in the model. The following SAS code is an exam le of how 
use the RCS macro to fit a cubic spline: 
 
p I 
 
%RCS( 
  TITLE=%STR(CAREHF),  
  DATA=LATESTEX,DIRDATA=%STR(C:\Documents and 
Settings\richarmz.ADF.000\Desktop\prog_card_dat\), 
  PROGRAM=%STR(C:\Documents and 
Settings\richarmz.ADF.000\Desktop\prog_card_dat\rcs\sbpspline.sas), 
  TIME=futime,STATUS=primary, 
  COV1=supsys,WHAT1=0,KNOTS1=105 117 130 165, 
  COV2=treat 
  ); 
The reader is directed to (Heinz e, l & Kaider 1997) for an explanation of the RCS cod
however it might be helpful to comment here on the above code. The line beginning 
with the keyword DATA is where I specify the name and location of a SAS dataset, in 
this example the dataset is called LATESTEX. The line beginning with the keyword 
PROGRAM allows me to specify the name and location of the SAS program 
sbpspline.sas. TIME and STATUS refer to survival time and censoring respectively. 
On the line beginning COV1 I specify supsys (systolic blood pressure), if set to 1 
WHAT1 allows modelling of time by covariate interaction with the cubic spline. The 
knots for the cubic spline are specified using KNOTS1, I have knots at 105, 117, 130, 
165.   COV2 specifies that the next independent variable in the model is treat (CRT). 
NB the above code will not produce any output in terms of analysis. The fitting of the 
cubic spline is performed by running the SAS program sbpspline.sas, this program 
calls PROC PHREG, PROC  IML and PROC GPLOT.  On running sbpspline.sas I 
obtain output from PHREG and GPLOT . Below is an extract of the output from 
PHREG. 
 
                            Analysis of Maximum Likelihood Estimates 
 
                                   The PHREG Procedure  
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                  Parameter   Standard                         Hazard  95% Hazard Ratio 
   Parameter DF   Estimate      Error Chi-Square Pr > ChiSq    Ratio Confidence Limi
 
   Supsys     1
ts  
   -0.01492    0.00697     4.5829     0.0323    0.985    0.972    0.999  
   __1_1      1  0.0000110  0.0000212     0.2678     0.6048    1.000    1.000    1.000 
 __1_2      1 -0.0000172  0.0000532     0.1047     0.7462    1.000    1.000    1.000 
eat      1   -0.47246    0.10505    20.2258     <.0001    0.623    0.507    0.766  
ctor of time to 
ath or unplanned hospitalisation as is whether or not a patient has received cardiac 
 In the parameter column of the output __1_1 and __1_2 
fer to the cubic spline representation of systolic blood pressure, neither are 
atistically significant. From this I would conclude that a cubic spline representation 
 systolic blood pressure does not represent an improvement in functional form over 
e assumed linear form, this is reflected in the linear hypotheses testing results.   
  
   tr
 
 
                               Linear Hypotheses Testing Results 
 
                                            Wald 
                           Label      Chi-Square      DF    Pr > ChiSq 
 
                           EFFECT1        9.7550       3        0.0208 
                           NONLIN1        2.0941       2        0.351 
It can be seen that systolic blood pressure (supsys) is a significant predi
de
resynchronisation (treat).
re
st
of
th
 
Figure 4.2 The restricted cubic spline (the red curve) approximation for the log hazard ra
ressure
tio as a 
function of systolic blood p . 
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The figure above shows the restricted cubic spline (the red curve) appro
two curves that cross, this is not the case. At the middle of the spline the two 
confidence curves are very close together. Using the notation and derivation from
(Heinzl & Kaider 1997) the restricted cubic spline is given by 
∑
ximation for 
the log hazard ratio as a function of systolic blood pressure (supsys). The blue dotted 
curves represent the confidence curves, at first glance one might think that there are 
 
−
=
jj r of knots, let the knots be ++=
2
1
)()(
k
j
uCuuC θββ  , where k is the numbe
kttt ,..., 21 . Also  
10
)(
)()()()(
)()( 113 −++−+
−−+−−−−= jkkjkkjj
tttutttu
tuuC  . 
1 2
estimates for 1
) 1
3
1
3
−− −− kkkk tttt
In the output from PHREG__1_1 and __1_2 refer to  uC  and uC  respectively, 
(
)( )(
θ  and 2θ  are 0.0000110 and -0.0000172.   
Again using the notation and derivation in (Heinzl & Kaider 1997) for a fixed value 
0u the estimated cubic function )(ˆ 0uC can be written as 00 ˆ)(ˆ UuC β ′= , where 
)ˆ,...,ˆ,ˆ,ˆ(ˆ 2110 ′= −kθθβββ  and tk uCuCuU ))(),...,(,,1( 020100 −= . If V is the sample 
 then a covariance matrix for βˆ α−1  confidence interval for )(ˆ 0uC  is given by 
2
1
000 )(ˆ VUUU ′±′ γβ  , 2 1, αχγ −= p  is the α−1  quantile of 2χ with p degrees of freedom 
(Heinzl & Kaider 1997). To understand why the two confidence curves are very close 
together at the middle of the spline, note that 2
1
000 )(ˆ VUUU ′−′ γβ  and 
2
1
000 0
distance between the confidence curves increases as 0u moves further from the mean.
)( VUU ′+ γ ean, i.e. the 
   
ˆ U′β will increase in size as u moves further from the m
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 Further material on the use of splines in statistics is to be found in (Smith 197
(Poirier 1979).  I now consider fractional polynomials.  
9) and 
4.3.0 Fractional Polynomials 
The cubic spline is one example of using polynomials to model data. Another 
approach is that of fractional polynomials, see (Royston Patrick et al. 1999), (Royston 
& Altman 1994), (Stocken D.D. et al. 2008), (Royston & Sauerbrei 2004) and (Meier-
s continuous 
orical variable. 
is the researcher 
ay encounter problems. If I have not pre-specified how I intend to form the groups, 
that is the location of the cut-points or group boundaries, I can end up with highly 
ata driven’ results. Also in moving from continuous to categorical data I introduce 
mps’ when a group boundary or cut point is crossed, for example if I where 
odelling the probability of some event occurring as a function of age, the  
p, perhaps quite substantially when a cut 
odel of the situation?   Altman and Royston 
at dichotomising variables leads to loss of 
wer and an increased risk of false positive results.  
 view of this, there is an argument for preserving continuous data. As shown earlier 
cubic splines can be used to model the relationship between the dependent variable 
 
Hirmer et al. 2003). In epidemiological and biostatistical application
variables such as age are often split into groups to form a new categ
This makes analysis easy perform and interpret; however in doing th
m
‘d
‘ju
m
probability of the event occurring will jum
point is crossed. Is this a realistic m
(Altman & Royston 2006) state th
information, reduced statistical po
In
Y and the independent variable X when the relationship is not a simple linear one. 
 & Altman 
94) allows the researcher to ider a number of possible functional forms for the 
ationship between and
The fractional polynomial developed by Royston and Altman (Royston
19 cons
rel  Y X . In (Royston & Altman 1994) the fractional polynomial 
is defined as follows 
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 ∑
=
0 +=
m
j
p jXpX
1
)(),;( ξξξφ , where 0>X and ),...,(jm 1 mppp = is a vector of powers 
with mpp << ...1 and ),...,,( 10 mξξξξ = a vector of coefficients, both p and ξ are real
valued. Also jj pp
 
XX =)( if 0≠jp , XX ep j log)( = if 0=jp ; the Box-Tidwell 
Transformation.  
 
Royston and Altman give what they say is their full and most concise definition as 
follows 
∑=
=
jjm XHpX ),;( ξξφ , where for 
m
j
p j
0
)( mj ,...,1=  and XXH =  if  , 
 if . In (Royston & Altman 1994) the authors state 
at for given values of  and 
)( p
j )( j  1−≠ jj pp
)(log)( 1 XHXH ejj −=  1−= jj pp
 m pth the fractional polynomial given in the form above 
an be regarded for the purpose of model development as a linear predictor. The best 
alues for and 
c
 m pv need to be determined, in (Royston & Altman 1994) the authors 
uggest that for most practical situations s )},3max(,...,2,1,5.0,0,5.0,1,2{ mp −−−= is 
he degree of the fractional polynomial   is determined on an informal 
provement in model fit is observed. It can be 
seen that fractional polynomials obtained using 
contains the straight line case, the natural log, 
ial is flexible in the sense that it allows me to 
ould view the fractional polynomial as a 
ed method for applying transformations. The fractional polynomial allows 
oduce a model with a sensible functional form. In regard to model fit Royston 
nd Altman assume that maximum likelihood is used. Based on a given  the best 
vector of powers is the one from the model with the greatest likelihood or the 
madequate. T
basis a priori or until no appreciable im
)},3max(,...,2,1,5.0,0,5.0,1,2{ mp −−−=
the square root. The fractional polynom
fit many of the ‘standard’ models. I c
generalis
me to pr
m
p~
a
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 smallest deviance D . In (Royston & Altman 1994) the authors use the quantity 
)ˆ,(),( pmDpmD − which is distributed (asymptotically) 2χ with m  degrees of 
freedom , pˆ is the full maximum likelihood estimate of p . This quantity may b
to assess the adequacy of a conventional polynomial versus a fractional polynomial 
the same degree. Another quantity which is defined in (Royston & Altman 1994) as 
the gain ),()1,1(),( pmDDpmGG −== uses the deviance of the straight line mode
)1,1(D as a reference against which to compare other models.  Unlike the deviance a 
e used 
of 
l 
 a better f ef s so far of a 
ial we are dealing with a single independent variable, it is possible 
to extend the definition of a fractional polynomial to include several independent 
ented i AS via the %mfp8 macro 
hall 
ials 
trates 
large value for the gain is an indication of it. In the d inition
fractional polynom
variables 
Multivariable fractional polynomials are implem n S
(MFP 2009).The %mfp8 macro has been ported to GNU R as the mfp library . I s
now look at an example using the mfp library in GNU R to fit fractional polynom
to the CARE-HF data (Richardson et al. 2007).  The following R code demons
basic usage of the mfp library: 
setwd("C:/Documents and 
Settings/richarmz.ADF.000/Desktop/phd_chapters") 
dd<-read.Table(file="latest_ex2.csv",header=T,sep=",") 
attach(dd) 
library(mfp) 
f<-
mfp(Surv(futime,primary)~fp(Roche)+fp(mitral_r)+fp(Supsys)+Ischaemic+
treat,select=0.05,verbose=TRUE,family=cox,data=dd) 
 
 
here I am fitting a Cox Proportional Hazards model which incorporates fractional 
polynomials for N-terminal pro-brain natriuretic peptide (Roche), Mitral regurgitation 
(mitral_r), and Systolic blood pressure (Supsys). An extract of the GNU R output is 
shown below: 
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           df.initial select alpha df.final power1 power2 
mitral_r           4   0.05  0.05        4     -2      2 
Ischaemic          1   0.05  0.05        1      1      . 
treat              1   0.05  0.05        1      1      . 
Roche              4   0.05  0.05        2      0      . 
Supsys             4   0.05  0.05        0      .      . 
 
 
 
 
 
 
 
 
Transformations of covariates: 
                                         formula 
Roche                         log((Roche/10000)) 
mitral_r  I((mitral_r/10)^-2)+I((mitral_r/10)^2) 
Supsys                                      <NA> 
Ischaemic                              Ischaemic 
treat                                      treat 
minal pro-brain natriuretic peptide (Roche) has been selected. 
is result is in accord with the findings in (Richardson et al. 2007), i.e. on 
The mfp function selects the best fitting fractional polynomial. The natural log 
transformation of N-ter
Th
comparing the AIC for two Cox Proportional Hazards models of the form 
CRTCRTXX ++ )*(  and CRTCRTXX ee ++ )*(loglog  is was found that for N-
terminal pro-brain natriuretic peptide the model that used the natural logarithm 
transform result in a smaller AIC. For mitral regurgitation (mitral_r) a fractional 
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 polynomial of the form 
22
1010 ⎠
⎞
⎝
⎛
⎠
⎞
⎝
⎛ − xx
21 ⎟⎜+⎟⎜ cc has been selected. The coefficients  and 1c
2c  can be obtained in GNU R , they are -30.6 and 0.000169 respectively. In 
(Richardson et al. 2007) the logarithmic transformation applied to mitral regurgitation 
was found to improve model fit. The transformation selected on the basis of a 
statistically significant difference in the AICs for models of the form 
 and CRTCRTXX ++ )*( CRTCRTXX ee ++ )*(loglog , may well be different 
from those obtained by using mfp in the wa onstrated. For Systolic blood 
pressure (supsys) has been om  (Richardson et al. 2007) 
systolic bloo  (systolic blood 
pressure*CRT) was found to be statistically ing with interaction 
term  such as 
(supsys*CRT) in mfp, i.e. I canno tion term. Instead I 
would create a new variable, for example supt=(supsys*CRT). After doing this it is 
possible to include the inte  
 
y just dem
itted from the ‘final’ model, in
d pressure was included because the interaction term
 significant. Deal
s in mfp involves setting up a new variable, I cannot use a term
t explicitly write an interac
raction term using in the following code in GNU R:
f2<-
mfp(Surv(futime,primary)~fp(Supsys)+supt+treat,select=0.05,verbose=TR
UE,family=cox,data=dd) 
 
If the above code is run then the resu with those found in lts are in agreement 
(Richardson et al. ed, also 2007), systolic blood pressure (supsys) is left un-transform
the hazard ratios and p-values for systolic blood pressure, CRT (treat) and the 
interaction term are as reported in Table 2 of (Richardson et al. 2007) (these models 
where produced using PHREG in SAS). Similarly for mitral regurgitation if a new 
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 variable is set up for the interaction with CRT, then mfp reports that the best 
fractional polynomial for mitral regurgitation is the natural logarithm. 
A question can be raised in regard to the attempt at fitting a fractional polynomial to 
supt=(supsys*CRT) i.e. including fp(supt)in the model statement above. Is this 
valid or would it be better to use another method of fitting the model? If a fractional 
polynomial is fitted for the interaction term the following output is obtained: 
       df.initial select alpha df.final power1 power2 
Supsys          4   0.05  0.05        1      1      . 
treat           1   0.05  0.05        1      1      . 
supt            4   0.05  0.05        2      3      . 
 
 
 
 
 
 
Transformations of covariates: 
                   formula 
Supsys   I((Supsys/100)^1) 
supt   I(((supt+1)/100)^3) 
treat                treat 
 
               coef exp(coef)  se(coef)      z        p 
Supsys.1 -1.466e-02    0.9854 3.950e-03 -3.711 2.06e-04 
treat.1  -1.118e+00    0.3270 2.513e-01 -4.449 8.63e-06 
supt.1    3.759e-07    1.0000 1.332e-07  2.822 4.77e-03 
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 Here the interaction term supt itself has undergone a non-linear transformation, I 
cannot interpret the transformed interaction term in an obvious way , the main effect 
Supsys is untransformed whereas supt is now a cubic term. The p-values for systolic 
blood pressure, CRT (treat) and the interaction term are smaller than those reported in 
Table 2 of (Richardson et al. 2007). It would be better to establish the fractional 
polynomial for the main effect first and then fit a model that uses the transformed (or 
un-transformed) variable for both the main effect and the interaction term. If in the 
xample models below e Z is a binary variable and is some transformation then 
when using mfp  model 4 produces the same results as model 2 using PHREG, 
whereas model 3 using mfp produces different results to model 2 using PHREG. 
 
 
 
 
 
 
Example Models 
1. 
            
()f
ZZXX ++ )*(  
2. ZZXfXf ++ )*)(()(  
3. ZZXfXf ++ )*()(  
4. ZZXXf ++ )*()(  
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 For instance in GNU o  Proportional Hazards m
with the transformed variables obtained from mfp. Ischaemic and treat (CRT) re
un-transformed of course. It should be re
 R I could use coxph to fit the C x odel 
main 
membered that when using fractional 
olynomials the independent variables are assumed to be positive. If the preceding 
mial for interventricular mechanical delay 
roduces warnings concerning th
 
 
th
 
l 
plines 
n e. 
e 
 the 
p
code is run, but this time a fractional polyno
is included then mfp p e failure of the algorithm to 
converge. By default mfp should shift and scale variables to avoid numerical 
problems if negative values are present, as is the case for interventricular mechanical
delay.  I have noted that interventricular mechanical delay is indeed shifted and 
scaled, yet the warnings from mfp persist, this is the case even if manual shifting and
scaling is employed.  
4.4.0 Splines versus Fractional Polynomials   
 
Is it better to use splines or fractional polynomials in statistical modelling? Both 
me ods have very appealing aspects. The fractional polynomial is elegant and 
compact; we can see that the standard transformations are continued with the 
definition of a fractional polynomial. Does the piecewise nature of the spline afford an
advantage over the fractional polynomial?  Royston and Altman criticise conventiona
polynomials as often not providing a particularly good fit. In their view cubic s
are considered to be too computationally intensive, and not amenable to easy 
interpretation. Also splines are not implemented in standard regressio  softwar
Splines do not provide equations that can be easily used for prediction. Royston and 
Altman made these remarks back in 1994, from a computational perspective things 
have moved on, the software is now available and fast processors now make it quite 
feasible to fit cubic splines routinely. Royston and Altman also suggest that th
concept of splines is difficult to explain to a ‘non-expert’ user. I take the view that
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 GNU R p
analysis using fractional polynomials is vital, when first encountered fractional 
p etermine 
 degree of strange behaviour 
near endpoints as that of conventional polynomials. This issue is of great interest to 
 numerical stability of cubic sp c  
to fractional polynomials would be a useful area for future research.  If appropriate a 
more simple approach such as fitting a quadratic or a cubic term should not be 
odel can be a lo
p  
method
r good reasons can be 
 model th sier to interp splines.  
I would suggest that categorising continuous variables if done sensibly is a perfectly 
   
I have talked about specifying the functional form for a model, but so far I have not 
discussed a means of selecting between different models. For example if I wish to 
establish whether using the natural log transformation has any benefit, I need to 
compare the model using the transformation with the model without the 
tr were to see an improvement in the fit of the model using the 
ort of the %mfp8 macro produces output that is easier to interpret than that 
produced in the SAS version. This is a matter of personal taste, but clear reporting of 
olynomials can be somewhat confusing, at first it can be a little difficult to d
what exactly the best polynomial is. In (Royston & Altman 1994) the authors state 
that fractional polynomials tend not to display the same
the present author, investigation of the lines ompared
abandoned, this approach avoids the need for additional macros and there is no doubt 
that the resulting m t easier to interpret. I would recommend that 
sim le transformations such as these are applied before recourse to more complex
s. Dichotomising continuous variables is widely used in medical and 
epidemiological applications. Although as discussed earlie
supplied to avoid dichotomising continuous variables, however this approach does 
result in a at is ea ret than one which includes say cubic 
reasonable approach.  
ansformation. If I 
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 transformation, then I would consider the transformation beneficial. Here I am 
presented with the proble el selection.  In the next chapter Im of mod  consider the use 
of the AIC (Akaike Information Criteria) as a model selection tool. 
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 CHAPTER 5 MODEL FIT, LIKELIHOOD, THE AIC 
 
 
 Introd
 
 In the previ
The functio
variables or
 
• Th
• A 
mo
• Th  
mo
• Th
• I
• AI
SA
• AI
dim
A
NL
5.0.0
example wo
chapter the 
selecting the
likelihood t
based upon 
 e AIC is a penalised log likelihood model selection criterion. 
modified AIC is required for small samples or where the number of 
del parameters is large relative to the sample size. 
ere are issues with the AIC regarding estimation of the order of the ‘true’
del. The AIC posits a ‘true’ model of infinite order. 
e BIC posits a ‘true’ model of small dimension, the BIC is said to be 
C and ants implemented for mixed models in SAS via GLMMIX, 
C and BIC implemented for models with time dependent covariates in 
S via PHREG. 
C for frailty models, further investigation may be required  
ension consistent. 
vari
MIXED and MIXED. uction 
ous chapter the question of the functional form of a model was discussed. 
nal form will have an effect on how well a model fits the data. For 
e nat l hm of one o
 fitting a cubic spline lead to an improvement in the fit of a model. In this 
a
 
uld taking th ura logarit r more of the independent 
idea of model fit is investigated in more gener l terms, the idea of 
 ‘best’ model is considered. I now review some standard topics in 
heory. I shall concentrate on the idea of likelihood and selection criteria 
the concept of maximising the likelihood. I wish to make it absolutely
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 clear that all of the mathematical derivations in this chapter are of known resu
attributable to others, 
lts 
and similar derivations may be found in a number of classic 
xts. A very comprehensive treatment of likelihood theory can be found in Pawitan’s 
book (Pawitan 2001). The graphical figures in this chapter where produced by myself 
sing simulated data in GNU R (R Foundation for Statistical Computing 2009). 
 
 
tical m delling. R.A Fisher (F
(Fisher 1934a) and (Fisher 1934b) formulated the idea of likelihood as a middle 
gro e an d frequentist camps. A basic distinction between the 
Bayesian and frequentist approach can be made with reference to the meaning of 
statements such as the probability of observing a HEAD with a fair coin is 0.5. The 
uentist would insist that the value 0.5 is only meaning
the coin where to be tossed a second time the Bayesian would be quite happy to say 
he 
ay that t
he 
a s 
and r ability. With likelihood methods the 
sing ‘pure’ 
obability. If I toss a coin 5 times and observe the sequence HEADS, TAILS, 
te
u
5.1.0 Likelihood 
Likelihood plays a central role in statis o isher 1932), 
und b tween the Bayesi  an
freq ful as a long run measure. If 
that that his or her degree of belief that the coin would show a HEAD was 0.5. T
frequentist would s his value is only meaningful in the long run. Note a 
Bayesian would also accept the idea of a probability being a long run measure. T
important point so far as a discussion of likelihood is concerned is that both B yesian
 frequentists make inferences based on p ob
likelihood function is used to make inferences, inference is not made u
pr
HEADS, HEADS, TAILS, then the probability of observing this sequence is 
)1()1( ppppp −×××−×  or 435 2 ppp −+ , w
EADS and 1-p is the probability of observing TAILS. If 
here p is the probability of observing 
X denotes the number of H
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 heads we observe then in the example above 435 2)5;3( pppnXP −+=== . 
435 2)5;3( pppnXP −+===  is called the likelihood function, denoted by L  
.What value of p makes the sequence HEADS, TAILS, HEADS, HEADS, TAILS 
most likely? 
 
 
Figure 5.1 Likelihood Function versus Probability 
against s that the 
likelihood is function is a maximu
 
In figure 5.1 a plot of p show
m for 6.0
435 2)5;3( pppnXP −+===
=p , this value of p for which the 
likelihood function is a maximum is know aximum likelihood estima
(MLE). I know that for a fair coin
n as a m te 
5.0=p , from figure 5.1 I see that for  the 5.0=p
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 sequence HEADS, TAILS, HEADS, HEADS, TAILS is less likely to be observed.  If 
I were to toss the coin say 1000 times and observed around 500 HEADS , then a plot 
 likelihood function against p would show that the likelihood function is a 
m  . In the coin tossing example above if I believed  p to be 0.01, 
then I obtain a likelihood of , if I believed p to be 0.6, then I obtain a 
likelihood of   0.03456. Likelihood can be said to provide a measure of belief. The 
l  principle states  information about a sample is contained within 
ovide evidence to support or contradict 
our belief, if I believe a coin to be fair (i.e. p=0.5) then if for example I obtained a 
y belief, if I estim
0.5 then I have evidence to support my belief. Population parameters such as p are 
generally denoted by
of the
aximum for p 5.0=
7108.9 −×
like ihood that all the
the likelihood function. The MLE can also pr
MLE of p = 0.89, I have evidence contrary to m ate p to be close to 
θ , in the following treatment of likelihood theory I will confine 
myself to the single parame
concern of this thesis (fitting a Cox model) requires a multi parameter formulation of 
likelihood theory. For discrete data we can write 
ter case, however the type of problem which is the 
. Continuous data 
 
)()( xXPL ==θ
presents a problem, I cannot talk about the probability of a continuous variable being
exactly equal to a particular value, e.g. )( xXP =  is not meaningful. However I ca
talk about the probability of a continuous variable lying with an interval 
n 
)
22
aa ,( xx +−  around x. If the interval )
22
aa ,( xx +−  is small then 
∫
+
−
2
2
ax
ax
= );()( dxxfL θθ , where  is the probability density function (p.d.f). It is );( θxf
∫
+
=
2
);()(
ax
dxxfL θθ  by );(
−
2
ax
θxaf , where a  is very small, this possible to approximate 
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 approxim ta is precise. If I now consider 1  and 2 , where 
1X  and 2X  are identically independently di ted (i.i.d) then 
ation is valid only if the da
stribu
X X
);();()(
2
2
1
1
θθ xafdxxfL == ∫ 1
1
θ
ax
ax
+
−
 and );();( 2
2
2
θθ xafdxxf =∫  I may combine 
these likelihoods to give );();()()()( 2121
)(2
2
2
θL
ax
ax
=
+
−
θθθθθ xafxafLLL == . For discrete data I 
have )()()( 2211 xXPxXPL ===θ . For continuous data I notice the presenc of te he 
constant a in the expressions for )(θL , the constant a can in fact be omitted from the 
ressions forexp  )(θL , this can be justified by using the following argument. Consider 
the model );( θxf  , (note a p.d.f can be described as a model), further  consider the 
likelihood with different values for θ  , 1θ  and 2θ . I wish to compare )( 1θL  and 
)( 2θL , let the likelihood ratio (Note I shall discuss the likelihood ratio in greater 
detail later in this chapter) b
L =)(
1
2θ , then )( 1L )(θ θL  and )( 2θL  are only meaningf
to a constant multiplier, we have )()( 12
ul up 
θθ bLL =  , so if I were to consider multiples of
)( 1
 
θL , )( 1θaL is only meaningful for a up to b. In view of this I may write 
);();()(
2
ax
ax
+
−
2
θθ xfdxxf ≈= ∫ and for combined 
21
θL
likelihoods )()()( 21 );();( θθθθθ xfxfLLL == .  In general I have 
∏ == n
i
xXPL )()(θ  discrete case ii
∏= n ixfL )()(θ  continuous case 
i
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 It is mathematically more convenient to work with the natural logarithm of the 
likelihood function, i.e. log ))(( θL . So I have for the discrete case 
ixXP  
tinuous case 
 
Often interest is focused on obtaining a point estimate of some population parameter, 
ean 
e
))((log∑ =n
i
ie
And for the con
))((log∑n ie xf  
i
e.g. the sample m x as estimate of the population mean, or as an estimate of 
lation varianc . The MLE offers another way of obtaining a point estimate, 
s where the data may not 
deal of information, and where there is a degree of uncertainty. The 
om earlier represents a situation where I have a small amount of data, 
the fact that conclusions I make about this data will be quite uncertain.  
ise
2s
e 2σpopu
but it is of great importance that attention be paid to the general shape of the 
likelihood function. Likelihood is a valuable tool in situation
provide a great 
coin example fr
I cannot ignore 
I wish to maxim  )(θL  or )(log θLe  i.e. I want to find θ  such that 
0)(log =∂ θLe∂θ . I said earlier that it is important to consider the overall shape of the 
likelihood function, if for example I have obtained a MLE of θ , θˆ , how certain  am I 
stimate ofthat θˆ  is the ‘best’ e  θ ? This question can be answered by looking at the 
re of the likelihood function.curvatu  θ . If   is a solution of θθ ˆ= 0)(log =∂
∂ θθ Le , 
then  0)(log2
2
<=∂− θθ
ˆ∂
θ Le , also if )(log2
2
θθ ˆθ =∂
∂− Le is large then )(log θLe  has
a tight or sharp peak, this is interpreted as meaning that there is less uncertainty in
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 regard to my estimate of θ . If )ˆ(log2 θθ2θ =∂
∂− L  is small, then )(loge θL  will no
have a sharp peak, this means that there are a number of values of θˆ  that are quite
close to the solution of
e t 
 
0)(log =∂ θLe . Put simply I am uncertain as to what 
numerical value of  θˆ  maximises )(log
∂θ
θLe . The quantity 0)ˆ(log
2
<=2∂
∂− θθθ Le
known as the observed Fisher information (as th ple size increase then the Fishe
informatio
 is 
e sam r 
n increas . There are m ces when a solu ed form 
solution) of
es) any instan tion (a clos
  0)(log =∂
∂ θθ Le  is not possible, in such cases I am obliged to use 
umerical methods to obtain an approximate solution. Taking the Taylor series of n
)(log θL about θˆ    I havee
)(log
2
ˆ
)(log)()(log)(log 2
22
θˆ)(ˆˆˆ θ
θθθθθθθθ LLLL eeee ∂
∂−∂ +∂−+≈   
The above is a quadratic approximation of )(log θLe , in order to make the expression 
a little more com act denote p )(log θθ Le∂
∂  by )(θCS  and )(log2
2
θθ Le∂
∂ )(θ−  by I
then I have 
F , 
 )ˆ()ˆ(log)(log θθθθ −+≈ LL ee )ˆ(θCS - 2
)( θθ − )ˆ(θIF .   
If a quadratic approximation is a good fit for )(log
ˆ 2
θL  then )(log θL  is said to be e e
regular. For regular log likelihood function   and θˆ )(θI
repres
F  can be used to 
ent )(log θLe .  The following example may help clarify some of the ideas 
 a i.i.d sample from a normal distribution with discussed above. Let nxxxx ,...,,, 321 be
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 2
parameters 2,σθ . I have
2
2
)(
2
1);( σ
θ
σπθ
−−=
ix
i exf . 
Also );()...;();()( 21 θθθθ nxfxfxfL = , hence it is seen that 
∑−= ie xn 2 )(lo) , and −ne L
1
2
22
1(log σ
θ
σπθ g 2
1)(
)(
σ
θ∑ −n ix
The Fisher Information 
θ =CS  .  
)(θIF  = 2σ
n , also
n
2
)ˆvar( σθ = , hence var())(( IF . The 
connection can be seen between the Fisher Information and the variance of , i.e. the 
connection between curvature (measure of uncertainty) of the likelihood function and 
the variance of . Fisher Information is of fundamental importance in likelihood 
formation theor  relevant to the discussion of the 
A nformation C
 
5.2.0 Likelihood Ratio 
Given a dataset it is possible to fit any number of models, amongst these models some 
. A method of com h e models is 
required in order that the ‘best’ one is selected. I can compare two models by 
)ˆ1 θθ =−
theory, in a later section I shall some of the basic ideas in what is known as 
In y. Information theory is highly
 θˆ
θˆ
kaike I riteria. 
 
may fit the data quite well, others not so well paring t es
),(
),(
yL
yL
b
a
µ
µ
 examining the likelihood ratio .Note aµ  refers to turated model the full or sa  
 and fm bµ  to some model . bm
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 0
),(
),(
log =⎟⎟⎠
⎞
⎜⎜⎝
⎛
yL
yL
b
f
e µ
µ
 suggests that  is a good fit. bm1),(
),( yL
b
f ≈
yL µ
µ
 or  So 
Let )),((log)),((log
),(
log yLyL
yL
befe
f
e µµς −=⎟⎟
⎞
⎜⎜
⎛= , large values of 
),( yL bµ
µ
⎠⎝
ς  indicate 
that  is a poor fit to the data. The quantity bm ⎟⎟⎠
⎞
⎜⎜⎝
⎛
),(
),(
log2
yL
yL
b
f
e µ
µ
is known
 ote y
 as the 
deviance, and is usually den d b ),( µyD . It is important to remember that when 
using the deviance to assess goodness of fit circumstances can easily arise that render 
the deviance useless as a means of gauging this. If we want to compare two nested 
models  and  we examine the change in the deviance 1m 2m
⎟⎟⎠
⎞
⎜⎜⎝
⎛=⎟⎟⎠
⎞
⎜⎜⎝
⎛−⎟⎟⎠
⎞
⎜⎜⎝
⎛=−
),(
),(log2
),(
),(
log2
),(
),(
log2),(),(
1
2
21
21 yL
yL
yL
yL
yL
yL
yDyD e
f
e
f
e µ
µ
µ
µ
µ
µµµ  
he deviance follows the  distribution with 2χ 21 dfdf − degrees of freedom. T
  
With nested models I use the deviance to assess whether a term is significant or not, 
for example I may want to compare the model XXcY 2211 ββ ++=  with odel the m
11 XcY β+= . I might be interested in whether  is significant or not, I look at the 
change in the deviance d
2X
ue to the inclusion/exclusion of . Note it should be 
remembered that for each of the models in the above example the deviance is a 
comparison of the fitted model to the full model. 
I must bear in mind that when comparing nested models I am assuming that 
2X
φ  the 
eter is equal to 1, if this is not the case then dispersion param ),(),( 21 µµ yDyD − is 
not meaningful. In situations where 1≠φ I use what is known as the scaled 
deviance φ
µµ ),(),( 21 yDyD − . 
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 Some discussion of  φ  is worthwhile, to understand the dispersion parameter I need
 
I now review some standard results relating to the Exponential Family of 
Distributions (Dobs  useful section on this topic. A distribution 
 to 
consider the Exponential family of distributions.  
5.3.0 The Exponential family of distributions 
on 2002) contains a
belongs to the exponential family if it is possible to write );( θxf  in the 
form , where are all known functions. Let 
and , then I may write . For example consider the 
n
)()()()( θθ bxaevxu bavu ,,, )()( xgexu =  
)()( θθ hev = )()()()();( θθθ bxahxgexf ++=
Poisson distributio
!
);(
x
exf
x θθθ
−
= , );( θxf  can be written .  
inition
))!(log)(log( xx eee −−θθ
By def 1, then );( =∫
β
α
θ dxxf 0);( =∫
α
θθ dxxfd
β
and 0);( =∫
β
α
θθ dxxfd
d . d
0);(2
2
=∫
β
α
θθ dxxfd
dUsing the same approach I find that . 
w in general  so No  )()()()();( θθθ bxahxgexf ++= ))()()()(;();( θθθθθ hxabxfxfd
d ′+′= . 
Using 0);( =∫
β
α
θθ dxxfd
d , I get  which can be 
written as
0))()()()(;( =′+′∫ dxhxabxf
β
α
θθθ
0)()]([)( =′+′ θθ hxaEb , or 
)(
)()]([ θ
θ
b
hxaE ′
′−= . 
I have ]))()()(()()()()[;();( 22
2
θθθθθθθ hbxahxabxfxfd
d ′+′+′′+′′= , 
22
2
22 )])([)(())((
)(b ⎟⎠⎜⎝ θ
)()())(())()()(( xaExabhxabhbxa −′=⎟⎞⎜⎛ ′
′+′=′+′ θθθθθ  . Also 
])])([)(())(()()()()[;();( 222
2
xaExabhxabxfxf
d
d −′+′′+′′= θθθθθθ , this leads to 
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 ∫ =′+′′+′′ θ [( aE=
β
α
θθθθ 0)](var[))(()()]());(
2
2
2
xabhxbxf
d
d . 
2))((
)()]([)()](var[ θ
θθ
b
hxaEbxa ′
′′−′′−= , but
)(
)()]([ θ
θ
b
hxaE ′
′−=So , so I get 
 
3))(( θ
)()()()()](var[ θθθθ
b′
hbhbxa
′′′−′′′= .  
gReturning to the Poisson distribution I have )lo (θeb = , b is what is known as a 
natural parameter. Now 2
2
)()]([
db
dhxaE
db
d θθ′−= , be=θ , therefore 
behx ()]( θ′−= te aE
db
d )[ and so I may wri θθ ==xaE
d ([1′−
be
dbh
)]
)(
, but from the 
I must have fact that be=θ bexaE
db
d =)]([ , therefore 1
)(
1 =′− θh . In fact )(
1
θh′−  is 
eterthe dispersion param φ , for the Poisson distribution I have 1=φ . In general I 
have ][)var( XE
b
X ∂
∂= φ . The dispersion parameter is of great importance in that it 
allows for a more flexible relations tween the mean and the variance. Certain 
distributions have limitations as far as statistical modelling is concerned; this is due to 
the relationship between the mean and the variance. For the binomial distribution I 
have  
hip be
np=µ  and , I see that the mean and variance are related. When 
ial distribution I can encounter the following problem. 
e ata exhibits a larger degree of variability than that assumed from the Binomial 
ution. The converse situation can also occur, the data is found to have a smaller 
degree of variability than that expected from the Binomial distribution.   In these 
situations I have over dispersion and under dispersion. The Exponential Dispersion 
npq=2σ
modelling data using Binom
Th  d
distrib
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 model φ
φφθθ
φθ
),()(
),;(
xVUx
exf
++
=
under dispersion. The dispersion param
allows me to circumvent the problem of over or 
eter φ  is an unknown scale parameter, earlier 
it was stated that in general ][)var( XE
b
X ∂
∂= φ , this indicates that statistical variance 
is closely related to the concept of scale. For instance the normal distribution is 
described in terms of two parameters, a location and a scale parameter. The location 
parameter corresponds to the mean µ and the scale parameter to the variance .  
.4.0 Information Theory 
a. Information theory may be 
athematical study of methods and limits for data communication.  In 
948 Claude Shannon (Shannon 1948) an American Mathematician and Electrical 
ngineer published a paper which may be regarded as laying the foundation of 
scinating area of study; 
und material on informati
sing the Akaike Information Criteria (Akaike 1974), and 
deed the general problem of accessing model fit. 
5.4.1 Information and Entropy 
 
Again I consider a simple coin t sing experiment; assuming I have a fair coin, and 
times, I observe the sequence  
2σ
5
 
Likelihood is connected to Information theory, as will be seen later the likelihood 
function appears in the Akaike Information Criteri
defined as the m
1
E
modern information theory. Information theory is a rich and fa
statisticians owe a great deal to the work of electrical engineers and mathematicians 
such as Shannon. As indicated earlier some backgro on 
theory is useful in discus
in
os
that I toss the coin say eight times. A typical outcome would be the sequence  
1 0 1 0 0 1 0 0, where 1 denotes HEADS. Now suppose I toss the coin another eight 
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 0 0 0 0 1 0 1 1. I repeat this operation a number of times, I build up a set of sequences 
such as those shown below: 
1 0 1 0 0 1 0 0 
0 0 0 0 1 0 1 1 
0 0 1 0 1 1 0 0 
0 0 0 0 1 1 0 1 
Etc. 
Now consider a similar experiment but this time I use a biased coin, let P(HEADS) 
1 1 1 1 1 1 1 1 
 1 1 1 
The
each sequence displays a degree of variety or variation, whereas those for the biased 
coin are identical. If these sequences were used to convey information then those 
1 1 1 0 0 1 1 0 
0 0 0 0 1 1 0 1 
1 0 1 1 0 0 0 1 
0 0 0 0 1 0 1 0 
=0.99. Then I might obtain the following set of sequences: 
1 1 1 1 1 1 1 1 
1 1 1 1 1 1 1 1 
1 1 1 1 1 1 1 1 
1 1 1 1 1 1 1 1 
1 1 1 1 1
1 1 1 1 1 1 1 1 
1 1 1 1 1 1 1 1 
Etc. 
 obvious difference between these two sets of sequences is that for the fair coin 
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 generated by using a fair coin would allow us to present ‘r
fair coin I am less certain that a HEAD will appear, but I have greater information. 
coin I am almost certain that a HEAD will appear, but there is a 
icher’ patterns. With the 
With the biased 
drastic reduction in the amount of information. Uncertainty and information can be 
measured by what is known as entropy.  For a random variable X  aving n possiblh e 
outcomes the Shannon information entropy  is given by 
Again using the example of a coin, figure 5.2 below is a plot of 
)(XH ∑− n ibi xpxp
1
)(log)( . 
)(XH  versus 
probability of getting HEADS. 
 
Fi e 5.2 Shannon information entropy versus Probability. 
 
gur
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 It can be seen that , i.e. for s quenc
sent. In situation whe e I am less certain o
the outcome, I find greater inform
 )(XH  is 0 for P(HEADS)=0 and P(HEADS)=1 e es 
such as 0 0 0 0 0 0 0 0 and 1 1 1 1 1 1 1 1 the Shannon information entropy is 0, 
sequences such as these are easily predicted. In situations where I am certain of the 
outcome I find very little information is pre r f 
ation is present. In the coin example if 
P(HEADS)=0.5, then is at a maximum. With a fair coin I obtain sequences 
such as 1 0 1 0 0 1 0 0 which is less predictable and so contains more information.  
For the benefit of the interested reader additional material on entropy and statistical 
physics is presented in Box 1, Material on entropy and comparing probability 
i resented in Box 2. I include this material because I believe it may 
provide an interesting historical background to the origins of quantities such as the 
AIC. 
Box 1 Entropy and Statistical Physics 
 
For the benefit of the interested reader we shall now look at the connection between Shannon informa y  
)(XH
distribut ons is p
tion entrop
and entropy as defined in statistical physics. I shall consider some standard results from thermodynamics. One the 
se  Ludwig Boltzmann see (Boltzmann 1872) and (Cercignani minal papers in statistical physics was written by
2007). An excellent treatment o ot cycle f statistical physics can be found in (Blundell & Blundell 2006). For a Carn
we have  
ll T
T
Q
Q ee = , wher and are the heat entering and leaving the system respectively, and  and  are the e eQ lQ eT  lT
temperatures of two heat reservoirs between the system, note . Lele TT > t rvQ∆  be the heat entering the system 
at each point, then 0=+∑
l
l
e
e
cycle
rv
TTT
, we may write this in the form of an integral 
)(−=∆ QQQ
∫ = 0TdQrv . Given that ∫ = 0TdQrv , then ∫
β
α
rv  is independent of the path, we may express 
T
dQ
T
dQrv  as 
an exact differential,
T
dQ
dS rv= , S is defined to be the entropy. The first law of thermodynamics may be stated 
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 in the form dWdQdu += . We may write TdSdQ =  and pdVdW −= , so pdVTdSdu −= . Also 
using total derivatives we have  
dV
V
UdS
S
UdU ⎟⎠
⎞⎜⎝
⎛
∂
∂+⎟⎠
⎞⎜⎝
⎛
∂
∂= , hence 
S
UT ∂
∂=  and 
V
U
∂
∂−p = y definition temp  T is given. B  erature
by 
dE
d e )(log1 Ω
TkB
 is th ostates associated with a particular macrostate. By =  where Ω e number of micr
combining 
dE
d
Tk
e )(log1 Ω=  and 
SB
UT ∂
∂= , we can obtain an expression for S as follows: 
Rearranging 
dE
d
TkB
)(log1 Ω
 gives e=
Be kd
dET
)(log Ω  . So we have= Be kd
dE
S
U
)(log Ω∂ =
∂
 , 
hence 
dE
kdS Be )(log Ω=∂ . 
U∂
Integrating we obtain )(log Ω= eBkS , this is the Boltzman expression for entropy.  
Let a system have an number of equally likely states , then the entropy S is )(log  However it obN obeB Nk .
may be that each of the tates comprises of a number of microstates, which may be extremely difficult to obN  s
observe or measure, the total entropy mt SSS += , wher  is the entropy connected with the microstates. e mS
Let a system have N equally likely microstates, if theses microstates are arranged into groups (macrostates) with 
iN   microstates contained within the ith macrostate, then NN
i
i =∑ . The probability iP that the system 
occupies the ith macrostates is given by 
N
N
P ii = . Now mt SSS −= , S is the measurable entropy. We 
have )(log NkS eBt = , and the entropy of the microstates within the ith macrostate is )(log ieBi NkS = . 
 We cannot measure mS  the entropy connected with being in any different microstate. However we can 
access mS , through the relationship )( im SES = , (note here E denotes the expected value), so 
)(log)( ieiBim NPkSES ∑== . From mt SSS −=  we see
i
 that 
∑−= iBeB PkNkS lo)(log
i
ie N )(g , th  written as is expression may
∑∑ −=∑ −
i
ieeiB NNPk ))(log)((log  or ⎟⎠
⎞
⎜⎝
⎛
i
ieiB
i i
eiB PPkN
Pk )(loglog .  ⎟⎜ N
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 ∑−= PPkS )(log  (The Shannon entropy), we see here the similarity in functional form of the Shanno
i
ieiB n 
entropy and the Shannon information entropy ∑−= n ibi xpxpXH
1
)(log)()( . 
 
 
 
Box 2 Entropy and the Comparison of Probability Distributions 
We notice that in the expression for both the Shannon entropy and the Shannon information entropy we are dealing 
 
 
 
 
w p.d.f by x  ith one probability distribution, let us assume this is the true distribution and denote the )(p  . Let us 
consider some other ution with p.d.f )(xq . An important question would be how different is distrib
)(xq from )(xp ? The expression 
∑∑ −−=⎟⎠
⎞⎜
⎝
⎛−
i i
i xpxpxqxpkxqxpk )(log)()(log)()(log)(  can be writ⎟⎜ ieiiee xp )( ten as i iBiB
)])([log)]([log( xpExqEk ieieB −− .  
he quantity [log( qE )])([log)](T xqEx ieie −  provides us with a measure of the ‘difference’ or 
distance between )(xq and )(xp . If  )(xq  is close to the true distribution )(xp  then 
)])  will be small. ([log)] E−([log( xpxqE ieie
 We can describe 
∑∑ −−=⎟⎟⎜⎜− ieiieiBieiB xpxpxqxpkxp xqxpk )(log)()(log)()( )(log)(  the generalised ⎠
⎞
⎝
⎛
ii i
 as
Boltzmann entro y , denoted GB  (Chakrabarti & Chakrabarty 2006) .  The quantity  p  
)])([log)]([log( xqExpE ieie −  is of particular importance in statistics as it relates closely to the 
Kullback Leibler distance, denoted  KL, see (Kullback  & Leibler 1951), (Bozdogan 1987) and (Nariaki  1978). 
For a discrete random variable we have KL given by∑ ⎟⎟⎞⎜⎜⎛
i i
i
ei
xpxp )(log)( , we see that xcept fo
⎠⎝ xq )(
 e r the 
constant . For a continuous random variable we have KL given Bk , GBKL −=
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 ∫ ∫∫ −=⎟⎟⎠
⎞
⎝
⎛ β
α
β
α
β
α xq
xp
)(
)(
by ⎜⎜ dxxqxpdxxpxpdxxp eee )(log)()(log)(log)( .  The first term in the 
previous expression is the Shannon entropy which is constant, the second term  is ∫−
β
α
dxxqxp e )(log)(
known as the cross entropy. The cross entropy gives us a measure of the distance between )(xp  and )(xq . 
Viewing KL as a measure of the distance between the true distribution  and to minimise the )(xp )(xq , we need 
cross entropy. 
The following example may elp us to see what the KL is about. Let the true distribution  of)(xp  X h be the 
standard normal distribution.  So 2
2
1)(
x
exp
−= π . 
Let 
2
2
2
)(
2
1)( σ
µ
σπ
−−=
x
exq , then using ∫∞
∞−
⎟⎟⎠
⎞
⎜⎜⎝
⎛ dx
xq
xpxp e )(
)(log)(  we have 
dxxedxeKL ee ∫∫ −+−= 222)2(log)2(log 222
22
πσππσπ
x xx ∞
∞−
−∞
∞−
− −
2
1)(1 22µ
. 
dxxxeKL
x
ee ∫∞
∞−
⎟⎜ −+−= 2πσπWe may write,  − ⎟⎠
⎞
⎜⎝
⎛ −
22
)(
2
1)2(log)2(log
2
2
22
σ
µ
π . 
So 
dxxxxeKL
x
ee ∫∞
∞− ⎠⎝ 222 2
2
σπ
−
⎟⎟
⎞
⎜⎜
⎛ −+−+−= 21)2(log)2(log
222
2 µµπσπ . 
Also the integral in the above expression can be written 
∫ ∫ ∫∫∞
∞−
∞
∞−
∞
∞−
∞
∞−
−+− dxxedxexdxedxxe
xxxx
22
2
2
2
2
2
2
222
2222222 ππσπσπσ
−−−− 22 111111 µµ  
This may be written as 
 ∫∫ ∫ ∞
∞−
−∞
∞−
∞
∞−
−− +−⎟⎞⎜⎛ − dxexdxedxxe
xxx
2
2
222
222
11111 µµ
 . ⎠⎝ 222 222222 πσπσπσ
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 Using the fact that for a continuous random variable µσ )( xxp , we may ∫ −=
β
α
222
write ∫ +=
β
α
µσ 222)( dxxxp , we know that X follows the standard normal distribution, so 
∫∞
∞−
− = 1
2
1 22
2
dxxe
x
π . Also ∫
∞
∞−
− = 0
2
1 2
2
xdxe
x
π and by definition 
∫∞
∞−
−1 =1
2
2
2
dxe
x
π , so ∫
∞
∞−
− 22 1 µµ = 222 222
2
σπσ dxe
x
.  
Thus  
2
22
222
22
1
2
1
22
1
2
1
2
1
2
1
22 µµ
π
µ
π +−=+−⎟⎠
⎞⎜⎝
⎛ − ∫ ∫∞
∞−
∞
∞−
−−
xdxedxxe
xx
. 2222 σσσσσ
So  ⎟⎟
⎞
⎜⎜
⎛ −+−=−++−= 11
2
1)(log
2
1
22
1)2(log)2(log 222 σ
µσσ
µ
σπσπ eeeKL  ⎠⎝
22
As a rule we of course do not know what the true distribution is. If the true distribution was for example the 
normal distribution with mean tµ  and variance t2σ , and we have )(xq as above, then 
⎟⎠
⎞
⎜⎝
⎛ −
⎟⎠
⎞
⎜⎝
⎛
tt
e 22
2
2
2 )(
2
1
2
1
σ
µµ
σ
σ
σ
σ
t⎟+−+⎟⎜= tKL 1log . We s at KL is expressed in terms of ⎜ t ee here th µ  
and t2σ . 
We can make the following remarks about KL: 
 0≥KL   and if )()( xqxp ≠ then );();( pqKLqpKL ≠  i.e. KL is not symmetric.  
The first result can be obtained as follows: 
Let 
)(xp
u = . )(xq
 Jensen’s inequality states 
][log)](log[ uEuE ee −≥−  , where u is a convex function. 
So we have 
]
)()( xpxp ⎠⎝
)([log])(log[ xqExqE ee −≥⎟⎟
⎞
⎜⎜
⎛−  
Therefore 
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 ⎟⎟⎠
⎞
⎜⎝
⎛
⎟⎠
⎞
⎜⎝
⎛
⎟⎠
⎞
⎜⎝
⎛
xp
xq
xp
xq
ee )(
)(
)(
)( β
α
β
α
⎜ ⎟⎜−≥⎟⎜− ∫∫ dxxpdxxp )(log)(log  
But 1)()( =⎟⎠
⎞⎜
⎝
⎛∫ dxxpxq
β
α
. 
)( ⎟⎜ xp
So 0)(
)(
)(log ≥⎟⎟
⎞
⎜⎜
⎛−∫ dxxpxp xqe  ⎠⎝
β
α
Hence 
0)(
)(
)( ⎞⎛ xpβ log ≥⎟⎟⎠⎜
⎜
⎝∫ dxxpxqe  α
Now ∫ ⎟⎟⎠⎜⎜⎝= α dxxpxqKL e )()(log , so 
⎞⎛β xp )(
0≥KL . 
We can show );();( pqKLqpKL ≠ as follows: 
∫ ⎟⎟⎠
⎞
⎜⎜⎝
⎛=
β
α
dxxp
xq
xpqpKL e )()( ∫ ⎟⎟⎠
⎞
⎜⎜⎝
⎛=
β
α
dxxq
xp
xqpqKL e )()(
)(log);()(log);(  and , so 
∫ ∫−= dxxpxqdxxpxp ee )()(log)()(log  
β
α
β
α
qpKL );(
∫ ∫
β
α
β
α
ee −= dxxqxpdxxqxqpqKL )()(log)()(log);(  
);( pqpKL  if and only if ∫ ∫=
β
α
β
α
dxxqxqdxxpxp )()(log)()(log . (); KLq = ee
 
There is a significant drawback to KL, bserve it. KL relies on us knowing the true distribution. As we cannot o
stated earlier KL is expressed in terms of the parameters of the true distribution which are unknown. We need then 
to consider how we might obtain an estimate of KL from the data. 
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5.4.2 Estimating theKullback Leibler distance by the AIC 
hen fitting models to a dataset I desire the model which maximises the likelihood 
r the log likelihood). That is, I want to maximise . I could 
lso look at maximising 
 
W
))((log)(log ∑= n
i
iee xfL θ(o
a
n
xf
n
L
n
i
ie
e
∑
=
))((log
)(log θ
.  
 
For a large enough dataset 
)](([log
))((log
XfE
n
xf
e
n
i
ie
=
∑
. 
 So in maximising the likelihood I maximise  (note f() is the model that 
I am trying to fit).  In my discussion of the Kullback Leibler (KL) distance I noted 
that I aim to minimise the cross entropy (and L) i.e. minimise 
 or maximise .  
KL can be estimated by
)](([log XfE e
 so minimise K
)]([log)(log)( xqEdxxqxp ee −=− ∫
β
α
)]([log)(log)( xqEdxxqxp ee =∫
β
α
n
xf
dxxpxp
n
i
ie
e
∑∫ −
))((log
)(log)(
β
α
eans that KL can be estim
. I said earlier that the 
Shannon entropy is constant; this m ated by 
n
xf
n
i
ie∑
−
))((log
 
I can make the following important statements.   
1 Maximising the likelihood is equivalent to minimising KL, i.e. maximising 
 is equivalent to minimising KL. )](([log XfE e
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 2 In fitting models to a dataset I seek the model that maximises  . 
n practical situations I would maximise  where  is a MLE of the 
paramete
)](([log XfE e
 I )]ˆ;([log θXfE e θˆ
rθ , (note  and θˆ θ  could of course be vectors). It is tempting to think that I 
can use , the maximised log likelihood, to estimate 
, but this quantity is biased. For instance if I have nested models; the 
est number of parameters will always give the largest value 
. Similarly this problem with bias means that estimating KL by 
∑n
i
ie xf )ˆ);((log θ
)]ˆ;([log θXfE e
model with the larg
for∑n
i
ie xf )ˆ);((log θ
n
xf
n
i
ie
−  leads to a distorted estimate of KL.  
thod can be used to obtain an estimate of standard error in the 
following way. Let  
∑ ))((log
There are several ways to tackle the problem of obtaining an unbiased estimate 
of , one example is The Jackknife method (Miller 1974). For example )]ˆ;([log θXfE e
the jackknife me
ijx ≠ be the sample mean of  based on the sample with the ith  
observation deleted. Let ()x  be the average of ijx ≠ .Then [ ]212
1
() )(
1∑
= n
the jackknife estimate of the standard error.  
Another method is the Akaike Information Criteria (AIC).  I shall alter slightly the 
th
model. The AIC is an unbiased estimate of kke XfnE θ , therefore I wish to 
≠ −−
n
j
ij xx
n  is 
notation and use )];([log kke XfE θ , this is to remind me that I am considering the k  
model from a number of possible models. The AIC is given by 
∑ +−= n pxfkAIC 2)ˆ;(log2)( θ , where p is the number of parameters in the 
ˆ
i
kike
)]ˆ;([log2−
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 find the model that minimises the AIC. I shall now look at how the AIC is deriv
from the derivation described in chapter 13 of Pawitan’s bo
ed; 
ok (Pawitan 2001). Given 
kthe model ,(k xf  , I have . Let the solution of )θ ∑= n
i
kikeke xfL );(log)(log θθ
0)];([log =ke XfE θ be kSθ , estimate kSθ  by , (kθˆ kSθ  and  are vectors).  Now 
define 
kθˆ
⎟⎟⎠
⎞
⎜⎝⎟⎠⎜⎝ ∂ k
k θ
⎜ ′∂
⎟⎜≡
k
kkekke XfEJ
θ
θ ),(  and ⎛ ∂⎞⎛ ∂ Xf θ log),(log ′∂∂
∂−=
kk
ke
k
Xf
EI
θθ
θ ),(log2
. I 
w need to make us  o lt  (Note ).()]ˆ()ˆ([ 1−≈−′− kkkSkkkSk IJtrInE θθθθ A′  ill e f the resu
denotes the transpose of a matrix, and tr is the trace of a matrix, i.e. the sum of the 
elements in the main diagonal).  The Taylor series for xfL );(log)(log θθ  
  
∑= n
i
kikeke
about kθˆ  is
...)ˆ(
)(log1ˆ)
ˆ(logˆ
*2
′∂∂
∂
∂
∂
k
k
k
LL
θ
θ
θ
θ
)ˆ(
2
)()(log)log +−′−+−+= kk
k
e
kkkk
ke
keke LL θθθθθθθθθ
, where 
(
kkkk θθθθ ˆ* −≤− . 
For large samples kpr θθ →ˆ  , so  obk 0)(log =⎟⎟⎜⎜ ∂
∂ ke LE θ
θ .  I now have the ˆ
⎠
⎞
⎝
⎛
k
approximation )ˆ()(log)ˆ(
2
1)ˆ(log)(log
*2
kk
kk
ke
kkkeke
L
LL θθθθ
θθθθθ −′∂∂
∂′−+= .   
Again appealing to large samples results I have  
k
kkkk ⎠⎝
ke
prob I
XfE −=⎟⎟
⎞
⎜⎜
⎛
′∂∂
∂
′∂∂ θθ
θ
θθ
);(log2
, which gives  ke
L →∂ θ )(log1
*2
n
kprob
ke nIL →′∂∂
∂
θθ
θ )(log *2
.  
kk
−
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 I may now write )ˆ()ˆ(1)ˆ(log)(log InLL θθθθθθ −′−+= , so with ksk2 kkkkkkeke θθ =  
and using )()] kkkSkkkSk IJtrInE θθθθ  ,I have ˆ()ˆ([ 1−≈−′−
)(1)ˆ(log)(g 1kkkekse IJtrLL
−−≈ θθ . Therefore 
2
lo
)(
2
)]([log)]([log kkkekse IJtrLELE −≈ θθ . Using the fact that 1ˆ 1−
)];([log)(log1 fEL θ → kseprobkse Xn θ , I arrive at the approximation  
)(
2
)]ˆ([log)];[log 1kkkekse IJtrLEXfnE
−−≈ θθ . The Taylor series for 
)];([log XfE
1(
ke θ  about ksθ  is 
...)(
)];([log
)(
2
)()];([log
*2
′∂∂′−+−∂+ kkkskkskkkse
XfE θθθθθθθθ
I then obtain the approximation 
1)];([log +−∂∂ kskkekse XfEXfE θθθθ
)()(
2
1)];([log)];([log kskkkskkseke IXfEXfE θθθθθθ −′−−≈ . 
Setting kk θθ ˆ=  I get 
)(
2
1)];([log)]]ˆ;([log[)]ˆ;([log kekke XfEEXfE = θθ 1kkkse IJtrnXfE
−−≈ θ . 
On combining )(
2
)]ˆ([log)];([log 1kkkekse IJtrLEXfnE
−−≈ θθ  and 1
)(
2
1ˆˆ 1
n
−
)()]ˆ([log)]ˆ;([log 1kkkeke IJtrLEXfnE
−−≈ θθ . From the last result I can say th
)()ˆ(log 1kkke IJtrL
−−θ  is an unbiased estimator of )]ˆ;([log ke XfnE θ . The AIC is 
based on the assumption that J
)];([log)]];([log[)];([log kkksekekke IJtrXfEXfEEXfE −≈= θθθ , I get  
at  
kk I=  , this means tha  is approximately 
 parameters in the model, i.e. . So I have 
t )( 1kk IJtr
−
equal to the number of pIJtr kk ≈− )( 1
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 pL ke −)ˆ(log θ  is an unbiased estimator of , hence 
ke 2)(log2)( +−= θ  is an unbiased estimator of . The 
AIC is an estimator of   (Bozdogan 1987). The first term in the AIC formula 
gives a m  model is to the data. The AIC penalises 
model complexity throu , I said earlier that when fitting models I look for the 
model that gives the sm e for the AIC, as a model becomes more complex p 
increases and so the AIC increases. It should be noted that single values of the AIC 
are not of use to me odel, I must look at changes in the AIC. For example 
I might exam e AIC when a new term is introduced into a model. 
A simple example might be to consider the models
)]ˆ;([log ke XfnE θ
pLk ˆAIC )]ˆ;([log2 ke XfnE θ−
][2 KLE
easure of how bad a fit a particular
gh p 
allest valu
 in fitting a m
ine the changes in th
110 Xββ +   and 22110 XX βββ ++ , 
let  be the AIC for the first model, and  be the AIC for the second model. 
past there has been some interesting discussion 
 
this approximation is not correct, then the AIC will not give an unbiased estimate 
of XfnE θ− . Concern has been expressed over the question of the 
 
eans of 
estimating the true order of the model. This last issue is of interest in that it relates to 
possible over-fitting or under-fitting. Bozdogan (Bozdogan 1987) argues that 
1AIC 2AIC
Then I look at AICAIC − . In the 21
concerning the term 2p in the AIC formula. Questions have been raised regarding the
adequacy of penalisation as implemented in the AIC (Bozdogan 1987). Put simply is 
2 a big enough multiplier?  The AIC hinges on the approximation pIJtr − )( 1 , if 
ke
consistency of the estimate of model order (k) obtained through minimising the AIC. 
As the sample size increases the order of the best model obtained by using the AIC 
will increase, however it may not be close to the order of the ‘true’ model. As far as
the AIC is concerned the true model could be of infinite order. It is important to note 
that the AIC can be used to select the best fitting model but not as a m
kk ≈
)]ˆ;([log2
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 ‘consistency is an asymptotic property and any real problem has a finite sample size 
ely important remark to the effect that consistency 
ood 
ure 
5.5.0 Extending the AIC 
The AIC in the form that I have considered is for want of a better description the 
‘classical’ form. With some effort I can see the connection between the AIC and KL. 
The ‘classical’ form of the AIC has some limitations. In this present work one of my 
AIC as a mo ce 
e 2)ˆ(o +θ , what 
n’. Bozdogan also makes an extrem
supposes that there is a ‘true’ model order.  I would argue that the AIC is a very g
model selection tool; it is attractive due to its relationship to the fundamental meas
KL. 
 
main concerns is the problem of over-fitting. An important question is, if I use the 
del selection tool am I liable to over-fit models?  In certain circumstan
the answer to this question is yes.  Using the formula AIC l g2−= pL
happens if p large is compared to the sample size? In this case I wi l fl ind that models 
e m of the AIC are prone to over-fitting. To overcome the s lected using this for
problem of over-fitting when the sample size n is small compared to p , I have to 
consider a corrected version of the AIC. This corrected AIC is denoted cAIC , and is 
given by the formula  
1
)1(22ˆ(log2 ) −−
++−= pppLAIC θ , see (Nariaki 1978) a
1995). It is seen that as AICAICc , it is suggested that cAIC  be used as 
opposed to AIC in situations where 
+
pnec
nd (Hurvich & Tsai 
∞→n , →
40<n ,see (Burnham & Anderson 2004). Can
use the AIC in situations where I might want it a mixed model, a model with tim
dependent covariates or a frailty model? I shall now consider these three cases. 
p
 I 
 to f e 
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 5.5.1 Mixed odels 
I make reference to mixed mo els in Cha ter 8, briefly the model 
kjjjk XY )( 10
 M
 
d p
βαζβ +++=  is known as a mixed model. The m del contains fixed 
and random effects, j
o
ς  is a random intercept and jα  is a random slope. Random 
effects are handled in the same way as the fixed effects, so that I have 
j
)(2)ˆ(log2 je ppLAIC ++−= θ  and 
jpp +  
parameters in the model ( p fixed and  random  be a vector, this gives  p ). Let θˆ
1)(
)1)((2
)(2)ˆ(log2 −+−
++++++−=
j
jj
ppn
pppp
ppLAIC θ .  Earlier I mentioned the jec
 total 
 and CAIC are implemented in a 
number of statistical software packages. For example in the SAS procedures MIXED 
and related quantities are implemented: 
problem of the consistency of the AIC, a consistent form of the AIC is 
)1)((log)ˆ(log2 ++−= npLCAIC ee θ , see (Bozdogan 1987). Again with pp +
number of parameters, I have )1))((log()ˆ(log2 +++−= nppLCAIC θ . In terms 
j
eje
of actually fitting a mixed model, the AIC, cAIC
and GLMMIX various forms of the AIC 
dlAIC 22 +−=  
)1(
22 * −−+−= dn
dnlAICC  
*
whe
(log2 Ll e−=  
)(loglog22 ndlHQIC ee+−=  
ndlBIC elog2 +−=  
)1(log2 ++−= ndlCAIC e  
re 
θˆ )
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 In t  
likeliho m likelihood) in fitting a model. 
The
(Schwarz 1978), Burnham (Burnham & Anderson 2004) contains a most interesting 
disc to 
information theory. In deriving the BIC unlike the AIC, it is not assumed that the 
mo
Buckla land te that the BIC is consistent in terms of the 
dim e rue’ model is of 
sma  is prone to select models that are under-
fitte f ould we do better to 
use r 
to use t
might h
dimension. Buckland et al. (Buckland et al. 1997) make some very astute remarks in 
regard to the question of whether it is better to use the AIC or the BIC.  I would say 
that there is no grave disadvantage in using the AIC, however the issues raised in 
Buckland et al. are thought provoking and I would find further investigation of this 
question fascinating. 
 
When using the AIC to gauge the fit of a mixed model the researcher should exercise 
some degree of caution. Vaida and Blanchard (Vaida & Blanchard 2005) consider 
clustered data, they show that the AIC in its classical form leads to rather strange 
results when applied for example to repeated measures. They develop a conditional 
AIC. Vaida and Blanchard consider an exam
he above formulae jppd += .  The MIXED procedure uses restricted maximum
od (sometimes known as residual maximu
 BIC (Bayesian Information Criterion) was developed by Schwarz in 1978 
ussion on the BIC, as Burham points out the BIC unlike the AIC is not related 
del used in the derivation is the ‘true’ model.  
nd et al. (Buck  et al. 1997) sta
ensions of the best models selected; the BIC assumes that th  ‘t
ll dimension. For small samples the BIC
d. Taking this into consideration, in regard to over- itting w
 the BIC rather than the AIC? This question is not at all straightforward, whethe
he BIC or the AIC depends upon the dimensions of the ‘true’ model. The BIC 
ave advantages over the AIC if the underlying ‘true’ model is of low 
ple using repeated measures, see (Vaida 
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 & Blanchard 2005), the data consists of six , they 
use
mo ured 
ove
mode ly  e 
AIC in its classical form when applied to mixed models leads to misleading results 
because the penalty term is not appropriate for the mixed model situation (penalty 
term is too large). Consequently they develop a form of the AIC with an adjusted 
pen  a riate o
the 
an 
to e
the
5.5.2 Time Dependent Covariates  
 
Wh al Hazards model, it is 
often assumed that covariates do not change with time. A covariate is taken as 
t. The Cox Proportional Hazards model 
t 
5.5.3 Frailty Models 
measurements taken on ten patients
 the nlme package in GNU R to produce a mixed model and a linear regression 
del. On comparing the AIC they find that the linear regression model is favo
r the mixed model, this they point out is strange given that the linear regression 
l has 21 parameters and the mixed model 6. Essential  their argument is that th
alty term pprop  for use in devel ping a mixed model. It should be noted that 
nlme package has been superseded by lmer4. SAS’s PROC MIXED implements 
appropriate form of the AIC (Fernandez 2007). It is advisable that researchers try 
stablish which form of the AIC is implemented in the particular software package 
y happen to be using. 
en analysing survival data with say the Cox Proportion
remaining constant up to the event of interes
can be extended by considering covariates that change with time, time dependent 
covariates. The SAS procedure PHREG allows one to fit a model with time dependen
covariates. PHREG reports the AIC and BIC (note the BIC is reported as SBC, 
Schwarz Bayesian Criterion). 
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 Do Ha et al. (Do Ha et al. 2007) develop an AIC for a set of frailty models, (the 
models need not be nested). The AIC  D  is based on conditional 
likelihood and an extended restricted likelihood. They define two AICs as follows: 
AIC
d rando cts and ty param h
 (dispersion parameters in the frailty 
distribution). In (Do Ha et al. 2007) the authors state that for a Cox Proportional 
odel  is the AIC as used in the SAS procedure PHREG. For a 
d  the SAS procedure MIXED. The 
to railty term  may be a better selection 
on han .  The work of Do Ha et al. is certainly very interesting; as far 
 Ha et al. 2007) have not been implemented 
as software. Further investigation of the results presented by Do Ha et al. would be 
well worth pursuing. In the next chapter will I shall further consider over-fitting and 
ine Harrell’s C and discuss the issue of validation techniques. 
 
 
 
 proposed by o Ha et al
*** 2)( pDDAIC +=  D
TddT )( pT 2
** +=  
)( *DAIC  deals with fixed an m effe frail eters, w ilst 
)( *TAIC deals only with the frailty parametersd
Hazards m )( *DAIC
linear mixed model )( *dTAIC  is the AIC as use in
s )( *dTAICauthors also suggest that in regard  f
)( *DAICcriteri  t
as I am aware the AICs developed in (Do
model optimism, exam
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 CHAPTER 6 OVER-FITTING, OPTIMISM AND VALIDATION 
the model to
redictive p
 
 
• Wh  
po
• Ov
• Ov
• Pro
 
6.0.0 Introd
 
I have made
could define
to produce m
does not jus
fine-grained
significant i
general ove
optimistic p
p
difference i
predictive p
predicted va
by Somer’s 
 en trying to develop a prognostic model including a large number of
tential predictor variables may lead to over-fitting 
er-fitted models are biased in regard to predictive power 
er-fitted models are poor prognostic tools 
o  sh vgnostic m dels ould be alidated e to
.If over-fitting is present then on applying 
 a new but similar data set I would see a change (deterioration) in the 
ower of the model when used to predict on the new data set. This 
 described in terms of optimism. I can gauge the 
ers 1962). Harrell (Harrell et al. 1996) defines optimism in terms 
uction 
 referenc  over-fitting numerous times in the preceding chapters. I 
 over-fitting to be the tendency in certain statistical modelling procedures 
odels that include substantial noise, that is I end up with a model that 
t describe the general patterns in a data set, but includes a deal of local 
 detail. Over-fitting leads to models that include variables that are 
n the sense that they model local detail, they may not be significant as 
rall predictors. A model that has been over-fitted is biased in terms of how 
redictions based on this model 
n predictive power can be
ower of a model by measuring the agreement between the observed and 
lues of the dependent variable. One way of measuring such agreement is 
D (Som
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 of the difference in two values of Somer’s D. It may be worthwhile looking at 
6.1.0 Somer’s D 
 The population value of Somer’s D is defined as follows
Somer’s D and some related measures. 
XX
XYD τ
τ=
where )]sgn()[sgn( jijiXY YYXXE
XY , 
−−=τ , for all ji, , XYτ  is Kendall’s aτ  (Kendall 
1938).  
The sgn function is defined as follows: 
<x  , 0,0)sgn( == xx , 0,1)sgn( >= xx0,1)sgn( −=x . 
 
 
X  and are sampled jointly from a bivariate distribution.  
endall’s
Y
 aτ  gives a measure of concordance, the  and are said to be sX ' sY 'K
concordant if the bigger of the sX '  is associated with the bigger of the sY ' . Somer’s 
D is the regression coefficient of )sgn( ji XX − with respect to )sgn( ji YY − . Both 
Kendall’s aτ  and Somer’s D can be applied to survival data, X  or Y or both could be
censored. If I have indicator variables U andV , where values of 1 indicate that the
event of interest has occurred and values of 0 indicate censoring, then Somer’s D for 
 
 
survival data can be defined as 
UXUX
UXVY
,,,
,,, τ
YUXD ,,
τ V,= .  
6.1.2 Harrell’s C 
 
Harrell (Harrell et al. 1996) has defined the quantity 12,,1, −= CD SYX , where it is 
assumed that X  is a continuous variable.C  is known as Harrell’s C . I can interpret 
Harrell’s C  as measuring how well X  predicts survival. Harrell’s C  is defined as 
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 “the proportion of all usable patient pairs in which the predictions and outcomes 
concordant” (Harrell et al. 1996). For a binary dependent variable C is “the pro
of all pairs of patients, one with and one without the disea
are 
portion 
se, in which the patient 
ell et al. 1996). 
r predictive power 
s the problem of possible over-fitting by examining values of Somer’s 
ine predictive 
ower o  model over these data sets. This leads to the idea of validation methods.  
6.2.0 Validation Methods 
model is known as model validation.  
number of data sets that are similar but different to the data set used to develop the 
known as data splitting, see (Picard & 
approaches in a little more detail. 
having the disease had a higher predicted probability of disease.” (Harr
Harrell’s C  takes on values from 0.5 to 1.0, 0.5 indicating poo
(poor level of agreement between predicted and observed sY ' ) and 1.0 indicating 
very good predictive power (high level of agreement between predicted and 
observed sY ' ). Somer’s D can take on values from -1 to 1.  
Assuming then that I have arrived at my final model, I could use Somer’s D or 
Harrell’s C  to obtain some measure of the predictive power of the model. However, I 
will not addres
D or Harrell’s C  for the original data set alone. Ideally to assess over-fitting I need to 
fit the model to a number of different but similar data sets and exam
p f the
 
The formal procedure for determining the predictive power or accuracy of the final 
I have said that in order to assess over-fitting I need to fit the ‘final’ model to a 
model. How do I obtain these data sets? I could reserve some of our original data and 
use it to test the model, or I could try to ‘build’ some data. The first approach is 
involve the use of the bootstrap (Efron & Gong 1983). I shall now consider these two 
Berk 1990). The second approach could 
 - 117 -   
  
6.2.1 Data Splitting   
The idea of splitting up the original data set into a portion on which to develop the 
model (the training sample) and a portion for validation seems quite reasonable. S
how is the data split up? This question is not trivial and Picard and Berk (Picard &
Berk 1990) draw attention to the problem which may result if the data is split in an 
arbitrary way. I may end up with n
 
o 
 
ot enough data to develop the model, or conversely, 
 I reserve a large portion of the data for development, I may not have sufficient data 
r validation.  A formal criterion for partitioning the data would be desirable, but it is 
often the case that the mathematical expressions for these criteria are intractable. 
Picard & Berk 1990) suggest that between 
if
fo
4
1  to 
2
1Picard and Berk (  of the data 
should be reserved for validation.  
validation (Stone 1974). With cross-validation I have multiple models (a model per 
split), if I have split the original data set  times, I have   training samples and 
 arises 
If I have a large data set I could consider repeated data splitting, this is called cross-
validation samples. I develop and validate the k  models and then ‘average’ the 
results, i.e. I could obtain averages for regression coefficients and Somer’s D. Data 
splitting and cross-validation tend to produce highly variable estimates. In data 
splitting I might see notable variation in, say, the estimate of regression coefficients 
dependent on how I split the original data. In cross-validation the same problem
due to the multiple training and validation samples used. In both data splitting and 
cross-validation the accuracy of the estimates is highly variable.  A way of 
overcoming this problem is to use the bootstrap.   
k k k  
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.2.2 The Bootstrap 
 
The bootstrap (Efron 1979) was devised by Bradley Efron as  extension of the 
jackknife (Miller 1974), (Efron & Stein 1981), (Efron 2000). fron described the 
bootstrap as “a muscularized big brother to the Quenoille-Tukey jackknife” (Efron 
2000).  The bootstrap method is described as follows. 
Suppose I have a data se . 
I can form the bootstrap sample by drawing at random and with replacement from 
original data set. The bootstrap sample is usually written in th orm  , 
f the original data set. A typical bootstrap sample from 
 
1 n
 now from another bootstrap sample and obtain the bootstrap replicate using this 
sample. I repeat this process 
6
an
E
t },...,{ 1021 xxx
**
2
*
1 ,..., nXXXe f
where n is the size o
},...,{ 1021 xxx  might be },,,,,,,,,{ 42811025733 xxxxxxxxxx . I may for example want to
obtain an estimate of the true standard error for some quantity or statistic, let this 
quantity beθˆ . 
 I use the bootstrap sample to obtain *θˆ  the bootstrap replication ofθˆ . 
 *θˆ  is often written as ),...,(ˆˆ **** XXXθθ = .  2
B times where B is a large number. I now have B  
2
1
1
2.**ˆ(⎢⎡∑B θ
bootstrap replicates . As *θˆ ∞→B  the quantity 
)1( ⎥
⎦
⎢
⎣
−B tends toward B
)ˆ
⎥
⎥⎥
⎤
⎢
⎢
−
=b
b θ
σˆ
the bootstrap estimate of the standard error ofθˆ , where
 
B
b∑≡ *.* ˆˆ θθ .  One extremely 
important feature of the bootstrap is that I do not have to know what distribution the 
original data comes from. The true standard error ofθˆ , )(Fσ , depends upon  knowing 
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 what distribution the original data comes from, the bootstrap allows me to estimate  
)(Fσ  by means of Bσˆ . The bootstrap estimate of )(Fσ , Bσˆ  depends upon the 
empirical distribution Fˆ , so I can write )ˆ(ˆ FB σσ =  . The empirical distribution Fˆ  
assigns equal probabili  (probabilityty  mass
n
1
bootstrap can be applied to quite complicated statistics with ease. I described B  as a 
large number, values of B  do not have to be huge, values of 200 or 300 can 
) to each x  in the original data set.  The 
ce 
good estimates. An excellent discussion of the bootstrap and jackknife can be found in 
fron & Gong 19 bootstrap is an ethod, as are data 
splitting and cross-validation; a portion of the original data set is used to validate the 
final model. A more rigorous validation procedure would involve entirely new data 
variety of reasons, for instance financial constraints, data collection may take a long 
Harrell (Harrell et al. 1996) recommends the bootstrap as a method of internal 
validation; the estimates of the predictive accuracy of a model produced by the 
splitting and cross-validation all of the data is used to develop the model. I now 
 described by Harrell in (Harrell et al. 1996).  
produ
(E 83). The  internal validation m
sets, this may not be a practical approach, it might be difficult to obtain new data for a 
time. 
bootstrap are virtually unbiased. One major benefit of the bootstrap is that unlike data 
consider a validation procedure as
6.3.0 Harrell’s validation procedure   
   
In (Harrell et al. 1996) Harrell lists the following steps needed in order to assess the 
internal validity of a model. These steps are given in Box 1 exactly as they appear in 
(Harrell et al. 1996). 
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 Box 1 Harrell’s Validation Steps 
1. Develop the model using all n subjects and whatever stepwise testing is 
deemed necessary. Let appD  denote the apparent D from this model, i.e., 
the rank correlation computed on the same sample used to derive the fit. 
2. Generate a sample of size n with replacement from the original sample 
(for both predictors and the response). 
3. Fit the full or possibly stepwise model, using the same stopping rule as 
was used to derive appD . 
4. Compute the apparent D for this model on the bootstrap sample with 
replacement. Call it bootD . 
5. ‘Freeze’ this reduced model, and evaluate its performance on the original 
dataset. Let origD  denote the D. 
6. The optimism in the fit from the bootstrap sample is origboot DD − . 
7. Repeat steps 2 to 6 100-200 times. 
8. Average the optimism estimates to arrive atO . 
9. The bootstrap corrected performance of the original stepwise model is 
OD − . This difference is a nearly unbiased estimate of the expected app
value of the external predictive discrimination of the process which 
generated . In other words appD ODapp −  is an honest estimate of the 
internal validity, penalizing for over-fitting.  
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 Initially in Harrell’s procedure the model M is developed using all of the origina
data, and Somer’s D is recorded. In the next step I generate a bootstrap sample by 
drawing at random and with replacement from the original data. Next I fit a model 
*
1M to this bootstrap sample, and record Somer’s D, i.e. bootD . Now obtain the
Somer’s D for *M  using the original data, i.e. D . The optimism is defined to
origboot
*
1 origboot
l 
 
 
, here the optimism refe . If 
1 orig
be DD − rs to M DD −  is < 5% this can 
be interpreted as meaning that the original model M is consistent in its 
performance, I do not see a degradation in predictive power when the original 
model is applied to the  bootstrap data set. Although   origboot DD −  refers to 1M  , 
I can say that the p
*
erformance of  on the or ast comparable to *1M iginal data is at le
that of M , i.e. I infer that M  and *1M  are the same model. In step 7 of Harrell’s 
sprocedure I now run through step  2 to 6 B times to obtain **2
*
1 ,...,, BMMM  and 
the associated bootD  and  whichorigD ,  is denoted 
*
bD  and 
orig
bD
* . The quantity  
B
DD
O
B
b
orig
bb∑
=  is the average optim
−
= 1
**
ism, OD −  gives a good estimapp ate of 
l validity of the model, with  acting as rm for over-fitting, 
er-fitting. It is important to 
remember that a single value of Somer’s D gives a measure of predictive power 
for a model, the difference in two values of Somer’s D measures optimism or 
over-fitting. Harrell has implemented the validation procedure described in steps 1 
to 7 in the Design library (Design Library Harrell Frank E. 2009b), (Design 
Library Harrell Frank E. 2009a).  
the interna O  a penalty te
large values forO  mean I incur a high penalty for ov
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      6.4.0 Validating the CARE-HF Model 
I shall look at an example of validating a model (the CARE-
 
HF model) using Harrell’s 
ation does not deal with optimism of the model fitting 
rocess, but from the final model alone. The model developed for the CARE-HF data 
has been described in Chapter 2, I will use GNU R and the Design library to validate 
the final model for the CARE-HF data. The variables in the final model for the 
CARE-HF data are shown in Table 6.1  
 
 
 
 Transformation  Hazard ratio  95% CI  P-value 
procedure. Note here the valid
p
Predicto u   rs of overall o tcome   
Mitral regurgitation    Log 1.71 1.38–2.12 0.0001 e
N-terminal pro-brain natriuretic peptide (pg/ml)  Loge 1.31 1.17–1.47 0.0001 
Systolic blood pressure (mmHg)    Linear 0.99 0.98–1.00 0.0698 
Interventricular mechanical delay (ms)   Linear 1 0.99–1.01 0.7617 
Aetiology (ischaemic) (yes/no)    Factor  1.89 1.45–2.46 0.0001 
CRT (ye 0.15 0.03–0.87 0.0347 s/no)  Factor   
Predictors of response to CRT     
Systolic blood pressure (mmHg)*CRT Linear 1.02 1.00–1.03 0.0183 
Interventricular mechanical delay (ms)*CRT Linear 0.99 0.98–1.00  0.0084 
Table 6.1 Predictors of outcome and response to CRT 
 
Let us denote the variables in Table 1 as follows: 
loge(Mitral regurgitation) 1x     
Systolic blood pressure 3x  
Aetiology (ischaemic) x
CRT 
Systolic blood pressure*CRT 
Interventricular mechanical delay*CRT 64 * xx  
loge(N-terminal pro-brain natriuretic peptide)  
Interventricular mechanical delay 
 
I will denote the primary event as and the time to as .  
To perform validation in GNU R using the Design library I use the following R code 
2x  
4x  
5
6x  
63 * xx  
p p t
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>setwd("C:/location of data file”) 
>dd<-read.Table(file="myfile.csv",header=T,sep=",") 
>attach(dd) 
>vl<-validate(f,B=200,dxy=T,pr=T) 
 
I first load the Design library. Next we set the working directory and then read in t
data file. I now make the data fr
>library(Design) 
>f<-cph(formula=Surv(t,p)~x1+x2+(x4*x6)+(x3*x6)+x5,x=T,y=Y,surv=T) 
he 
ame dd available through attach(). Next I fit the Cox 
Proportional Hazards model, justification for fitting the proportional hazards model 
violates this assumption is  discussed in 
t 
even though there is some evidence that CRT 
Chapter 2. f stores the result of the model fitting. Finally I validate the model using 
200 bootstrap samples, dxy=T means that I want to use Somer’s D, pr=T means prin
results for each of the 200 repetitions. The results of the validation procedure are 
shown in Table 6.2. 
 
       
 index.orig training test optimism index.corrected n 
Dxy -0.4090 -0.4198 -0.3982 -0.0216 -0.3874 200 
Table 6.2 Validation of Final CARE-HF model Using Harrell’s Design Library in GNU R 
In Table 6.2 Somer’s D (Dxy) is presented Dxy is the rank correlation between the 
predicted log hazard and the observed survival times. This is why we have the –ve 
values in Table 6.2, = -0.41, the index corrected value for Somer’s D (-0.3874) is a 
s 
approximately 2% in the values of Somer’s D between the original data and the ‘new’ 
 appD
better estimate of the predictive power of the model, i.e. how well the model perform
as a prognostic tool in the future.  In terms of optimism I can interpret the value of -
0.0216 from Table 6.2 as meaning that on average there is a difference of 
data, so if the model where to be applied to a new set of patient data I would expect a 
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 loss of predictive power of around 2%. As a rule of thumb an optimism of less than
5% is acceptable.  
6.5.0 What Motivates Validation? 
 
Discrimination 
Generalisabilty: 
Reproducibility 
 
 
The phrase predictive power is broad description of the positive attributes that should 
be considered in regard to a prognostic model. Predictive power comprises two 
fundamental parts: 
1. Accuracy     
2. Generalisabilty 
In (Justice et al. 1999) Justice defines accuracy as “The degree to which predicted 
outcomes match observed outcomes.” Generalisabilty is defined as “Ability of a 
prognostic system to provide accurate predictions in a new sample of patients.” 
(Justice et al. 1999). The aim of model validation is to assess whether the model is 
accurate and generalisable.  Both accuracy and generalisabilty can be further broken 
down into the following parts: 
Accuracy: 
Calibration 
 
Transportability 
 
hen considering accuracy, a calibration error occurs if the predicted probability of 
some event of interest is too high or too low. A discrimination error occurs if given 
that a patient has been assigned a risk score, they are incorrectly ranked on the basis 
 
 W
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 of individual risk. If patients are grouped based on their risk score, then the group 
comprising patients with a high score should have a high event rate, if a patient with
low risk score was allocated to the group with the high event rate, then a 
discrimination error has occurred. Similarly when considering generalisabilty, 
reproducibility refers to the accuracy of the prognostic model when applied to patien
who were not in the original dataset used to develop the model, but are from the sam
population. If the prognostic model is accurate for patients from a similar but not 
identical population, or is accurate for data collected using methods that are different 
than those used to collect the original data; then the model can be said to possess 
reproducibility. It may appear that model validation is confined to assessing th
validity of a model purely in statistical terms. Altman and Royston (Altman & 
Royston 2000) pose two questions of great importance:  
 a 
ts 
e 
e 
. With the available factors, is the model the best that can be found? 
an and 
ly validated model is one which passes all appropriate statistical 
hecks, including goodness-of-fit on the original data set and unbiased prediction on a 
new data set. 
. A clinically validated model is one which performs satisfactorily on a new data set 
ccording to context-dependent statistical criteria laid down for it. 
 
I would concur with the view that e y t h between clinically and 
statistically validated models. In regard to Harrell’s approach I believe that there is a 
 1
 2. Does the model predict accurately enough for its purpose? 
The above questions lead the authors of (Altman & Royston 2000) to suggest that 
validation be considered from both a statistical and a medical perspective. Altm
Royston (Altman & Royston 2000) supply the following definitions: 
1. A statistical
c
2
a
 it is n cessar  to dis inguis
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 potential danger that to lose sigh  i a  c l validation, Harrell’s 
approach appears to concentrate on st istical alidation. Researchers may be lulled 
into thinking that the validation m s s  H l are sufficient to 
produce a clinically useful prognostic model. s Altman and Royston point out, if the 
prognostic information is inheren ak  t  valid model as defined 
in (Altman & Royston 2000) may be of limite  use fr m a clinical perspective. The 
r r is strongly encouraged to t (  of 
model generalisation is of great intere the present autho ow far it is possible to 
produce general models is not cle  l a l to be general lies 
ultimately in the nature of the mathem tical techniques used in model fitting. It is 
perhaps not un-reasonable to que n bilty. Generalisabilty 
whilst desirable may be attainable to only a limited extent. I feel that this should be 
considered when carrying out statistical m
model with good predictive power and ease of interpreta ay well be that 
predictive power comes at the expen sibility will 
.6.0 Summary  
Validation is an important aspect of statistical modelling. Once I have obtained the 
‘final’ model it is not enough to be content if this model fits the original data set well.  
s the performance of the model over new data, that is perform 
xternal validation. If it is not practical to perform external validation then I should 
a idat t c a tting, cross-validation or 
t of the mport nce of linica
at  v
ethod sugge ted by arrel
A
tly we , then a statis ically
d o
eade consul Altman & Royston 2000). The problem
st to r, h
ar, and the fai ure of  mode
a
stion a xiety over generalisa
odelling. Clinicians want a prognostic 
tion; it m
se of ease of interpretation. This pos
be discussed in the final chapter. 
 
 
 
6
 
Ideally I need to asses
e
pply some internal val ion me hod su h as d ta spli
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 b rm x o nal validation I see 
d tion in the predictive pow e e I need to identify possible 
reasons, for example over- (o e g pecification of the functional 
f he model. Another b on for poor performance of a model is 
m  the original se i sing data then this will 
influence the final model. de a ethods of imputing missing 
d ter. Th e ld s as to whether it is clinically 
plausible; this is entirely se  f e  o istical validity.
ootstrap methods.  If after perfo ing e ternal r inter
eteriora er of th  mod l then 
fitting r und r-fittin ) miss
orm of t  possi le reas
issing data. If  data t has s gnificant mis
I consi r missing dat  and m
ata in the next chap e mod l shou  be as essed 
parate rom th  issue f stat
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 CHAPTER 7 MISSING DATA AND IMPUTATION 
 
.0.0 Introd
 the data s
ata ma
gression c
ARE-HF s
rong predi
ave missin
ffect upon 
urious sta
ow do I tr
e data is m
b
t ress th
have a high
v
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• Ty
• Co
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• Mi
this d
could see ho
re
C
st
h
e
sp
H
th
iased resul
o add
ariables y,
 ssing can lead to a poor prognostic model 
pes of mis  da
rrect imputation m
putation should be used with caution 
sing ta MCAR, MAR and MNAR
ssing data dealt with by imputation  
odel is crucial  
uction 
et contain riab for v a n e d  
y not be r ble, a l  
 number of missing values, estimates of the 
oefficients could be distorted. In developing the prognostic model for the 
tudy (Richardson et al. 2007) it was found that mitral regurgitation was a 
ctor of the primary outcome. However mitral regurgitation was seen to 
g values (208 values were missing). Missing data may have a marked 
the variables that appear in the ‘final’ model. A variable may attain a 
tistical significance due to missing values.  
eat the problem of missing data? This depends upon the reason for why 
issing. Under certain circumstances the missing data will not lead to 
na i te t e, and efforts must be undertaken 
e issue of m  d n o ould be to remove cases where I 
 level of miss t ha onsisting of the 
, and I  y  ry least squares regression of 
 
 
s va les  which alues re missing the a mod l fitte  to
elia  missing data may lead to bi sed resu ts. For example I 
w for variables with a large
ts. Unfortu tely th s is of n not he cas
issing ata. O e appr ach w
ing da a. If I d a data set c
21, xx  wished to carr  out a ordina
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 y against x  and 2x , b1 u nd number of missing values, then I 
ethod may lead to inflated 
n  ern ppro ou ply the missing values. In the 
imputation, the process of 
pplying ‘fill in’ the missing values can be computationally intensive. 
N at o  a  makes imputation practical. An 
i tant question I mu id w h  missing? I shall now look at 
different types of missing data. 
7  
 a group of patients have some measurement taken e.g. lung function, it is possible 
at some measurements may be missing due to failure of the measuring device or 
achine. In this situation I would assume that device or machine failure is a random 
event, the probability of missing data would be described as m g com y a
d be described as 
issing completely at random are if for example someone was unable to complete a 
uestionnaire due to common illness. Participants in a clinical study may move away 
om the area, they might die due to reasons unrelated to those specified within the 
udy.  
If the probability of mis
bserved variables then the missing data is said to be missing at random (MAR). If 
e probability of missing data for a particular variable depends on other observed 
ariables and unobserved variables then data is said to be missing not at random 
( NA A R d M e n alled the missingness 
t I fou  that 1  had ax  large 
might remove the pairs ),( , where  is missing. This m1xy 1x
varia ce and bias. The mod  a ach w ld be to sup
past the missing data problem tended to be ignored, 
su  or ing 
owadays the comput ional p wer is vailable that
mpor st cons er is hy is t e data
.1.0 Types of Missing Data 
 
If
th
m
issin pletel t 
random (MCAR). Other examples of situations where data woul
m
q
fr
st
  
sing data for a particular variable depends upon other 
o
th
v
M R). MC R MA  an NAR ar  what is ofte  c
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 mechanism, see (Buck 1960) and (Zhang 2003). If the missing data mechanism is 
CAR or MAR then the missing data is said to be ignorable, the missingness 
m ee e le r the missing data is MNAR the 
m gness is said to be o  atic of the missing data 
m . I need to d n  t a
that the data is not missing comp  en I should attempt to apply some 
988a) has developed a test based on the Chi squared distribution. However it is not 
ossible to conclusively prove the data are MCAR. There is no test for the MAR 
assumption. For a detailed discussion of issue missing data and prognostic models see 
(Marshall 2007)  
 
7.2.0 Dealing with Missing Data 
 
There are numerous methods for dealing with missing data; I have mentioned one 
approach already, simply delete the missing data. It can be argued that this approach 
is not particularly satisfactory; as potentially useful information is being discarded 
(put another way, the sample size is reduced). I shall consider some of the methods 
available that allow missing data to be imputed. A very simple way of imputing data 
is to use the mean, missing values are replaced with the sample mean. For example in 
the CARE-HF  data the variable mitral regurgitation has 208 missing values, if I 
impute these missing values by using the sample mean = 23.79 of the 605 non 
missing values for mitral regurgitation, then the sample mean for mitral regurgitation 
(n=813) with imputation = 23.79. Here I see that imputation using the sample mean 
has made no difference in the estimate of mean mitral regurgitation. What I do find 
however is that the standard deviations change, the standard deviation of the 605 non-
M
echanism does not n d to b model d, if howeve
ssin  non-ig nrable and is the most problem
echanisms etermi e why he dat  is missing, and once I have established 
letely at random, th
suitable imputation method.  It is possible to test the MCAR assumption, Little (Little 
1
p
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 missing values = 14.94, whereas the standard deviation for the imputed data (n=813) 
= 12.88. This reduction in standard deviation 
to the fact that I have increased the sample size from 605 to 813, but I have seen no 
difference in the estimate for mean mitral regurgitation. However if I were to use the 
sample median, I have the sample median for the 605 non-missing values = 21.81 and 
the sample median for the imputed data = 23.79. Another possible approach is to 
impute the missing data by using some regression technique; I predict the missing 
values using the regression model. If I were to use ordinary least squares regression I 
am in effect doing the same thing as with using the sample mean, I am still confronted 
ith the problem of producing a reduced standard deviation (or standard error) due to 
 gained any new information, i.e. I will 
is misleading in the sense that it is due 
w
the increased sample size, but I will not gave
not see an appreciable difference in the estimate of some population parameter based 
on the imputed data.  
Table 7.1 briefly describes some of the common imputation methods 
Method Comments 
Simple Mean Imputation, uses sa
missing values  
mple mean to impute Easy to perform, but may lead to distorted relationship between 
variable that has undergone imputation and other variables in dataset 
Regression Imputation, use a regression model to 
generate missing values 
Distribution of variable that has undergone imputation may be 
distorted, correlation with variable not included in the regression model 
egr im ted may be suspect. If the r ession model is not appropriate then pu
values are suspect. 
Random Regression Imputation, as above but a random 
he imputed value ge
. Random term can
normal distribution 
Works well with categorical and continuous variables, again depends 
ionterm is added to t nerated by the 
regression model  be drawn from a 
upon appropriate regress  model. 
Hot Deck Imputation, imputed value is selected at Method uses ‘real’ values, i.e. value is present in the data set.  
random from the non-missing cases 
Predictive Mean, a hot deck method that employs a etho  the regression method 
regression model 
M d is slightly more robust than
Last Value Carried Forward Last known values carried forward to supply the missing data 
Table 7.1 Imputation Methods 
 
I shall now briefly review the basic ideas for the imputation methods that are 
implemented in SAS and GNU R. In SAS PROC MI (SAS Proc MI 2009) allows me 
to perform what is known as multiple imputation, see (Zhang 2003), (Rubin 1976), 
(Rubin 1996) and (Schafer & Olsen1998). The imputed data can then be analysed 
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 using PROC MIANALYZE (SAS Proc Mianlyze 2009). In GNU R, Harrell’s Design 
(Design Library Harrell Frank E. 2009b) library used in conjunction with Harrell’s 
Hmisc library (Hmisc Library Harrell Frank E. 2009) allows me to perform 
imputation using the transcan and impute functions.  
7.3.0 Multiple Imputation  
 
So far my discussion of imputation has focused on trying to ‘fill in’ missing values for 
some variable, for each missing value of X I supply a single imputed value. Multiple 
imputation (Zhang 2003), (Rubin 1976), (Rubin 1996) does not supply a single 
imputed value, instead a set of possible values are considered. In multiple imputation 
I randomly sample from the existing data to generate this set of possible values.  More 
:  
l. 
noted problem with 
rtificially’ reduced standard deviation, multiple imputation overcomes the problem 
of reduced standard deviations or standard errors of estimates. 
The imputation model is of fundamental importance, if I take the most simple case 
where the data set consists of one continuous variable , then an example imputation 
model might be , the normal distribution model. If I have a data set 
, then I might use the 
multivariate normal model
formally multiple imputation can be described as follows
1. Create k complete data sets by filling in all missing values k times, by 
drawing k  times from the imputation mode
2. Analyse the k  complete data sets, these data sets are regarded as real data. 
3. Combine the results of the analysis of the k  complete data sets to form the 
repeated or multiple imputation inference. 
Earlier I looked at imputation using the sample mean, I 
 
‘a
1X
),(~ 21 σµNX
that consisted of the continuous variables pXXXX ,...,, 321
),(~ ΣmNX , where X is the vector 
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 ),...,,( 321 pXXXX and is a vector of means and m Σ is the variance covariance 
matrix. For a mixture of binary and continuous variables I might use the conditional 
Gaussian (Horton & Kleinman 2009). In ble to specify a 
‘customised’ imputation model, for exam
PROC MI it is possi
ple I could specify that 21 XX = . I must 
consider that if I have specified a particular imputation m
were to perform an analysis using the data set after I performe putation, 
there is a risk that this person may try fit a model different to that of m putation 
model, for instance . It is advisable to use as many variables as possible 
when performing m putation.  For multiple imputation maximum likelihood 
estimates of param d by using the EM algorithm (Dempster et al. 
In GNU R the transcan function which is found in Harrell’s Hmisc library performs 
both transformation and imputation for a variable. Results of applying the transcan 
 
 
n and 
n 
ee ler and has 
ndergone a sign change. The p-value for IVMD has decreased from 0.75900 to 
odel, then if someone else 
d multiple im
y im
431 XXX =
ultiple im
eters are obtaine
1977), (Gaetan & Yao 2003).   
7.3.1 Imputation using Design and Hmisc 
 
and impute functions to the CARE-HF data are shown in Tables 7.2 to 7.8. Tables 7.9
and 7.10 present validation results for the final CARE-HF model with and without 
imputation. By default transcan uses single predicted expected value imputation, this
is the case for the imputation performed here, it is possible to perform multiple 
imputation using transcan. If I want to perform multiple imputation using Desig  
Hmisc then the aregImpute function is a better choice; the results of performing 
multiple imputation using aregImpute are shown in Table 7.11. The main objective 
for the CARE-HF model was to determine possible treatment modifiers (interactio
terms). For IVMD it is s n that for the imputed data coefficient is smal
u
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 0.06000, the interaction term IVMD*CRT is no longer statistically significant, this 
in h p
to identify possible treatment modifiers 
nd not to produce a definitive prognostic tool, the treatment modifiers that were 
remained so, irrespective of the imputation method. The significance of CRT and the 
putation was performed or 
not. I would suggest that whilst this could be explained by missing data the fact that 
in the fashion described in Chapter 2 may have a considerable effect. I would 
recommend that orthogonalization should be carried out in situations where 
Where there is an appreciable level of missing data I would suggest that imputation 
ed, I would justify this based on the marked differences in the 
results  for the model with and without imputation. However I would consider this in 
conjunction with orthogonalization  
interaction term was borderline significant using the original data. Using imputed data 
the variable CRT is no longer significant, the p-value for systolic blood pressure has 
increased from 0.06959 to 0.34500, the interaction systolic blood pressure*CRT is no 
longer significant. Imputation has resulted in reductions in the coefficients for the 
variables mitral regurgitation, NT-pro-BNP and Ischaemia, all of these three variables 
rema ighly significant. If I perform im utation using agreImpute then the 
interaction term systolic blood pressure*CRT is no longer significant, however the 
interaction term IVMD*CRT is just about significant at the 5% level. To reiterate, the 
main objective of the CARE-HF model was 
a
originally identified were admittedly weak. However it is interesting to note the 
effects of using different imputation methods, I see that the strong predictors have 
interaction terms differ notably dependent on whether im
continuous variable had not been orthogonalization and binary variables not re-coded 
interactions between continuous and categorical variables are to be investigated.  
should be perform
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7.4.0 Summary  
 
e should be aware that imputation is not without its dangers. Choosing an 
o
 
imputation is that it has its origins in the problem of missing data in surveys, it has 
been suggested that this might be a limitation in terms of the efficiency of multiple 
sian multiple imputati y not 
3 wou  
pute function employs 
predictive mean matching. Predictive mean matching is an example of what is known 
as Hot Deck imputation (Altmayer 2009), Hot Deck imputation is one of the earliest 
imputation methods. Also in view of Nielsen’s arguments (Nielsen 2003) an 
investigation of the methods used in Harrell’s transcan and impute functions may be 
useful as Bayesian methods are an option for these functions.  
 
Imputation is not a simple matter; a careful approach is needed when applying it. The 
ating to imputation i
one; even the basic definitions of MCAR, MAR and MNAR can be somewhat 
u red. In the next cha
W
appropriate imputation model is crucial; if this imputation model is n t appropriate 
then subsequent analysis will be flawed. One important point in regard to multiple
imputation. Nielsen (Nielsen 2003) argues that Baye on ma
be efficient. For further discussion of some of the criticisms levelled at multiple 
imputation the reader is directed toward (Nielsen 2003) and (Rubin 200 ). I ld
consider an investigation of predictive mean matching, see (Little Roderick 1988b) 
and (Heitjan & Little 1991), a useful exercise, Harrell’s aregIm
literature rel s mathematically complex. The topic is a difficult 
conf sing when first encounte pter I will look at the idea of the 
frailty model. 
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 coef se(coef) z p 
 
Mitral Regurgitation a              0.7590 0.1220 6.2000 0.0000 
CRT 0.6140 0.5840 1.0500 0.2930 
Mitral Regurgitation a *CRT          -0.3350 0.1820 -1.8300 0.0666 
     
EVSI a 0.4162 0.1750 2.3761 0.0175 
CRT -0.4752 1.4120 -0.3366 0.7360 
ESVI a*CRT -0.0013 0.2920 -0.0044 0.9965 
     
Ischaemic 0.5220 0.1350 3.8800 0.0001 
CRT -0.7310 0.1580 -4.6200 0.0000 
Ischaemic*CRT 0.4010 0.2120 1.8900 0.0584 
     
Ejection Fraction a -0.9730 0.2840 -3.4280 0.0006 
CRT -1.1470 1.4470 -0.7930 0.4280 
Ejection Fraction a *CRT 0.2180 0.4550 0.4790 0.6320 
     
Age 0.0237 0.0073 3.2620 0.0011 
CRT -0.1452 0.7284 -0.1990 0.8420 
Age*CRT -0.0051 0.0108 -0.4690 0.6390 
     
Systolic Blood Pressure -0.0130 0.0040 -3.2600 0.0011 
CRT -1.9373 0.7484 -2.5900 0.0096 
Systolic Blood Pressure*CRT 0.0126 0.0064 1.9700 0.0489 
     
Glomerular Filtration Rate -0.0129 0.0037 -3.5070 0.0005 
CRT -0.2967 0.3495 -0.8490 0.3960 
Glomerular Filtration Rate*CRT -0.0032 0.0057 -0.5520 0.5810 
     
NT-pro-BNP a 0.3887 0.0589 6.5990 0.0000 
CRT -1.1054 0.7271 -1.5200 0.1280 
NT-pro-BNP a*CRT 0.0785 0.0905 0.8670 0.3860 
     
IVMD -0.0077 0.0026 -2.9950 0.0028 
CRT -0.0827 0.1985 -0.4160 0.6770 
IVMD*CRT -0.0077 0.0039 -1.9840 0.0473 
a
T
 = log transformed, * denotes an interaction 
able 7.2 Univariate Models For Each Potential Predictor (without imputation) 
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 z p coef se(coef) 
Mitral Regurgitation a              0.5299 0.0833 6.3639 0.0000 
CR 6 0.3947 -0.0092 0.9930 T -0.003
Mitral Regurgitation a *CRT          -0.1692 0.1253 -1.3506 0.1770 
     
EVSI 0.4225 0.1610 2.6228 0.0087 a
CR -0.0703 1.1980 -0.0587 0.9530 T 
ESVI *CRT -0.0807 0.2480 -0.3252 0.7450 a
     
Ischaemic 1350 3.8800 0.0001 0.5220 0.
CRT -0.7310 0.1580 -4.6200 0.0000 
Ischaemic*CRT 0.4010 0.2120 1.8900 0.0583 
     
Ejection Fraction a -0.9110 0.2490 -3.6630 0.0003 
CRT -1.3420 1.1680 -1.1490 0.2510 
Ejection Fraction a *CRT 0.2730 0.3670 0.7430 0.4580 
     
Age 0.0237 0.0073 3.2620 0.0011 
CRT -0.1452 0.7284 -0.1990 0.8420 
Age*CRT -0.0051 0.0108 -0.4690 0.6388 
     
Systolic Blood Pressure -0.0125 0.0040 -3.1600 0.0016 
CRT -1.6131 0.7302 -2.2100 0.0272 
Systolic Blood Pressure*CRT 0.0099 0.0062 1.5800 0.1130 
     
Glomerular Filtration Rate -0.0146 0.0035 -4.1500 0.0000 
CRT -0.3004 0.3237 -0.9280 0.3530 
Glomerular Filtration Rate*CRT -0.0032 0.0055 -0.5940 0.5520 
     
NT-pro-BNP a 0.3741 0.0564 6.6300 0.0000 
CRT -0.4602 0.6637 -0.6930 0.4880 
NT-pro-BNP a*CRT -0.0104 0.0832 -0.1250 0.9000 
     
IVMD -0.0058 0.0021 -2.7300 0.0064 
CRT -0.2558 0.1676 -1.5300 0.1270 
IVMD*CRT -0.0046 0.0031 -1.4800 0.1400 
a = log transformed, * denotes an interaction 
Table 7.3 Univariate Models For Each Potential Predictor (with imputation) 
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Imputed 
 
 
 
Mitral Regurgitation a            Obs Events Model L.R. d.f. P Score Score P R2 
 605 289 66.8400 3.0000 0.0000 67.4200 0.0000 0.1100 N 
 813 383 86.3100 3.0000 0.0000 82.5700 0.0000 0.1000 Y 
          
EVSI a 732 349 28.9300 3.0000 0.0000 29.4700 0.0000 0.0400 N 
 813 383 30.4900 3.0000 0.0000 31.3700 0.0000 0.0400 Y 
          
Ischaemic 812 383 67.8300 3.0000 0.0000 65.9500 0.0000 0.0800 N 
 813 383 67.8100 3.0000 0.0000 65.9200 0.0000 0.0800 Y 
          
Ejection Fraction a 745 357 33.4800 3.0000 0.0000 35.4000 0.0000 0.0400 N 
 813 383 38.4900 3.0000 0.0000 41.1300 0.0000 0.0500 Y 
          
Age 813 383 36.8700 3.0000 0.0000 37.7300 0.0000 0.0400 N 
 813 383 36.8700 3.0000 0.0000 37.7300 0.0000 0.0400 Y 
          
Systolic Blood Pressure 803 378 31.8900 3.0000 0.0000 34.0500 0.0000 0.0400 N 
 813 383 30.9900 3.0000 0.0000 32.9200 0.0000 0.0400 Y 
          
Glomerular Filtration Rate 739 338 45.9800 3.0000 0.0000 43.8600 0.0000 0.0600 N 
 813 383 59.2000 3.0000 0.0000 56.1100 0.0000 0.0700 Y 
          
NT-pro-BNP a 732 346 109.3300 3.0000 0.0000 105.0800 0.0000 0.1400 N 
 813 383 102.2200 3.0000 0.0000 101.0200 0.0000 0.1200 Y 
          
IVMD 735 346 52.3500 3.0000 0.0000 49.2400 0.0000 0.0700 N 
 813 383 45.9500 3.0000 0.0000 45.1000 0.0000 0.0600 Y 
a = log transformed 
Table 7.4 Fit Statistics for Univariate Models  
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 coef se(coef) z p 
Mitral Regurgitation a            0.5381 0.1088 4.9470 0.0000 
IVMD 0.0010 0.0034 0.3070 0.7590 
CRT -1.8753 0.8876 -2.1130 0.0346 
Systolic Blood Pressure -0.0087 0.0048 -1.8150 0.0695 
NT-pro-BNP a 0.2720 0.0591 4.6010 0.0000 
Ischaemic 0.6345 0.1349 4.7050 0.0000 
IVMD*CRT -0.0131 0.0050 -2.6390 0.0083 
Systolic Blood Pressure*CRT 0.0172 0.0073 2.3600 0.0183 
a = log transformed 
Table 7.5 Coefficients For Final Model (without imputation) 
 
 
Obs Events Model L.R. d.f. P Score Score P R2 
526 249 130.1900 8.0000 0.0000 121.0200 0.0000 0.2200 
Table 7.6 Fit Statistics For Final Model (without imputation) 
 
 
 coef se(coef) z p 
Mitral Regurgitation a            0.3131 0.0800 4.1100 0.0000 
IVMD -0.0046 0.0025 -1.8810 0.0600 
CRT -1.1993 0.7073 -1.6960 0.0900 
Systolic Blood Pressure  -0.0035 0.0038 -0.9440 0.3450 
NT-pro-BNP a 0.2362 0.0513 4.6070 0.0000 
Ischaemic  0.5280 0.1094 4.8260 0.0000 
IVMD*CRT  -0.0057 0.0034 -1.6550 0.0979 
Systolic Blood Pressure*CRT  0.0075 0.0058 1.2950 0.1950 
Table 7.7 Coefficients For Final Model (with imputation) 
 
 
 
 
 
 
Obs Events Model L.R. d.f. P Score Score P R2 
813 383 174.7200 8.0000 0.0000 165.3600 0.0000 0.1900 
Table 7.8 Fit Statistics For Final Model (with imputation) 
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 index.orig training test optimism index.corrected n 
 
 
Dxy -0.4090 -0.4233 -0.3984 -0.0249 -0.3841 200 
Table 7.9 Validation Results For Final Model (without imputation) 
 
 
 
 
 
 
 index.orig training test optimism index.corrected n 
Dxy -0.3919 -0.3984 -0.3855 -0.0130 -0.3789 200 
Table 7.10 Validation Results For Final Model (with imputation) 
coef se(coef) z p 
 
 
 
 
Mitral Regurgitation a            0.3799 0.0868 4.3800 0.0000 
IVMD -0.0046 0.0028 -1.6500 0.0984 
CRT -0.9963 0.7288 -1.3700 0.1720 
Systolic Blood Pressure -0.0046 0.0038 -1.2100 0.2280 
NT-pro-BNP a 0.2939 0.0471 6.2400 0.0000 
Ischaemic 0.5539 0.1094 5.0600 0.0000 
IVMD*CRT -0.0085 0.0043 -2.0000 0.0455 
Systolic Blood Pressure*CRT 0.0070 0.0059 1.1900 0.2350 
a = log transformed 
able 7.11 Coefficients For Final Model (with multiple imputation (5 imputations)) T
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Figure 8.1 measurement on 5 hypothetical patients differing slopes 
e figure 8.1 above illustrates a hypothetical situation for five patients on whom ten 
easurements , it appears that the intercept 
e  , but that the slop e  patient to patient. I need to 
 varying slopes. Assuming that the 
Th
kXm Y have been taken at different times
for each pati nt is the same e vari s from
develop a model that takes into account the
variation in the slopes is random, the model  incorporates the kjjk XY )( 10 βαβ ++=
random slopes through the term jα  .The term jα  is known as a random effect. 
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Figure 8.2 measurements on 5 hypothetical patients, differing slopes and intercepts 
e figure 8.2 shows a situation where both the intercept and the slope vary from 
atient to patient, again I need to incorporate the varying slope and intercept into the 
( 10
Th
p
model. The model Y kjjjk X)βαζβ +++= now c s itional random 
effect 
ontain  an add
jζ  , the random intercept; such a model is known as a mixed model. It is 
important to point out that I am not interested in obtaining numerical estimates for 
jα and jζ , I am concerned with whether or not their inclusion improves the model fit. 
I could consider a situation in which I have data on a number of patients who have 
ent at several different hospitals or clinics, for each patient I would 
have a repeated measure  taken at time , also let indicate at which of the 
hospitals or clinics the patient received their treatment. I might find that the slope, 
intercept or both vary depending upon which of the hospitals or clinics the patient 
attended. In this case the model should include 
received treatm
jkY kX mC m  
jα  and/or jζ , random effects for the 
intercept and slope. 
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8.1.0 Frailty 
 
The idea of frailty is another way of incorporating random effects and heterogeneity 
into a model for time to event data (survival model). In most biomedical and 
epidemiological applications the time to event data is assumed to be homogeneous, in 
reality there may be sources of unobserved heterogeneity within the data. For 
example, if x~  is a vector of independent variables (co-variants), it is quite possible 
tha , some powerful predictor of , is missing for whatever reason. It is not 
practical to include all possible covariates, such as when the number of events within 
a particular stratum is very small, or it may be that the particular co-variate has yet to 
be identified.  
 
In a clinical trial, one important potential source of heterogeneity is the treatment 
centre. Section 3.2 of ICH E9 (ICH E9. 1999), (ICH HARMONISED TRIPARTITE 
GUIDELINE 1998) which addresses multicentre trials, places great emphasis on a 
proper treatment of centre effects and states: 
“Up to this point the discussion of multicentre trials has been based on the use of 
fixed effect models. Mixed models may also be used to explore the heterogeneity of 
the treatment effect. These models consider centre and treatment-by-centre effects to 
be random, and are especially relevant when the number of sites is large.” Use of 
frailty models would seem to be in accord with the guidelines laid down in ICH E9 
although at present their use is not advocated. 
 
Taking the proportional hazards model
t unobX Y
xeyhyh
~~
01 )()(
β=
unob
, the hazard for each subject 
will be different and determined by . How can I include unobserved co-variates X
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 in the proportional hazards model? The answer lies in the idea of frailty. Frailty could 
be described as accident proneness, or in terms of the force of mortality upon a certain 
subject (force of mortality is the hazard function ).  
 
Vaupel (Vaupel et al. 1979) defines frailty in the following way, let 
)( yh
),,( zyxiµ  be the 
force of mortality for an individual in population group , at exact age , at time 
with frailty , then 
i x y  
z
z
z
zyx
zyx
i
i
′=′,,(
),,(
µ
µ
 
Now  describes a ’standard individual’, so we get1=′z )1,,(),,(1 yxzzyx iµµ = . An 
individual with a frailty of 3 is 3 times as likely to die or exp  
interest as the standard individual. Following Vaupel’s no
erience the event of
tation I write 
),,( zyxiµ as )(zµ , )1,,( yxiµ  as )1(µ orµ . So I have µµ zz =)( . I could apply this 
idea to the proportional hazards model to arrive at )~~exp(
)(
),(
0
1 xz
y
zy βµ
µ =
)
. Rearranging 
the above formula gives . The above is an example of a 
univariable frailty m odel is an extension of Cox Proportional 
Hazards model . The fra nt of the random effects model for 
time to event data. It m  is a random variable, also I must have 
, this dictates the choice of distribution for .  
 
Typical choices for the distribution of z include the Gamma 
distribution
~~exp()(),( 01 xzyzy βµµ =
odel; this frailty m
ilty model is the equivale
ust remembered that z
0≥z z
)(
),(
1
ϕ
λλ
λϕϕ
Γ=
−− zezzf .Where λ  is scale parameter, ϕ  is a shape parameter 
and )(λΓ is the Gamma function . The Gamma distribution is a ∫∞ −−=Γ
0
1)( dueu uλλ
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 logical choice for the distribution of ; as  is non-negative this makes the Gamma 
distribution a sensible choice. Vaupel (Vaupel et al. 1979) states that frailty was 
assumed to follow the Gamma distribution because the distribution is “analytically 
tractable and readily computable”. The Gamma distribution is flexible in the sense 
that, as
z z
 ϕ  varies, the distribution can take on different shapes. Also in Vaupel 
(Vaupel l. 1979) describes two convenient mathematical results that arise from the 
assumption that frailty follows the Gamma distribution. I see that if , then the 
hazard for an individual will be reduced, and if , then the hazard is increased.  
 
The important point is that, in the frailty model, the hazard for an individual is 
determined by both observed and unobserved factors. The following papers (Wienke 
2003), (Manton et al. 1986), (Hougaard 1991), (Hougaard 1984) and (Perperoglou et 
al. 2007) are highly informative and contain m terial detailing the motivation and 
development of frailty models along with discus on on the issue of the distribution of 
the frailty. Including frailty in a prognostic su odel seems to be a very natural 
and highly appealing thing to do.  
 
In recent years, faster CPUs have meant that so  of the previous difficulties (relating 
to numerical methods) encountered when tr models have been 
overcome. Consequently, it is now quite possi it a frailty model in situations 
where previously this may have been difficult and we no longer have to simply ignore 
centre effects.   
 
et a
1<z
1>z
a
si
rvival m
me
ying to fit frailty 
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8.2.0 Fitting a Frailty Model to the CARE-HF data 
 
 
I shall now proceed to fit a univariable gamma frailty model to the CARE HF data 
(Richardson et al. 2007) whilst at the same time applying elements of Harrell et al.’s 
(1996) approach. Earlier the following covariates where identified as being potential 
predictors of outcome and response to CRT: 
 
• Mitral Regurgitation (MR) 
• Interventricular Mechanical Delay (IVMD) 
• End-systolic volume index (ESVI) 
• Glomerular Filtration Rate (GFR) 
• Systolic Blood Pressure (SBP) 
• Ejection Fraction (EF) 
• N-terminal pro-brain natriuretic peptide (NT-pro-BNP) 
• Age 
• Aetiology  (Ischaemic)  
 
As before I start by fitting a proportional hazards model for each of the potential 
predictors identified above (univariable analysis), using Mitral Regurgitation as an 
example we would fit the model CRTCRTMRMR ++ )*(  where  is an 
interaction term. We assume also that the transformations applied in C re 
still used, so we would consider
CRTMR*
hapter 3 a
CRTCRTMRMR ee ++ )*)((log)(log .  Now in 
addition I shall include a frailty term, the frailty term is assumed to follow the gamma 
distribution; this extended Cox Proportional Hazards model is a gamma frailty model. 
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 For the CARE-HF study the treatment centre that each patient attended was recorded 
in the form of the variable SiteNum (site number), for the CARE-HF study there were 
82 centres across Europe. Centre effects are modeled using the idea of grouped frailty, 
for example patients who received treatment at the same hospital would be regarded 
as sharing a common frailty. Centre effects are of interest due varying clinical skills, 
case-mix, technology, funding and so on. I shall model site number as a grouped 
frailty term, i.e. each treatment centre represents a group of patients; frailty can be 
also be modeled at an individual level, an individual patient characteristic could be 
treated as a frailty term.   
 
Univariate models are produced for each of the other potential predictors; I then 
include significant (5% level) covariates and interaction terms from these univariable 
models as candidates in the final model. The models were fitted using coxph (R 
survival package Terry Therneau 2009) from the recommended base survival package 
in GNU R version 2.7.2 (R Foundation for Statistical Computing 2009). In Tables 
8.1-8.9, coefficients are presented for each of the univariable models. Note that, with 
coxph, automated stepdown or stepwise selection is not possible. Table 8.11 shows 
the final conventional Cox Proportional Hazards model presented in (Richardson et 
al. 2007) (see Chapter 2 for a full discussion of this model). 
 
The final frailty model shown in Table 8.10 is obtained in the following way: all co-
variates that are statistically significant (5% level) in the univariable analysis are 
considered as candidates for inclusion in the final model; a non-stepwise backward 
selection procedure is then applied resulting in the final (frailty) model. It can be seen 
from Table 8.10 that SiteNum is not significant; this suggests that the conventional 
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 Cox Proportional Hazards model may be adequate, i.e. the data not observed to be 
heterogeneous with respect to treatment centre. However it can be argued that even if 
the frailty term is not statistically significant, it should be retained, i.e. we adopt the 
frailty model. The overheads in terms of model complexity and computational 
resources are not so great that we would abandon the frailty model in favour of the 
conventional Cox Proportional Hazards model. It may in fact be natural and 
appropriate as far as the design of a model is concerned to include a frailty term.  
 
Comparing Tables 8.10 and 8.11 it is seen that the final models are similar. The 
likelihood ratio test for the frailty model gives a slightly larger value than that for the 
Cox Proportional Hazards model, however this result is not statistically significant. 
The confidence interval and p-values produced for both models are consistent. If 
heterogeneity had been present in the data, and I was to fit a conventional Cox 
Proportional Hazards model I am liable to obtain confidence intervals that are too 
narrow and p-values that are too small. The frailty models I have considered are 
relatively simple, for example I have not attempted to fit a frailty model where some 
of the co-variates required transformation via cubic splines or fractional polynomials. 
Validation of the frailty model presented in Table 8.10 was not performed as both  
Therneau’s survival package  and Harrell’s Design package do not have the facility to 
validate frailty models. This is a drawback I hope that at some point in the future it 
will be possible to routinely validate frailty models in GNU R. As far as I am aware 
the situation is no different in SAS, in fact it is rather difficult to even produce frailty 
models easily and efficiently in SAS.    
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8.2.1 Tables 8.1-8.9 Univariable Frailty Models For Each Potential Predictor 
(without imputation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Likelihood ratio test = 67.9 on 3.49 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.1 Univariate Analysis Mitral Regurgitation (MR) n=605 (208 observations deleted due to 
missingness) 
 
 
 
 
 
 
 
Likelihood ratio test = 62 on 17.0 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.2 Univariate Analysis End-systolic volume index (ESVI) n=732 (81 observations deleted due 
to missingness) 
 
 
 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
Mitral Regurgitation a              2.1300 1.6820 2.7200 p<0.0001 
CRT 1.8450 0.5870 5.8000 0.2900 
frailty(SiteNum)                              0.2400 
Mitral Regurgitation a *CRT   0.7160 0.5010 1.0200 0.0670 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
EVSI a 1.5250 1.0715 2.1700 0.0190 
CRT 0.5490 0.0326 9.2200 0.6800 
frailty(SiteNum)         0.1600 
ESVI a*CRT 1.0220 0.5701 1.8300 0.9400 
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 Hazard Ratio CI lower 95 % CI upper 95 % p 
Ischaemic 1.7070 1.3030 2.2360 p<0.0001 
CRT 0.4770 0.3490 0.6520 p<0.0001 
frailty(SiteNum)         0.1900 
Ischaemic*CRT 1.4980 0.9850 2.2780 0.0590 
Likelihood ratio test = 97.6 on 15.7 df,   p<0.0001 
* denotes an interaction 
Table 8.3 Univariate Analysis Aetiology (Ischaemic) n=812 (1 observation deleted due to missingness) 
 
 
 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
Ejection Fraction a 0.3820 0.2176 0.6700 0.0008 
CRT 0.3310 0.0191 5.7300 0.4500 
frailty(SiteNum)                        0.3200 
Ejection Fraction a *CRT 1.2260 0.5001 3.0000 0.6600 
Likelihood ratio test = 45.2 on 8.3 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.4 Univariate Analysis Ejection Fraction (EF) n=745 (68 observations deleted due to 
missingness) 
 
 
 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
Age 1.0240 1.0090 1.0400 0.0014 
CRT 0.8500 0.2030 3.5600 0.8200 
frailty(SiteNum)         0.3400 
Age*CRT 0.9950 0.9740 1.0200 0.6600 
Likelihood ratio test = 45.9 on 7.09 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.5 Univariate Analysis Age n= 813  
 
 
 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
Systolic Blood Pressure 0.9870 0.9795 0.9950 0.0012 
CRT 0.1440 0.0332 0.6260 0.0098 
frailty(SiteNum)       0.2900 
Systolic Blood Pressure*CRT 1.0130 1.0000 1.0250 0.0490 
Likelihood ratio test = 36.2 on 4.77 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.6 Univariate Analysis Systolic Blood Pressure (SBP) n=803 (10 observations deleted due to 
missingness) 
 
 
 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
Glomerular Filtration Rate 0.9870 0.9800 0.9940 p<0.0001 
CRT 0.7420 0.3740 1.4730 0.3900 
frailty(SiteNum)       0.2500 
Glomerular Filtration Rate*CRT 0.9970 0.9860 1.0080 0.5800 
Likelihood ratio test = 47.1 on 3.52 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.7 Univariate Analysis Glomerular Filtration Rate (GFR) n=739 (74 observations deleted due to 
missingness) 
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 Hazard Ratio CI lower 95 % CI upper 95 % p 
NT-pro-BNP a 1.4750 1.3142 1.6600 p<0.0001 
CRT 0.3310 0.0796 1.3800 0.1300 
frailty(SiteNum)       0.8900 
NT-pro-BNP a*CRT 1.0820 0.9058 1.2900 0.3900 
Likelihood ratio test = 109 on 3 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.8 Univariate Analysis N-terminal pro-brain natriuretic peptide (NT-pro-BNP) n=732 (81 
observations deleted due to missingness) 
 
 
 
 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
IVMD 0.9920 0.9870 0.9970 0.0023 
CRT 0.9250 0.6240 1.3690 0.7000 
frailty(SiteNum)       0.2000 
IVMD*CRT 0.9920 0.9840 1.0000 0.0400 
Likelihood ratio test = 77.5 on 13.6 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.9 Univariate Analysis Interventricular Mechanical Delay (IVMD) n=735 (78 observations 
deleted due to missingness) 
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 Hazard Ratio CI lower 95 % CI upper 95 % p 
Mitral Regurgitation a              1.7160 1.3857 2.1240 p<0.001 
IVMD 1.0010 0.9944 1.0080 0.7700 
CRT 0.1510 0.0265 0.8670 0.0340 
frailty(SiteNum)       0.2700 
Systolic Blood Pressure 0.9914 0.9821 1.0007   0.0720 
NT-pro-BNP a 1.3140 1.1699 1.4759 p<0.001 
Ischaemic 1.8887 1.4491 2.4618 p<0.001 
IVMD*CRT             0.9870               0.9774               0.9966  0.0084 
Systolic Blood Pressure*CRT 1.0174 1.0030 1.0321   0.0180 
Likelihood ratio test = 133 on 9.07 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.10 Final model n=526 (287 observations deleted due to missingness) 
 
 
 
 
 
 Hazard Ratio CI lower 95 % CI upper 95 % p 
Mitral Regurgitation a              1.7128 1.3839 2.1199 p<0.001 
IVMD 1.0010 0.9945 1.0080 0.7600 
CRT 0.1533 0.0269 0.8733 0.0350 
Systolic Blood Pressure 0.9914 0.9821 1.0010 0.0700 
NT-pro-BNP a 1.3126 1.1690 1.4739 p<0.001 
Ischaemic 1.8868 1.4486 2.4576 P<0.001 
IVMD*CRT 0.9870 0.9774 0.9966 0.0083 
Systolic Blood Pressure*CRT 1.0173 1.0029 1.0320 0.0180 
Likelihood ratio test = 130 on 8 df,   p<0.0001 
a = log transformed, * denotes an interaction 
Table 8.11 Final (non frailty) model  
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CHAPTER 9 CONCLUSION 
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troduction 
ork I have been concerned with producing a good quality prognostic model 
ARE-HF data (Richardson et al. 2007). The prognostic model developed for 
E-HF data represents a significant real world example of a prognostic model, 
 aware that the model has been made use of in practice. The prognostic model 
ARE-HF data indicates that all patients are likely to benefit from cardiac 
ronisation therapy, i.e. the treatment modifiers identified in the model are 
ne way of validating the model developed for the CARE-HF data would be to 
to new data. Apart from the COMPANION study (Bristow et al. 2004) there 
en no investigations comparable to the CARE-HF study. Unfortunately 
al patient data from the COMPANION study although requested has not been 
ailable. It is unlikely that further investigation of CRT will be undertaken as 
it has been established. The difficulties and problems encountered when 
g this model are likely to be experienced by other researchers when they 
forts to deal issues such as functional form, over-fitting, optimism and 
n. In producing the model for the CARE-HF data I found that when one 
 attempts to employ a strategy such as the one suggested by Harrell and colleagues 
(Harrell et al. 1996) one ends up having to consider the fundamental problem of 
model fitting. The topic of model selection is a deep one; I have great admiration for 
the skill and insight displayed by researchers into this problem.   
I have come to an appreciation of the complexity surrounding the problem of 
developing a good prognostic model. This work it is hoped has served as an 
accessible guide to some of the main methods that feature in the process of fitting a 
prognostic model, (or a model in general). Implementing an approach such as 
Harrell’s is not a trivial task. I believe that I have identified some important 
limitations in Harrell’s strategy. I shall now present a brief summary of the material 
covered in the course of this work and indicate important points that have arisen.  
9.1.0 Summary of Main Topics 
 
Chapter 1 contained an introductory discussion a definition of a prognostic model was 
ver-fitting was introduced along with the idea of optimism. In 
Chapter 2 the prognostic model developed for the CARE-HF data was described and 
discussed.  The development of this model was in itself a substantial piece of work. 
Absolute risk estimates and risk score where discussed in chapter 3, I presented a risk 
score calculator based on the prognostic model for the CARE-HF data. The problem 
of functional form was investigated in chapter 4. Use of cubic splines and fractional 
polynomials was discussed. In chapter 5 model fit was considered, the AIC was 
described in some detail. Over-fitting and optimism were discussed in further detail in 
chapter 6. Validation methods were also considered. Missing data and imputation 
were discussed in chapter 7. Chapter 8 introduced the idea of a frailty model.  
This work has provided me with a great many questions and future areas of 
investigation. In chapter 1 of this work I stated that the whole question of 
given, the problem of o
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 generalizabilty is a complex one. The following questions were then asked. Should we 
expect to achieve more general results in the physical sciences? Do biomedical 
applications present us with special problems? The answer to both of these questions 
is probably no. Over-fitting is a problem for researchers working in the fields of 
Physics, Astronomy and other physical sciences. Over-fitting is also a problem in 
Ecological, Economic and Financial models (Ginzburg & Jensen 2004). The 
prognostic model described in chapter 2 of this work prompts me to consider a 
practical question that researchers may have to consider in regard to choice of 
software. An implementation of Harrell’s design library does exist for SAS; however 
this is an old version, development is focused on the S-Plus and R versions. Given 
that SAS is a widely used system an up-to-date and user friendly version for SAS 
would be of great value. There may be many researchers who for a variety of reasons 
may not be able to adopt R or S-Plus. Hmisc also seems to suffer from a lack of up-to-
date versions that could easily be installed on a recent version of SAS.   
In the discussion of cubic splines in chapter 4 it might be useful to reflect on Harrell’s 
use of the restricted cubic spline (Harrell et al. 1996), (Herndon & Harrell 1990). 
What clinical/biological evidence there is to support this particular choice for the 
functional form of the model? Use of cubic splines may improve the fit of the model 
(on the original data), and when considering model validation goodness of fit is a 
basic criterion. As Altman and Royston point out in (Altman & Royston 2000) a 
statistically valid model may be clinically invalid. A choice of functional form that 
improves model fit and so leads to a statistically valid model, may not lead to a 
clinically valid model. The biological plausibility of the model is a matter for the 
medical expert to consider. Harrell’s strategy has been central element of many of the 
discussions in the work, what general remarks would I make about Harrell et al.’s 
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 approach? I am of the view that adopting Harrell’s recommendations for avoiding 
over-fitting should certainly be included as part of the process of fitting a prognostic 
model. Harrell encourages inter-disciplinary collaboration, clinicians should be 
consulted by the statistician throughout the modelling process, this is vital if the 
model is to be a sensible.  Harrell’s approach allows the researcher to determine if 
there is a risk of over-fitting by use of the inequality 10<
p
N E . The extent of over-
fitting is gauged via an estimation of the optimism. What in built mechanism exists 
within Harrell’s approach that will minimise the risk of over-fitting? This question 
could be answered by noting that model selection based on the AIC or BIC is 
implemented as part of Harrell’s software. However using Harrell’s approach it is still 
quite easy to produce a model that is over-fitted. In chapter 8 of this work frailty 
 that it does not 
cant omission.  What alternative 
t enable the researcher to produce reliable and 
t I have found to offer 
s to model fitting. In no way do I mean to suggest 
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9.2.0 Alternative Modelling Techniques 
could be 
ere 
odelling that could offer better results in 
thmic Modelling  
t e that the 
 a model the better. This is on the surface a quite 
reasonable assumption, as the number of variables is in some way equated to 
‘information’. The more variables we have in the model, the better the description of 
reality provided by the model. It can be difficult for someone to appreciate the 
concept of parsimo
 a model, but 
t be clearly elucidated.  It might be argued that if 
 a parsimonious 
to difficulty with over-fitting. The conventional 
istic for a model, one 
a 
. There is an alternative view of 
parsimony; it could be argued that by seeking to produce a model based on Occam’s 
razor unrealistic restrictions have been imposed. Real world situations such as those 
echanisms; therefore the model may be 
 
Throughout this work the modelling techniques discussed have been what 
described as traditional, i.e. the Cox proportional hazards model. Are th
alternatives to the traditional approaches to m
regard to the problem of over-fitting? 
9.2.1 Data Modelling and Algori
 
 uncommon for a researcher new to statistical modelling to assumIt is no
more variables that are included in
ny in statistical modelling. In some introductory courses on 
statistics the idea of parsimony is mentioned as an important feature of
the reason for its importance may no
researchers new to statistical modelling do not appreciate the idea of
model they may be likely to get in
view is that parsimony is a necessary and desirable character
would expect a simple parsimonious model to be more easily interpreted than 
complex model containing a large number of variables
presented in medicine involve complex m
ex ely complex. Breiman argues in (Breiman 2001) that instead trem of aiming to 
 - 159 -   
 minimise the dimension of a model it should be increased. Breiman propounds the 
acy is concerned the best model is the most 
on.    
Breiman describes two approaches toward statistical
 
• Data Modelling 
ic Modelling 
stochastic model, conventional techniques 
ression, Cox regression are examples of data 
rithmic 
g s chas c mo el; ins  a black box approach 
is adopted. The independent variables 
idea that so far as predictive accur
complex one; in fact so complex that it may defy interpretati
 
 modelling 
• Algorithm
 
Data modelling supposes the existence of a 
such as linear regression, logistic reg
modelling. The data is used to estimate the parameters in the model. Algo
modelling does suppose some existin to ti d tead
X of the data model are considered as inputs to 
rates the dependent 
(s) . The aim of data modelling is to find some function  that will 
l network, or a support 
vector. Algorithmic modelling is not based on the principle of parsimony; Breiman 
 demands a more complex prediction method, i.e. a 
rithmic models 
els. There is with the algorithmic 
lling the problem of interpretability of the resulting model. If the 
odel is so complex as to be beyond interpretation what good is this to a clinician? 
ble to acquire useful information the independent 
nformation and 
 model is easy to interpret but provides no 
a black box which contains the unknown mechanism that gene
variable  Y )(xf
predict y . The function )(xf  is an algorithm such as a neura
argues that predictive accuracy
more complex model; further Breiman (Breiman 2001) states that algo
can provide better predictive accuracy than data mod
approach to mode
m
Breiman argues that it is still possi
and the dependent variables. A distinction is made between i
interpretability, it might be that a simple
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 ‘real’ information about e relation hip betwe n th  independent and dependent 
r too simple a picture. I 
ely interesting. 
nces would there be a genuine benefit in using an Algorithmic 
ping a prognostic model as opposed to the ‘traditional’ data 
r an advantage in so far as a reduced 
is concerned?  Are Algorithmic models inherently less prone to 
fitting? Is it possible with an Algorithmic model to build into it a mathematical 
‘resistance’ to over-fitting?  Neural networks are certainly prone to over-fitting 
vector machines (Mierswa 2007). The present 
iques.  
r-
 in the theory 
ic complexity and information theory. In the MDL context a statistical 
model is considered as a description of the data, model selection is then based on the 
idea of choosing the smallest description. If a data set possesses regularity then it is 
possible to compress the data. By compress is meant the idea that the data can be 
described using less symbols or characters than would be needed to provide a literal 
description.  The size of the description depends upon the detecting regularity within 
the data, the more regularity that the data exhibits the smaller the description, i.e. the 
smaller the model. The process of finding patterns or regularity within a data set is 
known as learning the data. Hansen and Yu (Hansen & Yu 2003) point out a major 
deficiency in model selection based on maximum likelihood, i.e. that the largest 
th s e e
variables, I can picture the model, but it is the wrong picture, o
find Breiman’s arguments extrem
In certain circumsta
approach in develo
modelling approach? Do Algorithmic models offe
risk of over-fitting 
over-
(Lawrence et al. 1997) as are support 
author would very much like to pursue an investigation of Algorithmic modelling 
techniques and compare them against comparable data modelling techn
9.3.0 MDL  
 
An exciting approach to model selection which may overcome the problem of ove
fitting is MDL (the Minimum Description Length). MDL has its origins
of algorithm
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 model is the preferred choice. In chapter 5 of this work the AIC was discussed as a 
model selection tool, the AIC introduced a penalty term in order to correct the 
maximum likelihood model selection process.  Hansen and Yu (Hansen & Yu 2003) 
state that the AIC performs well as a model selection tool if the underlying model is 
known to be of infinite dimension, but we do not generally have this information. 
MDL is proposed as a model selection method that is independent of the underlying 
model, and so is described as an adaptive method. The claim that MDL automatically 
protects against over-fitting (Rissanen 1978) can also be made for the AIC (due to the 
penalty term), the fact that MDL does not require the assumption of some underlying 
‘true’ model is highly attractive feature. In the same way MDL may have benefits 
ompression is a fundamental idea in MDL methods, there is a relationship between 
equality (Kraft 1949)) this leads to the idea that MDL methods search for a model 
 also 
lated to cross validation (Rissanen 1978). MDL unlike the Algorithmic modelling 
 a 
parsimonious model. The present author considers MDL as a potentially serious 
alternative to Harrell’s approach. A comparison of models produced using MDL 
methods against those produced using Harrell’s approach would be a most interesting 
project. The automatic protection against over-fitting afforded by MDL is of 
considerable benefit. With Harrell’s approach the onus is to a greater extent on the 
 
rmed the impression that MDL may represent a more cohesive approach than 
over the BIC, in the sense that the BIC performs well if the underlying model is of 
finite dimension, again for the BIC a ‘true’ underlying model is assumed. Data 
c
data compression and probability (this relationship can be expressed through Kraft’s 
in
with good predictive power on new unseen data (Rissanen 1978).  MDL is
re
discussed by Breiman (Breiman 2001) is based on Occam’s razor, and so aims at
researcher so far as taking steps to reduce the risk of over-fitting is concerned. I have
fo
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 Harrell’s.  The following material provides useful information MDL methods 
(Rissanen 1986), (Rissanen 1987), (Grunwald 2004) and (Hansen & Yu 2001) 
 
9.4.0 Recommendations 
 
9.4.1 Statistical Training And Accessible Literature 
 
I believe that for Harrell’s approach to be widely and routinely adopted the key issues 
of over-fitting and optimism need to be explained in a way that is intelligible to the 
troductory courses on statistical modelling should cover the topics of over-fitting 
It 
ppears that the issues of over-fitting, optimism and model validation come back to 
is all about. Harrell el al’s modelling strategy as described in (Harrell et al. 
e developed.  
isc, the RCS macro and the MFP macro can be rather daunting. I 
wkward to 
ates cubic splines, fractional polynomials, imputation and validation methods 
would be of considerable value. Harrell’s software does indeed combine cubic splines 
 
non-technical expert at the point when they begin learning about statistics. 
In
and optimism as a matter of routine and in tandem with modules on regression. 
a
haunt researchers some while after they have learnt what a Cox proportional Hazards 
model 
1996) can be hard to follow and understand, a clearer exposition aimed at the non-
atistician could bst
9.4.2 User friendly software 
 
Software such as Hm
can imagine that even fairly computer literate researchers might find them a
use. Efforts to develop a more user friendly integrated modelling package that 
incorpor
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 imputation and validation methods; however there are instances when the software 
proves to be awkward or limited. 
 
9.4.3 Investigation of MDA Methods 
 
An investigation of MDA methods applied to prognostic models would be in my 
opinion a useful piece of work. I intend to investigate further the theoretical and 
simulation studies relating to the AIC and BIC in conjunction with material on MDA 
methods. This will be done with a view to clarifying what advantages MDA may 
present as a model selection tool. 
9.4.4 Frailty Models 
 
Further investigation of frailty models is also an area that I intend to explore. The 
survival package in GNU R offers the facility to fit frailty models; model fit is 
007); I 
would be interested attempting to implement this form of the AIC in software. 
Application of MDA methods to frailty models is of considerable interest to me.
reported via the likelihood ratio test. A form of the AIC for the frailty model as 
discussed in Chapter 5 has been proposed by Do Ha et al. (Do Ha et al. 2
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Appendices 
Appendix 1.0.0 SAS CODE 
 
 
 
proc univariate data=card.prognostic; 
    var mitral_r IVMD ESVI GRF QRS supsys supdia BSA HeartRate 
a4cLVEjectionFraction Roche Age; 
run; 
data card.progex; 
   set card.prognostic;  
   if mitral_r ^= '.' and mitral_r < 11. then mitral_grp=1; 
   if mitral_r ^= '.' and (mitral_r >= 11 and mitral_r < 22) then 
mitral_grp=2; 
   if mitral_r ^= '.' and (mitral_r >=22 and mitral_r < 34) then 
mitral_grp=3; 
   if mitral_r ^= '.' and mitral_r >= 34 then mitral_grp=4; 
   trmit=treat*mitral_r; 
   lmit=log(mitral_r); 
   trlmit=treat*lmit; 
   pmit=1/(sqrt(mitral_r)); 
   tpmit=treat*pmit; 
   tanmit=tan(mitral_r); 
   if IVMD ^= '.' and IVMD < 31 then IVMD_grp=1; 
   if IVMD ^= '.' and (IVMD >= 31 and IVMD < 49) then IVMD_grp=2; 
   if IVMD ^= '.' and (IVMD >=49 and IVMD < 67) then IVMD_grp=3; 
   if IVMD ^= '.' and IVMD >= 67 then IVMD_grp=4; 
   trivm=treat*IVMD; 
   ShIVMD=IVMD+60; 
   lShIVMD=log(ShIVMD); 
   trlShIVMD=treat*lShIVMD; 
    
   if ESVI ^= '.' and ESVI < 93 then ESVI_grp=1; 
   if ESVI ^= '.' and (ESVI >= 93 and ESVI < 119) then ESVI_grp=2; 
   if ESVI ^= '.' and (ESVI >=119 and ESVI < 149) then ESVI_grp=3; 
   if ESVI ^= '.' and ESVI >= 149 then ESVI_grp=4; 
   tresv=treat*ESVI; 
   lesv=log(ESVI); 
   trlesv=treat*lesv; 
   if GRF ^= '.' and GRF < 46 then GRF_grp =1; 
   if GRF ^= '.' and (GRF >= 46 and GRF < 60) then GRF_grp =2; 
   if GRF ^= '.' and (GRF >= 60 and GRF < 73) then GRF_grp =3; 
   if GRF ^= '.' and GRF >= 73 then GRF_grp=4; 
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    trgrf=treat*GRF; 
   lgrf=log(GRF); 
   trlgrf=treat*lgrf; 
   if QRS ^='.' and QRS < 152 then QRS_grp =1; 
   if QRS ^='.' and (QRS >= 152 and QRS < 160) then QRS_grp =2; 
   if QRS ^='.' and (QRS >= 160 and QRS < 180) then QRS_grp =3; 
   if QRS ^='.' and QRS >= 180 then QRS_grp=4; 
   trqrs=treat*QRS; 
   lqrs=log(QRS); 
   trlqrs=treat*lqrs; 
   if supsys ^='.' and supsys < 105 then supsys_grp =1; 
   if supsys ^='.' and (supsys >= 105 and supsys < 117) then 
supsys_grp =2; 
   if supsys ^='.' and (supsys >= 117 and supsys < 130) then 
supsys_grp =3; 
   if supsys ^='.' and supsys >= 130 then supsys_grp=4; 
   trsup=treat*supsys; 
   lsup=log(supsys); 
   trlsup=treat*lsup; 
   if supdia ^='.' and supdia < 60 then supdia_grp =1; 
   if supdia ^='.' and (supdia >= 60 and supdia < 70) then supdia_grp 
=2; 
   if supdia ^='.' and (supdia >= 70 and supdia < 80) then supdia_grp 
=3; 
   if supdia ^='.' and supdia >= 80 then supdia_grp=4; 
   trdia=treat*supdia; 
   ldia=log(supdia); 
   trldia=treat*ldia; 
   if BSA ^='.' and BSA < 1.73 then BSA_grp=1; 
   if BSA ^='.' and (BSA >= 1.73 and BSA < 1.88) then BSA_grp=2; 
   if BSA ^='.' and (BSA >= 1.88 and BSA < 2.01) then BSA_grp=3; 
   if BSA ^='.' and BSA >=2.01 then BSA_grp=4; 
   trbsa=treat*BSA; 
   lbsa=log(BSA); 
   trlbsa=treat*lbsa; 
   if HeartRate ^='.' and HeartRate < 60 then HeartRate_grp=1; 
   if HeartRate ^='.' and (HeartRate >= 60 and HeartRate < 69) then 
HeartRate_grp=2; 
   if HeartRate ^='.' and (HeartRate >= 69 and HeartRate < 78) then 
HeartRate_grp=3; 
   if HeartRate ^='.' and HeartRate >=78 then HeartRate_grp=4; 
   trhea=treat*HeartRate; 
   lhea=log(HeartRate); 
   trlhea=treat*lhea;  
   if a4cLVEjectionFraction ^= '.' and a4cLVEjectionFraction < 22 
then EF_grp =1; 
   if a4cLVEjectionFraction ^= '.' and (a4cLVEjectionFraction >= 22 
and a4cLVEjectionFraction < 25) then EF_grp =2; 
   if a4cLVEjectionFraction ^= '.' and (a4cLVEjectionFraction >= 25 
and a4cLVEjectionFraction < 29) then EF_grp =3; 
   if a4cLVEjectionFraction ^= '.' and a4cLVEjectionFraction >= 29 
then EF_grp=4; 
   tra4c=treat*a4cLVEjectionFraction; 
   la4c=log(a4cLVEjectionFraction); 
   trla4c=treat*la4c; 
   if Roche ^='.' and Roche < 744 then Roche_grp =1; 
   if Roche ^='.' and (Roche >= 744 and Roche < 1814) then Roche_grp 
=2; 
   if Roche ^='.' and (Roche >= 1814 and Roche < 4198) then Roche_grp 
=3; 
   if Roche ^='.' and Roche >= 4198 then Roche_grp=4; 
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    trroc=treat*Roche; 
   lroc=log(Roche); 
   trlroc=treat*lroc; 
   if Age ^= '.' and Age < 59 then Age_grp =1; 
   if Age ^= '.' and (Age >= 59 and Age < 66) then Age_grp =2; 
   if Age ^= '.' and (Age >= 66 and Age < 72) then Age_grp =3; 
   if Age ^= '.' and Age >= 72 then Age_grp=4; 
   trage=treat*Age; 
   lage=log(Age);   
   trlage=treat*lage; 
run; 
quit; 
  
proc phreg data=card.progex; 
     title 'phreg treat treat*mitral_r futime';  
     model futime*primary(0)=treat mitral_r trmit /RL; 
run; 
quit; 
 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(mitral_r) futime'; 
  model futime*primary(0)=treat lmit trlmit /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(Mital_r Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\mitral.sas), 
   TIME=futime, status=primary, 
   COV1=mitral_r,WHAT1=0,KNOTS1=11 22 34 66,  
   COV2=trmit,WHAT2=0,KNOTS2=11 22 34 66, 
   COV3=treat 
);  
 
proc phreg data=card.progex; 
     title 'phreg treat treat*IVMD futime';  
     model futime*primary(0)=treat IVMD trivm /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(IVMD)futime'; 
  model futime*primary(0)=treat lShIVMD trlShIVMD /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(IVMD Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\IVMD.sas), 
   TIME=futime, status=primary, 
   COV1=IVMD,WHAT1=0,KNOTS1=31 49 67 115,  
   COV2=trivm,WHAT2=0,KNOTS2=31 49 67 115, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*ESVI futime';  
     model futime*primary(0)=treat ESVI tresv /RL; 
run; 
quit; 
proc phreg data=card.progex; 
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      title 'phreg treat treat*log(ESVI) futime'; 
  model futime*primary(0)=treat lesv trlesv /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(ESVI Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\ESVI.sas), 
   TIME=futime, status=primary, 
   COV1=ESVI,WHAT1=0,KNOTS1=93 119 149 295,  
   COV2=tresv,WHAT2=0,KNOTS2=93 119 149 295, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*GRF futime';  
     model futime*primary(0)=treat GRF trgrf /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(GRF) futime'; 
  model futime*primary(0)=treat lgrf trlgrf /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(GRF Spline), 
 DATA  =progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\GRF.sas), 
   TIME=futime, status=primary, 
   COV1=GRF,WHAT1=0,KNOTS1=46 60 73 125,  
   COV2=trgrf,WHAT2=0,KNOTS2=46 60 73 125, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*QRS futime';  
     model futime*primary(0)=treat QRS trqrs /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(QRS) futime'; 
  model futime*primary(0)=treat lqrs trlqrs /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(QRS Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\QRS.sas), 
   TIME=futime, status=primary, 
   COV1=QRS,WHAT1=0,KNOTS1=152 160 180 218,  
   COV2=trqrs,WHAT2=0,KNOTS2=152 160 180 218, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*supsys futime';  
     model futime*primary(0)=treat supsys trsup /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(supsys) futime'; 
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   model futime*primary(0)=treat lsup trlsup /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(Supsys Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\Supsys.sas), 
   TIME=futime, status=primary, 
   COV1=supsys,WHAT1=0,KNOTS1=105 117 130 165,  
   COV2=trsup,WHAT2=0,KNOTS2=105 117 130 165, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*BSA futime';  
     model futime*primary(0)=treat BSA trbsa /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(BSA) futime'; 
  model futime*primary(0)=treat lbsa trlbsa /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(BSA Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\BSA.sas), 
   TIME=futime, status=primary, 
   COV1=BSA,WHAT1=0,KNOTS1=1.73 1.88 2.01 2.38,  
   COV2=trbsa,WHAT2=0,KNOTS2=1.73 1.88 2.01 2.38, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*HeartRate futime';  
     model futime*primary(0)=treat HeartRate trhea /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(HeartRate) futime'; 
  model futime*primary(0)=treat lhea trlhea /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(HeartRate Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\HeartRate.sas), 
   TIME=futime, status=primary, 
   COV1=HeartRate,WHAT1=0,KNOTS1=60 69 78 105,  
   COV2=trhea,WHAT2=0,KNOTS2=60 69 78 105, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*a4cLVEjectionFraction futime';  
     model futime*primary(0)=treat a4cLVEjectionFraction tra4c /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(a4cLVEjectionFraction) futime'; 
  model futime*primary(0)=treat la4c trla4c /RL; 
 - 169 -   
 run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(a4cLVEjectionFraction Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\a4c.sas), 
   TIME=futime, status=primary, 
   COV1=a4cLVEjectionFraction,WHAT1=0,KNOTS1=22 25 29 43,  
   COV2=tra4c,WHAT2=0,KNOTS2=22 25 29 43, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*Roche futime';  
     model futime*primary(0)=treat Roche trroc /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(Roche)futime'; 
  model futime*primary(0)=treat lroc trlroc /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(Roche Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\Roche.sas), 
   TIME=futime, status=primary, 
   COV1=Roche,WHAT1=0,KNOTS1=744 1814 4198 26132,  
   COV2=trroc,WHAT2=0,KNOTS2=744 1814 4198 26132, 
   COV3=treat 
);  
proc phreg data=card.progex; 
     title 'phreg treat treat*Age futime';  
     model futime*primary(0)=treat Age trage /RL; 
run; 
quit; 
proc phreg data=card.progex; 
     title 'phreg treat treat*log(Age) futime'; 
  model futime*primary(0)=treat lage trlage /RL; 
run; 
quit; 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(Age Spline), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\Age.sas), 
   TIME=futime, status=primary, 
   COV1=Age,WHAT1=0,KNOTS1=59 66 72 84,  
   COV2=trage,WHAT2=0,KNOTS2=59 66 72 84, 
   COV3=treat 
);  
quit; 
 
 
%INC 'C:\splines\rcs.mac'; 
%RCS( 
   TITLE=%STR(Card Sync), 
   DATA=progex, DIRDATA=%STR(C:\prog_card_dat), 
   PROGRAM=%STR(C:\prog_card_dat\card_splines\All_sig.sas), 
   TIME=futime, status=primary, 
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    COV1=supsys,WHAT1=0,KNOTS1=105 117 130 165,  
   COV2=trsup,WHAT2=0,KNOTS2=105 117 130 165, 
   COV3=BSA,WHAT3=0,KNOTS3=1.73 1.88 2.01 2.38, 
   COV4=trbsa,WHAT4=0,KNOTS4=1.73 1.88 2.01 2.38, 
   COV5=mitral_r, 
   COV6=trmit, 
   COV7=IVMD, 
   COV8=trivm, 
   COV9=lroc, 
   COV10=ESVI, 
   COV11=GRF, 
   COV12=HeartRate, 
   COV13=a4cLVEjectionFraction, 
   COV14=Age, 
   COV15=QRS, 
   COV16=treat 
    
 
);  
               
Code for Final Model  
   
proc phreg data=card.progex3; 
      
  class Ischemic treat /desc; 
  model futime*primary(0)= treat mitral_r IVMD ESVI GRF supsys 
a4cLVEjectionFraction Roche Age Ischemic trsup trivm /RL 
selection=forward slentry=0.5  details; 
  
run; 
proc phreg data=card.progex3; 
      
  class Ischemic treat /desc; 
  model futime*primary(0)= treat mitral_r Roche supsys IVMD 
Ischemic trsup trivm  /RL details; 
     baseline covariates=card.progex3 out=card.PrScore2  
survival=S/nomean; 
run; 
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